

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Cohorts' profile: Shanghai PreConception Cohort, Shanghai, China (SPCC)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031076
Article Type:	Protocol
Date Submitted by the Author:	15-Apr-2019
Complete List of Authors:	Zhang, Yi; Children's Hospital of Fudan University Wang, Dingmei; Children's Hospital of Fudan University Jiang, Yuang; Children's Hospital of Fudan University Ye, Ying; Clinical Epidemiology Ji, Mi; Children's Hospital of Fudan University Dou, Yalan; Children's Hospital of Fudan University, Dermatology Chen, Xiaotian; Children's Hospital of Fudan University Li, Mengru; Children's Hospital of Fudan University Ma, Xiaojing ; Children's Hospital of Fudan University Sheng, Wei; Children's Hospital of Fudan University Huang, Guoying; Children's Hospital of Fudan University, Pediatric Heart Center Yan, Weili; Children's Hospital of Fudan University,
Keywords:	serum folate, red blood cell folate, vitamin, congenital heart diseases, periconceptional health care

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5 **Cohorts' profile: Shanghai PreConception Cohort, Shanghai, China**  
6  
7 **(SPCC)**  
8  
9

10 Yi Zhang\*<sup>1,2</sup>, Dingmei Wang\*<sup>1,2</sup>, Yuan Jiang<sup>1,2</sup>, Ying Ye<sup>1,2</sup>, Mi Ji<sup>1,2</sup>, Yalan  
11  
12 Dou<sup>1,2</sup>, Xiaotian Chen<sup>1,2</sup>, Mengru Li<sup>1,2</sup>, Xiaojing Ma<sup>1,2</sup>, Wei Sheng<sup>1,2</sup>,  
13  
14 Guoying Huang<sup>1,2#</sup>, Weili Yan<sup>1,2#</sup>  
15  
16  
17  
18  
19

20  
21 1 Children's Hospital of Fudan University, Shanghai, China.  
22

23 2 Shanghai Key Lab of Birth Defect, Children's Hospital of Fudan University,  
24  
25 Shanghai, China.  
26  
27  
28  
29

30  
31 \* contribute equally to this work.  
32

33 # corresponding author.  
34  
35

36 Weili Yan, PHD  
37

38 86-21-64931215  
39

40  
41 Email: yanwl@fudan.edu.cn  
42  
43

44 Guoying Huang, MD PHD  
45

46 86-21-64931913  
47  
48

49 Email: gyhuang@shmu.edu.cn  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT (264/300)**

**Purpose:** The Shanghai PreConception Cohort (SPCC) was set up to investigate associations between parental periconceptional key nutritional factors with the development of birth defects, with congenital heart diseases (CHD) being the primary aim. Based on nested case-control analysis, we aim to explore the optimal nutrition levels which is in relation to the offspring defects.

**Participants** Recruitment sought to enroll parenting-plan women and men in Shanghai city of China during 2016-18; the participants were followed up throughout the entire pregnancy till the delivery. By the end of the study enrollment in March, 2018, 24,446 women and 30% of their husbands (n=6,573) had been enrolled. It considers genetic, biological, social and other environmental exposures in relation to a similarly diverse range of health, social and CHD outcomes.

**Findings to date** The established cohort holds clinical, biological, nutritional, genetic and other environmental exposures of mother–infant–father triads representing a valuable resource for studying the pathogenesis of CHD. Until now, research has suggest that a large proportion of women planning pregnancy were below the optimal RBC folate concentration for preventing NTDs and the prevalence of FA supplement use was low in pregnancy planners(15.8% in men and 42.6% in women).



1  
2  
3  
4  
5 **Future plans** Ongoing cohort will describe the status of key nutrients  
6  
7 (eg.folic acid and vitamins) biological levels and dietary intake among peri-  
8  
9 conception population (women and husbands) in Shanghai. This study will  
10  
11 find out the association between the biological levels of key nutrients during  
12  
13 periconceptual period and the incidence of congenital heart defects (CHD)  
14  
15 in newborn through a nested case-control study design. The findings will  
16  
17 help to propose recommended nutrients levels.  
18  
19  
20  
21  
22

23 **Key Messages:** serum folate, red blood cell folate, vitamin, congenital  
24  
25 heart diseases, periconceptual health care  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Strengths and limitations of this study

- The SPCC cohort is the first prospective birth cohort with CHD as primary outcome and recruitment starting from preconception.
- Blood samples were collected and stored which allows for direct measurement of individual exposure levels before the development of CHD and make causal inference.
- This cohort also allows for investigating associations between periconceptional maternal and paternal nutrition exposures with other birth defects, early onset-diseases, and neurodevelopment outcomes.
- The established cohort holds clinical, biological, nutritional, genetic and other environmental exposures of mother–infant–father triads representing a valuable resource for studying the pathogenesis of congenital heart diseases (CHD).
- A major strength of this study is its multicenter prospective design with preconceptional parental biological nutrients levels, and linking to the municipal medical care data sources which enable chance for longer term follow-up of participants for future studies.

## Introduction

Congenital heart disease (CHD) is a common congenital malformation, which seriously affects quality of children's life [1]. CHD is a leading cause of infant death in high-income countries, and affect eight of 1 000 live births [2]. According to the report from National Health and Family Planning Commission of the People's Republic of China, CHD accounts for about a quarter of the birth defects of newborns in China, ranking the first among birth defects[3]. In a prospective, nation-wide large-scale study in more than 120 000 newborns in China in 2013, the prevalence of CHD was identified 8.94 ‰ in live births; the rate of severe CHD was 2.9 ‰[4].

The cause of CHD is multifactorial. With the development of genetic engineering technology, the genetic factors have been better understood in the past decade[5]. Multiple environmental risk factors have been reported in epidemiological studies, the maternal social variables such as occupation, educational background, health status, unhealthy life style, maternal medical history and emotional status, family history of disease, consanguineous marriages and so on [6-10]. In addition, maternal key nutrients related to the risk of offspring's CHD as a modifiable environmental factor during periconception [11, 12]. Periconceptional intake of folic acid supplement has been shown to reduce the risk for CHD [13, 14] and women worldwide have been recommended to take folic acid supplements before conception and in

1  
2  
3  
4  
5 the beginning of pregnancy. Awareness of the relationship between folic acid  
6  
7 deficiency and CHD is actually a by-product result from the well-known  
8  
9 Hungarian RCT study of folic acid supplementation to prevent neural tube  
10  
11 defects. The study found that prenatal supplementation with a vitamin  
12  
13 complex containing 0.8 mg of folic acid daily reduced the incidence of  
14  
15 congenital neural tube defects. At the same time, the incidence of various  
16  
17 heart defects has also been reduced by nearly half[15]. Longitudinal data  
18  
19 from more than one million births in Canada over a total of 22 years from  
20  
21 1990 to 2011 also show that the food fortification with folic acid reduced 20-  
22  
23 30% risk of CHD [16]. The current folic acid supplementation recommends  
24  
25 that all women of childbearing potential be supplemented with at least 0.4  
26  
27 mg of folic acid daily prior to conception and during pregnancy, which is  
28  
29 designed for preventing neural tube dysplasia[17]. However, excessive folic  
30  
31 acid intake may increase the risk of cancer[18], vitamin B12 deficiency[19]  
32  
33 and autism spectrum disorder[20]. The optimal dose of folic acid for  
34  
35 preventing CHD warrants further investigation. In addition, most of previous  
36  
37 studies only focused on the supplement of folic acid or the serum folate level  
38  
39 during or after pregnancy, which may not be the optimal time period and  
40  
41 way to reflect the exposure level to risk of CHD.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 To investigate the association between parental periconceptual key  
55  
56 nutritional factors such as folate with the development of CHD and to  
57  
58  
59  
60

1  
2  
3  
4  
5 explore the cutoff biomarker levels, we conducted Shanghai PreConception  
6  
7 Cohort (SPCC) and a nested case-control analysis.  
8  
9

### 10 11 12 13 **Who is in the cohort?** 14

15 The SPCC cohort recruited parenting-plan women and men who were  
16 permanent residents and took part in the preconception clinical visit at 28  
17  
18 maternity institutions in 10 districts (Minhang District, Huangpu District,  
19  
20 Xuhui District, Changning District, Jing'an District, Putuo District, Yangpu  
21  
22 District, Pudong District, Songjiang District, Qingpu District) in Shanghai  
23  
24 from March 2016 to December 2018. The preconception clinical visit is the  
25  
26 preconception examination policy in the city of Shanghai providing a unique  
27  
28 opportunity and clinical resources to support SPCC, the basis for the  
29  
30 proposed study. Since 2010, married couples in Shanghai have been  
31  
32 encouraged to attend a free preconception health visit at a medical clinic. In  
33  
34 addition, these maternity institutions have strong local support and integrated  
35  
36 maternal health-care networking and provide service to 15 000–20 000  
37  
38 annual deliveries in Shanghai (Figure 1). Eligible participant live in  
39  
40 Shanghai who are preparing pregnancy in one year and intend to receive  
41  
42 antenatal care and deliver at Shanghai. Informed, written consent is obtained  
43  
44 from all study participants. In addition, we recruited early pregnant women  
45  
46 at their first antenatal examination whose gestational week <14 week.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 The SPCC cohort includes a longitudinal birth cohort, based on which,  
6  
7  
8 a nested case-control study will be conducted. The study has been registered  
9  
10 with Clinical Trials Registry (NCT02737644). In the cohort, we recruited  
11  
12 participants in the preconception clinical visit. Among the enrolled  
13  
14 participants, once a woman was confirmed for pregnancy, she would have  
15  
16 been followed throughout the entire pregnancy. CHD outcome was  
17  
18 abstracted from Shanghai CHD screen platform that is a routine screen and  
19  
20 diagnosis policy covering all Shanghai newborns. The nested case-control  
21  
22 subjects included couples and women at periconceptual stage whose baby  
23  
24 with confirmative CHD diagnosis (case group) and four controls matched by  
25  
26 delivery hospital and maternal age (control group) randomly selected from  
27  
28 the rest of the cohort. Participants were identified by their unique national  
29  
30 identification number during follow up. Serum key nutrients levels in cases  
31  
32 and controls was examined for association analysis (Figure 2). The sample  
33  
34 size for the case-control analysis was planned as 180 cases and 600 controls  
35  
36 to detect a maternal folate deficiency with prevalence of 50% in controls  
37  
38 with odds ratio of 1.6 in association with the offspring CHD at power of 80%  
39  
40 at alpha of 0.05. Based on CHD incidence above 8.94 per 1 000 live birth[4],  
41  
42 20 000 pregnancies will be needed. For a continuous nutrient variable with  
43  
44 standard deviation 2.0 , 50 matched-pairs are required to achieve 90% power  
45  
46 to detect an odds ratio of 1.3 calculated using conditional logistic regression  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 with a 0.05 significance level[21, 22].  
6  
7

8 The SPCC began recruitment in March 2016. By the end of the study  
9  
10 enrollment in March, 2018, 24 446 women and 30% of their husbands  
11  
12 (n=6 573) had been enrolled in the SPCC. At the preconception clinical visit,  
13  
14 a questionnaire survey/interview and a health exam were conducted on  
15  
16 couples of men (n=6 573) and women (n=9 243). The preconception  
17  
18 questionnaires were also assigned to additional 15 203 pregnant women  
19  
20 before 14 gestational weeks, to recall information about dietary supplements  
21  
22 and health history during 3-6 month before pregnancy. Table 1 describes the  
23  
24 basic demographic characteristics of the preparing pregnant participants and  
25  
26 pregnant women, respectively. In preparing pregnant participants, the  
27  
28 average age of female and male was  $29.9\pm 3.9$  and  $31.4\pm 4.5$  years  
29  
30 respectively and there was a relatively larger proportion of both with high  
31  
32 educational attainment. One-third and two-third of male had a habit of  
33  
34 smoking and drinking. One-third of female had a habit of drinking. In  
35  
36 pregnant women, the average age was  $29.9\pm 4.0$  years, half of them was the  
37  
38 first pregnancy, and most of all did not have drinking and smoking habit.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 **Follow-up procedure**

52 At enrollment, the participants completed the questionnaire of key nutrients  
53  
54 supplementation and blood samples collection. When participants were  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 pregnant, the same investigation conducted during early pregnancy (first  
6 antenatal visit at 16-20 gestational week). Pregnancies were followed up  
7  
8 along with routine maternal health-care procedures. Besides, blood samples  
9  
10 were also collected at the second (24-28 gestational week) and third trimester  
11  
12 (32-34 gestational week). The follow-up of CHD outcome and birth data was  
13  
14 obtained by Shanghai CHD screen platform.  
15  
16  
17  
18  
19

20  
21 The routine clinical data of participants and offspring birth data was  
22  
23 extracted from three clinical data sources (Figure 2). First, The  
24  
25 preconception clinical visit data was from the preconception care electronic  
26  
27 data system supported by national and local government, including height,  
28  
29 weight, age, infections, sexually transmitted disease, and family history, etc.  
30  
31  
32 Second, the pregnant routine data were obtained in maternal clinic antenatal  
33  
34 medical record system, managed by Shanghai Center for Women and  
35  
36 Children's Health, including height, gestational weight, last menstrual period,  
37  
38 childbearing history, delivery outcomes, infections, hematocrit, coagulation  
39  
40 function, liver and kidney function and so on. Third, the maternal and  
41  
42 neonatal data at delivery came from Shanghai neonatal CHD screen platform  
43  
44 including birth weight, CHD diagnosis, birth defects, Apgar score, etc. The  
45  
46 maternal identification card number was applied as index variable through  
47  
48 the three data sources. The detail of clinical variable codebook please see  
49  
50  
51 Appendix 1.  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5 Comprehensive strategies were used to retain participants in the study.  
6  
7  
8 For mothers, we provided a variety of engagement activities including green  
9  
10 channel in antenatal care, nutrition consulting. Site investigators at early  
11  
12 pregnant clinics in collaborative hospitals were provided a smartphone APP  
13  
14 to identify cohort subjects timely and manage the data and blood sample  
15  
16 collection procedures. We provided green channel echocardiography of  
17  
18 CHD for all site hospital to enhance the compliancy of the participants. In  
19  
20 addition, an automated text message system is adopted to remind participants  
21  
22 of schedule and appointment of follow-up.  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Study measures**

#### 32 Personal characteristics questionnaires

33  
34 Questionnaire 1 was administered at baseline and early pregnancy to collect  
35  
36 information on folic acid supplement, vitamin supplement, the brand and  
37  
38 content of nutrient supplement, maternal education, socio-demographic  
39  
40 status, occupation, smoking status, alcohol consumption, BMI, medication,  
41  
42 health status. In addition to the content of Questionnaire 1, Questionnaire 2  
43  
44 added drug information, reproductive history and health status.  
45  
46 (Questionnaire 1 for baseline, Questionnaire 2 for the visit in early pregnancy,  
47  
48 please see Appendix 2a & Appendix 2b).  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Collection of blood samples

We kept the rest of fasting serum and EDTA anticoagulation blood samples of peripheral venous blood from routine laboratory examination. The fasting serum were divided into three light-proof EP tubes within six hours, as well as EDTA anticoagulation blood samples. After the completion of the blood sample distribution, the serum and the whole blood were stored at the site laboratory in -20 degree freezers temporarily and were transported by three trained investigators to the central biobank for storage in -80 degree freezers within two weeks. The protocol for blood sample tagging, isolation, temporary storage, transportation and permanent storage please see Appendix 3.

## Blood sample examinations

EDTA anticoagulation blood was collected to measure RBC folate and serum to folate, homocysteine, vitamin D, vitamin B12 and iron protein assays. All six biomarkers are performed on an electrochemiluminescence assay (ARCHITECT i2000SR Analyzer, Abbott Laboratories, USA). A standard solution with known concentration (produced by Abbott Laboratories) was used to quality control every day before the examination. If the level of quality control were out of the range of concentration, the examination would be suspended and adjusted. External quality control was

1  
2  
3  
4  
5 carried out with the control lab data program from Abbott Laboratories  
6  
7 (Abbott Laboratories, Shanghai, China). RBC folate concentrations were  
8  
9 adjusted for hematocrit. If the RBC folate concentration is below 126.0  
10  
11 ng/ml or above 651.1 ng/ml, we need to adjust the serum folate level. The  
12  
13 hematocrit data were extracted from the hospital laboratory information  
14  
15 system. Those examinations were performed in central laboratory of  
16  
17 Children's Hospital of Fudan University.  
18  
19  
20  
21  
22

23 The serum concentration of vitamin A and vitamin E were quantitatively  
24  
25 detected by liquid chromatography-tandem mass spectrometry in central  
26  
27 laboratory of Children's Hospital of Fudan University. The testing  
28  
29 instrument was triple quadrupole mass spectrometer LC/MS/MS System  
30  
31 (NO: API 3200MDTM, ABSciex Pte.Ltd.). A standard solution of vitamin  
32  
33 A-d6 and vitamin E-d6 were applied as internal standards.  
34  
35  
36  
37  
38

39 We also planned to measure other blood chemicals using the stored  
40  
41 serum including cholesterol, high-density lipoprotein, low-density  
42  
43 lipoprotein, triglyceride, fasting glucose and heavy metals. Cholesterol,  
44  
45 high-density lipoprotein, low-density lipoprotein, triglyceride, and fasting  
46  
47 glucose were performed on Beckman coulter AU chemistry analyzers  
48  
49 (Beckman, USA) in central laboratory of Children's Hospital of Fudan  
50  
51 University. Serum heavy metals including Mg, Fe, Zn, Se, Mn, As, Cu and  
52  
53 Ca, were analyzed by inductively coupled plasma mass spectrometry (ICP-  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 MS) (Inductively Coupled Plasma Optical iCAP6300, Thermo®, USA) in  
6  
7 standard mode [23]. The metals examination was conduct in Instrumental  
8  
9 Analysis Center of Shanghai Jiaotong University.  
10  
11

### 12 CHD Outcome

13  
14  
15 The diagnosis of CHD was the primary outcome of study at this stage and  
16  
17 obtained from Shanghai neonatal CHD screen network platform, which was  
18  
19 initiated as routine screen for newborn in Shanghai since Jun 1st 2016. The  
20  
21 standard protocol of CHD screening of the platform was previously  
22  
23 described in detail [24]. All newborn babies received the screen by using  
24  
25 double-index method (i.e. cardiac murmur auscultation and pulse oximetry)  
26  
27 during 6-72 hours after delivery, and those screen-positive babies would  
28  
29 receive a subsequent echocardiography for further comformative diagnosis.  
30  
31  
32  
33  
34  
35

36 SPCC also focus on the other birth defects as secondary outcomes  
37  
38 including Down's syndrome, neural tube defects, hydrocephalus, digestive  
39  
40 tract malformations, urinary malformations, and behavioral cognitive  
41  
42 developmental disorder. After delivery, the infants will attend routine child  
43  
44 care procedures organized by Shanghai child health care system which is  
45  
46 administered by Shanghai Center for Women and Children's Health. All  
47  
48 birth defects records which diagnosed in afterlife, as well as routine neuro-  
49  
50 development examinations and longitudinal anthropometric data will be  
51  
52 abstracted from the system by professional clinical team from Children's  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 hospital of Fudan University. The offspring of participant will be followed  
6  
7  
8 up to school age. After that, health data will be abstract from Shanghai  
9  
10 Student Health Surveillance information system.  
11  
12  
13  
14

## 15 **FINDINGS TO DATE**

16  
17 Findings from the SPCC cohort currently are limited in the available sample  
18  
19 recruited in 2016[25]. A total of 4 122 people participated in the study,  
20  
21 including 2 268 (55.0%) women and 1 854 men, with average age of  
22  
23 30.5±4.3 years, 94.5% of which were highly educated. Among  
24  
25 preconception subjects, the proportion of using folic acid supplement was  
26  
27 15.8% (292/1 854) in men and 42.6% (970/2 268) in women. The proportion  
28  
29 in women is far below the National Health and Family Planning Commission  
30  
31 requirements (70%) of China. In women of childbearing age in Europe and  
32  
33 North America, the proportion of folic acid supplements used also does not  
34  
35 exceed 50% [26-28]. In the face of lower usage ratios, Canada, the United  
36  
37 States and the United Kingdom have successively carried out folic acid  
38  
39 fortification in grains. However, there is no such fortification in china. Our  
40  
41 findings suggest that education of folic acid supplement knowledge is deeply  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53 needed.

54  
55 As the study is still ongoing, findings of blood nutrients based on  
56  
57 limited processed blood sample are described below. The blood nutritional  
58  
59  
60

1  
2  
3  
4  
5 levels of the preconceptional and pregnancy was based on 553 available  
6 participants. The concentrations of RBC folate median level is 247.0 ng/ml  
7 (IQR: 184.8-340.5 ng/ml) in preconception and 416.6 ng/ml (IQR: 305.4-  
8 542.2 ng/ml) in pregnancy. Twenty percent of preconceptional subjects and  
9 44.9% pregnant subjects had folate level over 400 ng/ml, which was  
10 suggested as optimal level for preventing neural tube development defects  
11 [29, 30]. Our findings suggest that effort is urgently needed to improve the  
12 effectiveness of folic acid supplementary for this prepare-for pregnancy  
13 population, especially before pregnancy.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **STRENGTHS AND WEAKNESS**

32  
33 This study has two important strengths. First, the SPCC cohort is the first  
34 prospective birth cohort with CHD as primary outcome and recruitment  
35 starting from preconception. Blood samples were collected and stored which  
36 allows for direct measurement of individual exposure levels before the  
37 development of CHD and make causal inference. Up to date, none published  
38 studies measured maternal blood levels of folate levels before conception  
39 and link it to disease outcomes. Second, this cohort also allows for  
40 investigating associations between periconceptional maternal and paternal  
41 nutrition exposures with other birth defects, early onset-diseases, and  
42 neurodevelopment outcomes. Third, a major strength of this study is its large  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 multicenter prospective design with opportunities for follow-up through  
6  
7 linking to the municipal medical care data sources as well as the recalling of  
8  
9 participants for future studies.  
10  
11  
12

13  
14 Two challenges of this cohort study should be considered. First, there  
15  
16 are 200000 pregnant women giving birth every year in Shanghai,  
17  
18 and 20000 of them will take part in the free preconceptional care in Shanghai,  
19  
20 where our participants came from. These people may have better health  
21  
22 awareness and may introduce selection bias. Second, in this study, biological  
23  
24 samples (cord blood, placenta) of the newborns are not collected.  
25  
26  
27  
28

### 29 **Acknowledgements**

30  
31 We are extremely grateful to all the families who took part in this study, the  
32  
33 doctors for their help in recruiting them, and the whole SPCC team, which  
34  
35 includes interviewers, computer and laboratory technicians, clerical workers,  
36  
37 research scientists, volunteers, managers, receptionists and nurses (See  
38  
39 supplement file: SPCC team).  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 **Contributors:** YZ and DW prepared the original draft of the manuscript.  
6  
7 Substantial contributions to the conception or design of the work were made  
8  
9 by GH and WY. YZ, DW, YY, JY, ML, MJ, YD and XC led study  
10  
11 implementation at participating sites. DW and YZ were responsible for the  
12  
13 day-to-day project management at each site. XM and WS were responsible  
14  
15 for the biobank of the cohort. All authors provided critical review of the  
16  
17 manuscript for important intellectual content and approved the final version.  
18  
19  
20  
21  
22

23 **Funding:** This work is supported by National key research and development  
24  
25 program (Grant No: 2016YFC1000506) and Natural Science Foundation of  
26  
27 China (Grant No: 81273168). Three-year Planning for Strengthening the  
28  
29 Construction of Public Health System in Shanghai (GWIV-24).  
30  
31  
32

33 **Conflict of interest:** The authors have no conflicts of interest  
34  
35

36 **Ethics approval:** This study was approved by Ethics Committee of  
37  
38 Children's hospital of Fudan University, Shanghai, China.  
39  
40

41 **Provenance and peer review** Not commissioned; externally peer reviewed.  
42  
43

44 **Data sharing statement:** No additional data are available.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## REFERENCES

1. Mahle WT, Newburger JW, Matherne GP, Smith FC, Hoke TR, Koppel R, Gidding SS, Beekman RH, 3rd, Grosse SD, American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young CoCN *et al*: **Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics.** *Circulation* 2009, **120**(5):447-458.
2. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW: **Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis.** *Journal of the American College of Cardiology* 2011, **58**(21):2241-2247.
3. China MoPHo: **China's birth defects prevention report.** In. Edited by China MoPHo. Beijing; 2012.
4. Zhao QM, Ma XJ, Ge XL, Liu F, Yan WL, Wu L, Ye M, Liang XC, Zhang J, Gao Y *et al*: **Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study.** *Lancet* 2014, **384**(9945):747-754.
5. Bruneau BG: **The developmental genetics of congenital heart disease.** *Nature* 2008, **451**(7181):943-948.
6. Alverson CJ, Strickland MJ, Gilboa SM, Correa A: **Maternal smoking and congenital heart defects in the Baltimore-Washington Infant Study.** *Pediatrics* 2011, **127**(3):e647-653.
7. Lee LJ, Lupo PJ: **Maternal smoking during pregnancy and the risk of congenital heart defects in offspring: a systematic review and metaanalysis.** *Pediatr Cardiol* 2013, **34**(2):398-407.
8. Shi M, Wehby GL, Murray JC: **Review on genetic variants and maternal smoking in the etiology of oral clefts and other birth defects.** *Birth Defects Res C Embryo Today* 2008, **84**(1):16-29.
9. Kuciene R, Dulskiene V: **Selected environmental risk factors and congenital heart defects.** *Medicina (Kaunas)* 2008, **44**(11):827-832.
10. Carmichael SL, Shaw GM: **Maternal life event stress and congenital anomalies.** *Epidemiology* 2000, **11**(1):30-35.
11. Czeizel AE: **Periconceptional folic acid-containing multivitamin supplementation for the prevention of neural tube defects and cardiovascular malformations.** *Ann Nutr Metab* 2011, **59**(1):38-40.
12. Botto LD, Mulinare J, Erickson JD: **Occurrence of congenital heart defects in relation to maternal multivitamin use.** *Am J Epidemiol* 2000, **151**(9):878-884.
13. Ionescu-Ittu R, Marelli AJ, Mackie AS, Pilote L: **Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada.** *Brit Med J* 2009, **338**.
14. Liu SL, Joseph KS, Luo W, Leon JA, Lisonkova S, Van den Hof M, Evans J, Lim K, Little J, Sauve R *et al*: **Effect of Folic Acid Food Fortification in Canada on Congenital Heart Disease Subtypes.** *Circulation* 2016, **134**(9):647-655.
15. Czeizel AE, Dudas I: **Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation.** *N Engl J Med* 1992, **327**(26):1832-1835.
16. Liu S, Joseph KS, Luo W, Leon JA, Lisonkova S, Van den Hof M, Evans J, Lim K, Little J, Sauve R *et al*: **Effect of Folic Acid Food Fortification in Canada on Congenital Heart Disease Subtypes.** *Circulation* 2016, **134**(9):647-655.
17. Cordero AM, Crider KS, Rogers LM, Cannon MJ, Berry RJ: **Optimal serum and red blood cell folate**

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- concentrations in women of reproductive age for prevention of neural tube defects: World Health Organization guidelines.** *MMWR Morb Mortal Wkly Rep* 2015, **64**(15):421-423.
18. Kim YI: **Will mandatory folic acid fortification prevent or promote cancer?** *Am J Clin Nutr* 2004, **80**(5):1123-1128.
19. Selhub J, Rosenberg IH: **Excessive folic acid intake and relation to adverse health outcome.** *Biochimie* 2016, **126**:71-78.
20. Wiens D, DeSoto MC: **Is High Folic Acid Intake a Risk Factor for Autism?-A Review.** *Brain Sci* 2017, **7**(11).
21. Lachin JM: **Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model.** *Stat Med* 2008, **27**(14):2509-2523.
22. Tang YQ: **Comments on 'Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model'.** *Stat Med* 2009, **28**(1):175-177.
23. Bolann BJ, Distant S, Morkrid L, Ulvik RJ: **Bloodletting therapy in hemochromatosis: Does it affect trace element homeostasis?** *J Trace Elem Med Biol* 2015, **31**:225-229.
24. Hu XJ, Ma XJ, Zhao QM, Yan WL, Ge XL, Jia B, Liu F, Wu L, Ye M, Liang XC *et al*: **Pulse Oximetry and Auscultation for Congenital Heart Disease Detection.** *Pediatrics* 2017, **140**(4).
25. WANG Ding-mei ZY, YE Ying, JIANG Yuan, MA Xiao-jing, YAN Wei-li, HUANG Guo-ying: **A cross-sectional study on prevalence of paternal and parental preconception folic acid supplement use and its influencing factors.** *Chinese Journal of Evidence-based Pediatrics* 2017, **12**(1):1-6.
26. Nilsen RM, Leoncini E, Gastaldi P, Allegri V, Agostino R, Faravelli F, Ferrazzoli F, Finale E, Ghirri P, Scarano G *et al*: **Prevalence and determinants of preconception folic acid use: an Italian multicenter survey.** *Ital J Pediatr* 2016, **42**(1):65.
27. Cueto HT, Riis AH, Hatch EE, Wise LA, Rothman KJ, Mikkelsen EM: **Predictors of preconceptional folic acid or multivitamin supplement use: a cross-sectional study of Danish pregnancy planners.** *Clin Epidemiol* 2012, **4**:259-265.
28. Hoyo C, Murtha AP, Schildkraut JM, Forman MR, Calingaert B, Demark-Wahnefried W, Kurtzberg J, Jirtle RL, Murphy SK: **Folic acid supplementation before and during pregnancy in the Newborn Epigenetics Study (NEST).** *BMC Public Health* 2011, **11**(1):46.
29. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM: **Folate levels and neural tube defects. Implications for prevention.** *JAMA* 1995, **274**(21):1698-1702.
30. Tam C, McKenna K, Goh YI, Klieger-Grossman C, O'Connor DL, Einarson A, Koren G: **Periconceptional folic acid supplementation: a new indication for therapeutic drug monitoring.** *Ther Drug Monit* 2009, **31**(3):319-326.

**Table 1. Socio-demographics of participants including 6,573 couples of parents and 15,203 pregnant women that were enrolled in the Shanghai PreConception Cohort (SPCC).**

Characteristics	Couples of parents completed preconception questionnaires				Additional pregnant women completed both preconception and first-trimester questionnaires	
	Male (n=6573)		Female (n=9243)		Pregnant women (n=15203)	
Age (years), Mean±SD	6573	31.4±4.5	9243	29.9±3.9	15203	29.9±4.0
Ethnicity	6536		9188		15176	
Han Nationality		6403 (98%)		8966 (97.6%)		15245 (97.8%)
Other		133 (2%)		222 (2.4%)		342 (2.2%)
Educational level	6530		9147		15143	
<College		514 (7.8%)		795 (8.7%)		2052 (13.6%)
>College		6016 (92.2%)		8352 (91.3%)		13091 (86.4%)
Annual household income	6530		9147		-	
<0.1 million		1424 (21.8%)		2214 (24.2%)		
≥0.1 million		5106(78.2%)		6933 (75.8%)		
Occupation	6530		9147		14789	
Entrepreneur		157 (2.4%)		128 (1.4%)		171 (1.1%)
Farmer		26 (0.4%)		46 (0.5%)		79 (0.5%)
Self-employed		216 (3.3%)		274 (3%)		862 (5.6%)
Manager		1410 (21.6%)		1765 (19.3%)		2650 (17.2%)
Technician		2462 (37.7%)		1903 (20.8%)		3239 (20.6%)
Company clerk		2259 (34.6%)		5031 (55%)		8451 (54.7%)
Attending pregnant examination	-		-		14996	
Yes						3374 (22.5%)
No						11622 (77.5%)

1	Frequency of pregnant	-	-	15162	
2	1				7569 (49.9%)
3	2				4604 (49.9%)
4	>=3				2989 (19.7%)
5	Abnormal delivery history	-	-	15159	
6	Yes				4838 (31.2%)
7	No				10385 (68.7%)
8	Smoking history	6552	9212	15159	
9	Yes		2073 (31.6%)		218 (2.4%)
10	No		4479 (68.4%)		8994 (97.6%)
11	Alcohol Drinking history	6448	9075	15164	
12	Yes		3962 (61.5%)		2865 (31.6%)
13	No		2486 (38.5%)		6210 (68.4%)
14	Location of home	6573	9243	-	
15	Developed districts		3034 (46.2%)		5452 (59.0%)
16	Developing districts		3539 (53.8%)		3791 (41.0%)

**Table 2. Maternal biomarkers evaluated in the SPCC study**

Biomarkers	Sample type	Mother			
		Baseline	16-20 weeks	24-28 weeks	32-36 weeks
Folate, ng/ mL	Serum	○	○		
RBC Folate, ng/ mL	Whole blood	○	○		
Homocysteine, $\mu\text{mol/L}$	Serum	○	○		
Vitamin D, ng/mL	Serum	○	○		
Vitamin B12, pg/mL	Serum	○	○		
Vitamin A, $\mu\text{g/mL}$	Serum	○	○		
Vitamin E, $\mu\text{g/mL}$	Serum	○	○		
Iron protein, ng/mL	Serum	○	○		
Metals (Mg, Fe, Zn, Se, Mn, As, Cu, Ca, ect) ,mg/L	Serum	○	○		
DNA	Whole blood	○	○	○	○
CHOL, HDL, LDL, TG, fasting glucose	Serum	○	○		

Note: RBC folate means red blood cell folate

1  
2 Figure 1 Map showing the location of Shanghai in China and the distribution of study sites in Shanghai  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Figure 2 Diagram of the protocol and follow up of Shanghai PreConceptional Cohort (SPCC)

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 Map showing the location of Shanghai in China and the distribution of study sites in Shanghai

254x190mm (96 x 96 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2 Diagram of the protocol and follow up of Shanghai PreConceptional Cohort (SPCC)

338x190mm (96 x 96 DPI)

## Appendix 1 variable list

**Table 1 Intervention trial variable list**

NO	variable	
	<b>Pre-pregnancy</b>	
1	hospital card number	T
2	Recruited number	T
3	Recruited date	D
4	Female name	T
5	Female height	N
6	Female weight	N
7	Female age	N
8	Male name	T
9	Male height	N
10	Male weight	N
11	Male age	N
12	Tel No	T
13	Community (basis for grouping)	N
14	Nutrient Interventions	B (1=intervention 0=control)
	<b>Nutrient first test</b>	
15	Nutrient first test date	D
16	Serum folate	N
17	Red blood cell folate	N
18	Serum ferritin	N
19	VD(Vitamin D)	N
20	HCY(homocysteine)	N
21	Vitamin B12	N
22	LDL low density lipoprotein cholesterol	N
23	HDL high density lipoprotein cholesterol	N
24	TG total cholesterol	N
25	TC triglyceride	N
26	FBG(fasting blood-glucose)	N
27	Genotyping (BHMT (rs3733890), CBS (rs2850144, rs2851391), FIGN (rs2119289), MTHFD1 (rs2236225), MTHFR (rs1801131, rs1801133, rs3737965), MRT (rs1805087, rs28372871, rs1131450), MTRR (rs1801394, rs326119), RFC1 (rs1051266), and SHMT (rs1979277))	B
28	Clinical information (see Table 3)	-

29	Insufficient serum folate	B
30	Insufficient RBC folate	B
<b>Nutrient repetition measurement</b>		
29	Nutrient repetition measurement date	D
30	Serum folate	N
31	Red blood cell folate	N
32	HCY (Homocysteine)	N
<b>Pregnancy</b>		
33	Ultrasound image screen in mid-gestation	T
34	Report detail (positive)	B
35	Confirm image diagnosis	T
36	Therapeutic plan	T
37	birth defect diagnosis	T
38	Clinical information (see Table 2)	-

Note: T, text variable; D, The date type; N, Continuous variable; B, binary variable.

**Table 2 Pregnant variable list in routine system**

NO	variable	
	<b>basic information</b>	
1	hospital card number	T
2	inpatient number	T
3	name	T
4	age	N
5	Pregnant times	N
6	Delivery times	N
7	last menstrual period	D
8	Gestational week at the first visit	N
9	The first visit date	D
10	Height	N
11	Weight	N
12	Systolic blood pressure at the first visit	N
13	Diastolic blood pressure at the first visit	N
14	Occupation	T
15	Education	T
	<b>Antenatal care record</b>	
16	Weight at each antenatal care	N
17	Systolic blood pressure at each antenatal care	N
18	Diastolic blood pressure at each antenatal care	N
19	Gestational week at each antenatal care	N
20	Antenatal care date	D
	<b>Lab data</b>	
21	Cytomegalovirus	N
22	Cytomegalovirus date	D
23	Rubella virus	N
24	Rubella virus date	D
25	Toxoplasmosis	N
26	Toxoplasmosis date	D
27	Syphilis screening	N
28	Syphilis screening date	D
29	Fasting blood-glucose	N
30	Fasting blood-glucose date	D
31	HCT(hematokrit)	N
32	HCT(hematokrit) date	D
33	Serum folate	N
34	Serum folate date	D
35	HCY(homocysteine)	N
36	HCY(homocysteine) date	D

37	OGTT 0 hours	N
38	OGTT 1 hours	N
39	OGTT 2 hours	N
40	OGTT date	D
41	Triglyceride	N
42	Triglyceride date	D
43	Total cholesterol	N
44	Total cholesterol date	D
45	Hemoglobin date	N
46	Hemoglobin date	D
	<b>Delivery date</b>	
47	Gestational week at delivery	N
48	Delivery mode	T
49	Birth weight	N
50	Birth weight(second baby)	N
51	Systolic blood pressure at delivery	N
52	Diastolic blood pressure at delivery	N
53	Apgar scoring	N
54	Delivery date	D
55	Birth defect records	T
56	Weight blood pressure at delivery	N

Note: The data will be extracted from maternal clinic antenatal medical record system.

T, text variable; D, The date type; N, Continuous variable; B, binary variable.

**Table 3 Pre-pregnant variable list in routine system**

	<b>variable</b>	
	<b>Basic information</b>	
1	Wife id	T
2	Husband nation	T
3	Husband age	N
4	Husband education	T
5	Husband id	T
6	Husband occupation	T
7	Wife nation	T
8	Wife age	N
9	Wife education	T
10	Wife occupation	T
11	Tel no	T
12	Mobile phone No	T
	<b>Medical history</b>	
13	Female anemia	B
14	Female EH	B
15	Female heart disease	B
16	Female DM	B
17	Female epilepsy	B
18	Female thyroid disease	B
19	Female CGN	B
20	Female mental disease	B
21	Female tumour	B
22	Female TB	B
23	Female HBV	B
24	Female VD	B
25	Male anemia	B
26	Male EH	B
27	Male heart disease	B
28	Male DM	B
29	Male epilepsy	B
30	Male thyroid disease	B
31	Male CGN	B
32	Male mental disease	B
33	Male tumour	B
34	Male TB	B
35	Male HBV	B
36	Male VD	B
	<b>Vaccine</b>	
37	Female rubella vaccine	B
38	Female hepB vaccine	B

39	Male hepB vaccine	B
	<b>Durg</b>	
40	Female current medicine	B
41	Female medicine name	B
42	Male current medicine	B
43	Male medicine name	B
	<b>Childbearing history</b>	
44	Birth history	B
45	Pregnancy times	B
46	Live birth	B
47	Dead fetus	B
48	Dead birth	B
49	Term delivery	B
50	Premature delivery	B
51	Natural abortion	B
52	Abactio	B
53	Children number	B
54	Birth defect	B
55	Defect type	B
56	Menarche age	B
57	Period menstruation	B
58	Menstrual cycle	B
59	Menstrual quantity	B
60	LMP	D
	<b>Family history of disease</b>	
61	Female family history thalassemia	B
62	Female family history albinism	B
63	Female family history favism	B
64	Female family history hemophilia	B
65	Female family history CHD	B
66	Female family history DS	B
67	Female family history openNTDs	B
68	Female family history DM	B
69	Female family history dysnoesia	B
70	Female family history daysaudia	B
71	Female family history viaual disorder	B
72	Female family history neuropsychiatric	B
73	Female family history other birthdefects	B
74	Female family history fetal death	B
75	Female family history intermarry	B
76	Female family history relations	B
77	Male family history thalassemia	B
78	Male family history albinism	B

79	Male family history favism	B
80	Male family history hemophilia	B
81	Male family history CHD	B
82	Male family history DS	B
83	Male family history openNTDs	B
84	Male family history DM	B
85	Male family history dysnoesia	B
86	Male family history dysaudia	B
87	Male family history vidual disorder	B
88	Male family history neuropsychiatric	B
89	Male family history other birth defects	B
90	Male family history fetal death	B
91	Male family history intermarry	B
92	Male family history relations	B
	<b>Anthroposomatology</b>	
93	Female height	N
94	Female weight	N
95	Female BMI	N
96	Female heart rate	N
97	Female SBP	N
98	Female SDP	N
99	Male height	N
100	Male weight	N
101	Male BMI	N
102	Male heart rate	N
103	Male SBP	N
104	Male SDP	N
	<b>Lab data</b>	
105	Leucorrhoea check	N
106	Clue cell	N
107	Monilia infection	N
108	Trichomomas	N
109	Cleanness	N
110	Whiff test	N
111	PH	N
112	Wom blood analysis	N
113	Female hb	N
114	Female wbc	N
115	Female rbc	N
116	Wom urine test	N
117	Female ABO	N
118	Female Rh	N
119	Female GLU	N



120	Female GLU levels	N
121	Female NG	N
122	Female chlamydia	N
123	Female syphilis	N
124	Female HIV	N
125	Female ALT	N
126	Female ALT levels	N
127	Female HBs-Ag	N
128	Female HBs-Ab	N
129	Female HBe-Ag	N
130	Female HBe-Ab	N
131	Female HBc-Ab	N
132	Female HCV-Ab	N
133	Female CMV IgM	N
134	Female CMV IgG	N
135	Female RV IgM	N
136	Female RV IgG	N
137	Female TOX IgM	N
138	Female TOX IgG	N
139	Male blood analysis	N
140	Male hb	N
141	Male wbc	N
142	Male rbc	N

Note: The data will be extracted the preconception care electronic data system T, text variable; D, The date type; N, Continuous variable; B, binary variable.



## A 一般情况

A1 联系电话（请您认真填写，以助于医生和您联系） Contact number: _____ (手机) _____ (固定电话) _____ (Email)
A2 家庭住址 Address: _____ 区/县 _____ 街道/小区 _____ 门牌号码/村
A3 您的出生日期是 Birth date _____ 年 _____ 月 _____ 日
A4 民族 Nationality <input type="checkbox"/> 1 汉族 <input type="checkbox"/> 2 其他（请注明） _____
A5 您的最高学历 Education <input type="checkbox"/> 1 初高中以下 <input type="checkbox"/> 2 大专本科 <input type="checkbox"/> 3 硕士研究生以上及以上
A6 您现在的主要职业 Occupation <input type="checkbox"/> 1 管理人员/干部 <input type="checkbox"/> 2 技术人员 <input type="checkbox"/> 3. 企业主 <input type="checkbox"/> 4 工人 <input type="checkbox"/> 5 农民 <input type="checkbox"/> 6 个体户 <input type="checkbox"/> 7 其它 _____
A7 上一年您的家庭年收入是： Income of a year <input type="checkbox"/> 1. <2 万元 <input type="checkbox"/> 2. (2~3.9)万 <input type="checkbox"/> 3.(5.9)万 <input type="checkbox"/> 4.(6~9.9)万 <input type="checkbox"/> 5.(10~14.9)万 <input type="checkbox"/> 6.15 万及以上 <input type="checkbox"/> 9. 不详
A8 填表日期 Date _____ 年 _____ 月 _____ 日

## B 营养补充剂使用情况

营养补充剂种类 Nutritional supplement types	叶酸 Folic acid	复合维生素 multi-vitamins	单一维生素 Single vitamin
您在近三个月是否服用 Have you taken it in the last three months?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂？（如果没有对应选项请在其他处写明） Brand name	<input type="checkbox"/> 1、创盈金斯利安多维片 <input type="checkbox"/> 2、福施福胶囊营养素 <input type="checkbox"/> 3、汤臣倍健 <input type="checkbox"/> 4、安利纽崔莱铁 <input type="checkbox"/> 5、其他 _____	<input type="checkbox"/> 1、爱乐维 <input type="checkbox"/> 2、汤臣倍健孕妇专用 <input type="checkbox"/> 3、惠氏玛特纳 <input type="checkbox"/> 4、21 金维他 <input type="checkbox"/> 5、其他 _____	<input type="checkbox"/> V <sub>C</sub> <input type="checkbox"/> V <sub>E</sub> <input type="checkbox"/> V <sub>B1</sub> <input type="checkbox"/> V <sub>B2</sub> <input type="checkbox"/> 其他 _____
您这三个月的服用频率？（如果食用频率小于每天/周一次，请填写每周/月食用几次，并勾出周/月） How often did you take in	_____ 次/□天 □周 □月	_____ 次/□天□周□月	_____ 次/□天 □周 □月

营养补充剂种类 Nutritional supplement types	铁 Fe	钙 Ca	锌 Zn
您在近三个月是否服用 Have you taken it in the last three months?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂？（如果没有，选项请在其他处写明） Brand name	<input type="checkbox"/> 1、汤臣倍健叶酸亚铁片 <input type="checkbox"/> 2、安利纽崔莱铁片 <input type="checkbox"/> 3、金康倍叶酸铁片 <input type="checkbox"/> 4、其他_____	<input type="checkbox"/> 1、惠氏金钙尔奇 <input type="checkbox"/> 2、君宝康孕妇钙片 <input type="checkbox"/> 3、十月妈咪维生素 AD 钙锌咀嚼片 <input type="checkbox"/> 4、安利钙镁片 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、美康利健 MK 硒金牡蛎锌片 <input type="checkbox"/> 2、汤臣倍健 锌咀嚼片 <input type="checkbox"/> 3、宫诺肽片 <input type="checkbox"/> 4、其他_____
您这三个月的服用频率？（如果食用频率小于每天/周一次，请填写每周/月食用几次，并勾出周/月） How often did you take in	_____次/□天 □周 □月	_____次/□天□周□月	_____次/□天 □周 □月

## B 营养补充剂使用情况

C 吸烟情况	
C1 您有吸烟史吗？ Have you smoked cigarettes ever before?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 (跳至 F6)
C2 在您最近的 3 个月内，您是否吸烟？ Did you smoke cigarettes in 3 month	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C3 如果是，您平均每天吸多少支烟？ On average, how many cigarettes did you smoke each day in the month after your last menstrual period?	_____ 支
C4 如果您曾经戒过烟，您戒了多少次？ How many times did you stop smoking?	_____
C5 在您生活的大多数时间里，您是否暴露于他人烟草烟雾中？ On most days during your pregnancy, were you exposed to someone else's cigarette smoke?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 (跳至 G1)
C6 您在哪里暴露与烟草烟雾中 Where were you exposed to the smoke?	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<input type="checkbox"/> 1 仅在家中 <input type="checkbox"/> 2 仅在工作单位 <input type="checkbox"/> 3 在家和在工作单位均暴露
<b>D 酒精</b>
D1 您最近三个月的饮酒情况？ During the 3 months before or during your pregnancy, did you ever drink any alcoholic beverages?
<input type="checkbox"/> 0.从未饮酒；
<input type="checkbox"/> 1.尝试饮酒（曾饮至少半瓶或一听啤酒，一小盅白酒等）；
<input type="checkbox"/> 2.现在饮酒（过去 30 天，至少有一天喝过一杯酒）；
<input type="checkbox"/> 3.重度饮酒（过去 30 天，至少有一天在 2 小时内喝过五杯酒）；
<input type="checkbox"/> 4.醉酒（过去 12 个月内，因喝酒太多而感到头晕/头疼/嗜睡等醉酒症状）。

核查人员签名： \_\_\_\_\_

For peer review only

Name of pregnancy: \_\_\_\_\_

ID no: \_\_\_\_\_

## 孕期危险因素暴露调查表

## Pregnancy risk factor exposure questionnaire

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### A 一般情况 General information

A1 您的出生日期是 Birth date	_____年_____月_____日
A2 民族 Nationality	<input type="checkbox"/> 1 汉族 Han <input type="checkbox"/> 2 其他 other_____
A3 您的最高学历 Education	<input type="checkbox"/> 1 初高中以下 Mid <input type="checkbox"/> 2 大专本科 High <input type="checkbox"/> 3 硕士研究生以上及以上 College
A4 您现在的主要职业 Occupation	<input type="checkbox"/> 1 管理人员/干部 <input type="checkbox"/> 2 技术人员 <input type="checkbox"/> 3. 企业主 <input type="checkbox"/> 4 工人 <input type="checkbox"/> 5 农民 <input type="checkbox"/> 6 个体户 <input type="checkbox"/> 7 其它_____
A6 家庭住址: Address	_____区/县_____街道/小区_____门牌号码/村
A7 联系电话 (请您认真填写, 以助于医生和您联系): Contact number	_____(手机) _____(固定电话) _____(Email) _____(微信号)

### B 本次妊娠情况

B1 您孕前体重通常为? Current weight	_____ (公斤 Kg)
B2 您身高是? Height	_____ (厘米 cm)
B3 您的腰围是? Waist	_____ (厘米 cm)
B4 您此次怀孕的末次月经时间? What was the first day of the menstrual period that came right before this pregnancy (LMP)?	_____年_____月_____日
B5 孕期是否发生过重大负性生活事件而使您的精神受到刺激? Have you ever experienced the negative events which irritate you and generate some negative emotion?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
B6 生这个孩子是您第几次怀孕? How many times have you been pregnant?	_____次
B7 是否有不良生育史? Did you have the adverse reproductive history?	<input type="checkbox"/> 1 有 (继续回答 B6.1) <input type="checkbox"/> 0 无 (跳至 B7)
B6.1 流产史 Abortion	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B6.2 早产史 Preterm	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B6.3 死产史 Stillbirth	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B8 您是否有糖尿病和高血压疾病? Do you have hypertension or diabetes	<input type="checkbox"/> 1 是 (继续回答 B8) <input type="checkbox"/> 0 否 (跳至 C1) <input type="checkbox"/> 999 不知道 (跳至 C1)
B9 您的直系亲属中是否患有糖尿病、高血压疾病? Is there the family history of hypertension or diabetes in children's immediate family members	<input type="checkbox"/> 1 是 (继续回答 B8) <input type="checkbox"/> 0 否 (跳至 C1) <input type="checkbox"/> 999 不知道 (跳至 C1)
B10 若有, 请选择出该亲属与您的关系 (可多选) If so, please choose the relationship with the child	

1. 父亲    2. 母亲    3. 爷爷    4. 奶奶    5. 兄弟    6. 姐妹

### C 叶酸使用

C1 在您末次月经前三个月内，您是否服用过叶酸？ Did you take folic acid in the month before your last period?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否		
C2 在您末次月经之后至今，您是否服用过叶酸？ Did you take any folic acid after your last period and during pregnancy ?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否		
	叶酸 1	叶酸 2	叶酸 3
C3 药物名称(商品名) Brand name			
C4 使用时间 When did you take it?	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always
C5 是否在怀孕期间一直使用？ Did you take it during the rest of your pregnancy?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C6 是否停止使用过？ Did you stop taking it?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C7 使用频率？ How often did you take it?	____次/□天 □周 □月	____次/□天 □周 □月	____次/□天 □周 □月
C8 每次的使用量 What is the usage per time?	一次____片	一次____片	一次____片

### D 维生素使用

D1 在您末次月经的前三个月内，您是否服用过维生素？ Did you take any vitamins in the three months before your last period ?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否		
D2 在您末次月经之后至今，您是否服用过维生素？ Did you take any vitamins after your last period and during pregnancy?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 (跳至 E1)		
	维生素 1	维生素 2	维生素 3
D3 维生素名称 Vitamin name			
D4 维生素商品名称 Brand name			



D5 是否是医生给药? Did your doctor give it to you?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
D6 是否包括叶酸? Does it contain folic acid?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道
D7 使用时间 When did you take it?	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always
D8 是否停止使用过? Did you stop taking it?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
D9 使用频率? How often did you take it?	____次/□天 □周 □月	____次/□天 □周 □月	____次/□天 □周 □月
D10 每次的使用量 What is the usage per time?	一次____片	一次____片	一次____片

### E 其他营养补充剂使用情况 Other nutritional supplement use

营养补充剂种类 Nutritional supplement types	铁 Fe	钙 Ca	锌 Zn
您在近三个月是否服用 Did you take it around the time you became pregnant?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂? (如果没有, 选项请在其他处写明) Brand name	<input type="checkbox"/> 1、汤臣倍健叶酸亚铁片 <input type="checkbox"/> 2、安利纽崔莱铁片 <input type="checkbox"/> 3、金康倍叶酸铁片 <input type="checkbox"/> 4、其他_____	<input type="checkbox"/> 1、惠氏金钙尔奇 <input type="checkbox"/> 2、君宝康孕妇钙片 <input type="checkbox"/> 3、十月妈咪维生素 AD 钙锌咀嚼片 <input type="checkbox"/> 4、安利钙镁片 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、美康利健 MK 硒金牡蛎锌片 <input type="checkbox"/> 2、汤臣倍健 锌咀嚼片 <input type="checkbox"/> 3、宫诺肽片 <input type="checkbox"/> 4、其他_____
您这三个月的服用频率? (如果食用频率小于每天/周一一次, 请填写每周/月食用几次, 并勾出周/月) How often did you take it?	____次/□天 □周 □月	____次/□天□周□月	____次/□天 □周 □月

## F 草本药物使用

F1 在您末次月经前三个月内，您是否使用过任何一种草本药物/传统医学药物？ Did you take any herbal supplements/traditional Chinese medicine in the three months before your last period □ 1 是 □ 0 否			
F2 在您末次月经之后，您是否使用过任何一种草本药物/传统医学药物 Did you take any herbal supplements/traditional Chinese medicine after your last period and during pregnancy? ? □ 1 是 □ 0 否 (跳至 F1)			
	草本药物 1 Herbal 1	草本药物 2 Herbal 2	草本药物 3 Herbal 3
F3 草本药物类型 Name of herb	□ 1 中成药 □ 2 中医草药	□ 1 中成药 □ 2 中医草药	□ 1 中成药 □ 2 中医草药
F4 药物名称(如果选择中医草药，请填写中药功效) The use of traditional Chinese medicine			
F5 用药持续多少天 How long did you take in?	_____天	_____天	_____天

## G 吸烟情况

G1 您在怀孕前或者怀孕期间吸烟吗？ Did you smoke cigarettes before or during your pregnancy with the baby?	□ 1 是	□ 0 否(跳至 F9)
G2 在您末次月经的当月，您是否吸烟？ Did you smoke during the month before your last menstrual period ?	□ 1 是	□ 0 否
G3 在您末次月经的一个月后（末次月经结束直至一个月后），您是否吸烟？ (跳至 5) Did you smoke during the month after your last menstrual period, that is between LMP and LMP+1 month	□ 1 是	□ 0 否
G4 如果是，您平均每天吸多少支烟？ On average, how many cigarettes did you smoke each day in the month after your last menstrual period ? 支		
G5 在您怀孕期间，您是否吸烟？ Did you smoke during your pregnancy?	□ 1 是	□ 0 否(跳至 F7)
G6 在您怀孕期间，您平均每天吸多少支烟？ On average how many cigarettes did you smoke each	_____支	

G7 在您末次月经期间至今，您是否戒过吸烟？ Did you stop smoking at any time between your last menstrual period and the end of your pregnancy?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否 (跳至 F9)
G8 您戒烟有多少次？ How many times did you stop? _____ 次		
G9 在您怀孕的大多数时间里，您是否暴露于他人烟草烟雾中？ On most days during your pregnancy, were you exposed to someone else's cigarette smoke?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否 (跳至 G1)
G10 您在哪里暴露与烟草烟雾中？ Where were you exposed to the smoke?	<input type="checkbox"/> 1 仅在家中 <input type="checkbox"/> 2 仅在工作单位 <input type="checkbox"/> 3 在家和在工作单位均暴露	

**H 酒精**

H1 在您怀孕前三个月至今，您是否饮用过任何含有酒精的饮料？ During the 3 months before or during your pregnancy, did you ever drink any alcoholic beverages?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否
H2 在这三个月内，您通常每次饮几杯酒？ On those days that you drank, how many drinks did you have?	_____ 杯	

**I 环境暴露情况**

I1 怀孕前三个月到现在，您是否染烫发？ Did you dye perm in the first three months of pregnancy?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否
I2 怀孕前三个月到现在，后您工作的地点或家里是否装修过？ Did you exposed to formaldehyde in the first three months of pregnancy?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否
I3 怀孕前后您是否接触过下列物质？ Have you been exposed to the following substances before and after pregnancy? (Toxic chemicals)	<input type="checkbox"/> 1 除草剂 <input type="checkbox"/> 2 杀虫剂 <input type="checkbox"/> 3 灭鼠剂 <input type="checkbox"/> 4 有机溶剂 <input type="checkbox"/> 5 消毒剂 <input type="checkbox"/> 6 金属制剂 <input type="checkbox"/> 7 有害气体 <input type="checkbox"/> 8 有害固体	

**J 药物使用情况**

以下问题是有关于您在末次月经之前三个月内至今期间的用药情况

	治疗高血压 药物 Medication for hypertension	胰岛素 Insulin for diabetes	口服降血糖 药物 Oral hypoglycemic for diabetes	抗癫痫药物 Medications for epilepsy	每天都要服用 的药物 Medications at least once a day
1 您是否使用过？ Did you take?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
2 您使用的药物 名称？ What	_____	_____	_____	_____	_____

did you take?						
<b>如果下一个问题令您感到不安且不愿意回答，请在“拒答”上打√，我们将对您所有回答进行严格保密!</b>						
	安定\有助于 您放松药物 Valium\drugs to help you relax	使您感觉良 好\精力旺盛 Make you feel good\have more energy	美沙酮\氧可酮\ 其他止痛药 Methadone oxymoron\other pain killers	可卡因 Cocaine or crack cocaine	海洛因 Heroin	大麻 Marijuana
1 您是否使用 过? Did you take?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚
2 您使用的药 物名称? What did you take?	_____	_____	_____	_____	_____	_____

**I 您在怀孕期间是否患过以下疾病?**

I.3 发热性疾病及呼吸道感染 Febrile illness and respiratory infections	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
I.3.1 您发烧时的最高温度是多少? _____ °C What was the highest temperature of your fever during your illness?	
I.3.2 您发烧有几天? _____ 天 How long did you have a fever?	
I.6 其他 _____	

**调查结束，谢谢您的配合!**

调查员姓名 \_\_\_\_\_

调查日期 \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
                  年       月       日

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41


# Management of blood samples

# Recognition and Collection


## Subjects with marks need to collect the blood sample



Cohord card & Recognized label



Recruiting message



ID no checking

# Blood sample dividing

- Repacked within 6 hours after blood collection
- Serum is collected in three parts, no less than 200ul each
- 1ml of whole blood and divided it into the frozen storage tube.
- Taging the antifreezing label to the tube(red for serum & purple for whole blood)





Antifreezing label

Purple(two identical Numbers are a group)

Red (four identical Numbers are a group)

# Blood sample transportation

- Keep away from light
- **Blood samples are saved at -20 degrees in each site**
- Samples will be collected from each site every two weeks
- Guarantee -10 degrees during transportation
- **Blood samples are saved at -80 degrees in central biobank**





# BMJ Open

## Cohort profile: Shanghai PreConception Cohort (SPCC) for association of periconceptional parental key nutrition factors with health outcomes of children: I -congenital heart disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031076.R1
Article Type:	Cohort profile
Date Submitted by the Author:	09-Aug-2019
Complete List of Authors:	Zhang, Yi; Children's Hospital of Fudan University Wang, Dingmei; Children's Hospital of Fudan University Jiang, Yuang; Children's Hospital of Fudan University Ye, Ying; Clinical Epidemiology Ji, Mi; Children's Hospital of Fudan University Dou, Yalan; Children's Hospital of Fudan University, Dermatology Chen, Xiaotian; Children's Hospital of Fudan University Li, Mengru; Children's Hospital of Fudan University Ma, Xiaojing ; Children's Hospital of Fudan University Sheng, Wei; Children's Hospital of Fudan University Huang, Guoying; Children's Hospital of Fudan University, Pediatric Heart Center Yan, Weili; Children's Hospital of Fudan University,
<b>Primary Subject Heading</b>:	Research methods
Secondary Subject Heading:	Public health, Obstetrics and gynaecology, Nutrition and metabolism
Keywords:	red blood cell folate, vitamin, congenital heart diseases, periconceptional health care

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **1 Cohort profile: Shanghai PreConception Cohort (SPCC) for**  
5  
6  
7 **2 association of periconceptual parental key nutrition factors with**  
8  
9  
10 **3 health outcomes of children: I -congenital heart disease**

11  
12 4 Yi Zhang\*<sup>1,2</sup>, Dingmei Wang\*<sup>1,2</sup>, Yuan Jiang<sup>1,2</sup>, Ying Ye<sup>1,2</sup>, Mi Ji<sup>1,2</sup>, Yalan  
13  
14  
15 5 Dou<sup>1,2</sup>, Xiaotian Chen<sup>1,2</sup>, Mengru Li<sup>1,2</sup>, Xiaojing Ma<sup>1,2</sup>, Wei Sheng<sup>1,2</sup>,  
16  
17  
18 6 Guoying Huang<sup>1,2</sup>#, Weili Yan<sup>1,2</sup>#; SPCC group

19  
20 7 1 Department of Clinical Epidemiology & Clinical Trial Unit (CTU),  
21  
22  
23 8 Children's Hospital of Fudan University, Shanghai, China.

24  
25 9 2 Shanghai Key Lab of Birth Defect, Children's Hospital of Fudan University,  
26  
27  
28 10 Shanghai, China.

29  
30  
31 11  
32  
33 12 \* Contributed equally to this work.

34  
35  
36 13 # Co-corresponding author.

37  
38  
39 14 A full list of SPCC group can be found after Acknowledgements.

40  
41  
42  
43 15 Weili Yan, PhD

44  
45  
46 16 86-21-64931215

47  
48  
49 17 Email: yanwl@fudan.edu.cn

50  
51  
52 18 Guoying Huang, MD PhD

53  
54  
55 19 86-21-64931913

56  
57  
58 20 Email: gyhuang@shmu.edu.cn  
59  
60

## 1 ABSTRACT (293)

2 **Purpose:** The Shanghai PreConception Cohort (SPCC) was established  
3 initially to investigate associations of parental periconceptional nutritional  
4 factors with congenital heart disease (CHD), and has extended to children  
5 growth, development and pediatric diseases.

6 **Participants** Prepare-for-pregnant couples who presented at Shanghai pre-  
7 conception examination clinics and early-pregnant women before 14  
8 gestational weeks were enrolled to comprise a periconceptional baseline  
9 study population. General characteristics, routine clinical data, consumption  
10 of diet supplements, such as folic acid and multivitamins, were collected.  
11 Blood samples were collected at pre-conception, early, middle and late  
12 gestation respectively by standard procedures. Multiple nutrition factors in  
13 blood sample of participants that were selected by case-control design will  
14 be examined, including folates, homocysteine, vitamin A, vitamin D,  
15 vitamin E and metals. Genomic DNA was extracted.

16 **Findings to date** The baseline population included 8045 preconceptional  
17 couples, 3054 single women, and 15 615 early-pregnant women,  
18 respectively. Birth data from 12 402 births were collected and follow-up of  
19 the cohort for more outcomes is ongoing. Currently, 151 CHDs were  
20 identified after birth. Pilot analysis in a small subgroup showed that only  
21 about 15% of 656 pre-conception women and 49% of early-pregnant women  
22 had red blood cell folate concentration meeting the international  
23 recommendation for preventing neural tube defects.

### 24 **Future plans**

25 Once a sufficient number of CHD cases is achieved, we will investigate  
26 quantitative association of preconceptional red blood cell folate levels with  
27 CHD using nested case-control design. The SPCC cohort will be followed  
28 up for 18 years to investigate extensive outcomes of growth, development,  
29 obesity, and common and rare diseases during childhood and adolescence  
30 according to our plan. Blood nutrition factors will be examined in  
31 participants selected for specific aims. The SPCC cohort will also allow for  
32 prospective cohort studies on extensive research questions.

33 **Trial registration number:** NCT 02737644.

34 **Key Messages:** red blood cell folate, vitamin, congenital heart diseases,  
35 periconceptional health care.

### Strengths and limitations of this study

- The SPCC cohort is the first prospective birth cohort with CHD as primary outcome with recruitment starting from preconception stage. Temporal sequence of exposures and outcomes can be achieved for causal inference of birth defects and other diseases that occur during early stage of gestation.
- Preconception blood samples were appropriately collected and stored which allow examination of individual blood levels for nutrition factors and other exposures.
- Clinical data and blood samples from both father and mother from before conception were collected, which will allow for testing the effect of both maternal and paternal genetic and nutrition factors on fetal and children diseases.
- Although response rate was high (over 95%), pre-conception participants were recruited from the population who voluntarily presented at Shanghai city pre-conception physical examination sites. They may have a stronger willingness for a healthy pregnancy, which may induce selection bias.
- Biological samples (cord blood, placenta) of the newborns were not collected.

view only

## 1 Introduction

2 Congenital heart disease (CHD) is a common congenital malformation,  
3 which seriously affects quality of children's life [1]. CHD is a leading cause  
4 of infant death in high-income countries affecting eight of 1000 live births  
5 [2]. According to the report from National Health and Family Planning  
6 Commission of the People's Republic of China, CHD accounts for about a  
7 quarter of the birth defects of newborns in China, ranking the first among  
8 birth defects[3]. In a prospective, nation-wide large-scale study in more than  
9 120 000 newborns in China in 2013, the prevalence of CHD in live births  
10 was identified 8.94 ‰; the rate of severe CHD was 2.9 ‰[4].

11 The cause of CHD is multifactorial. With the development of genetic  
12 engineering technology, the genetic factors have been better understood in  
13 the past decade[5]. Multiple environmental risk factors have been reported  
14 in epidemiological studies, the maternal social variables such as occupation,  
15 educational background, health status, unhealthy life style, maternal medical  
16 history and emotional status, family history of disease, consanguineous  
17 marriages and so on [6-10]. In addition, maternal key nutrients related to the  
18 risk of offspring's CHD as a modifiable environmental factor during  
19 periconception [11, 12]. The periconceptional intake of folic acid  
20 supplement has been shown to reduce the risk of CHD [13, 14] and women  
21 worldwide have been recommended to take folic acid supplements before

1  
2  
3  
4 1 conception and in the beginning of pregnancy. Awareness of the relationship  
5  
6  
7 2 between folic acid deficiency and CHD is actually a by-product finding from  
8  
9  
10 3 the well-known Hungarian RCT study of folic acid supplementation to  
11  
12 4 prevent neural tube defects. The study found that prenatal supplementation  
13  
14  
15 5 with a vitamin complex containing 0.8 mg of folic acid daily reduced the  
16  
17  
18 6 incidence of congenital neural tube defects. At the same time, the incidence  
19  
20  
21 7 of various heart defects have also been reduced by nearly half[15].  
22  
23  
24 8 Longitudinal data from more than one million births in Canada over a total  
25  
26  
27 9 of 22 years from 1990 to 2011 also show that food fortification with folic  
28  
29  
30 10 acid reduced risk of CHD by 20-30% [16]. The current folic acid  
31  
32  
33 11 supplementation recommends that all women of childbearing potential be  
34  
35  
36 12 supplemented with at least 0.4 mg folic acid daily prior to conception and  
37  
38  
39 13 during pregnancy, which is designed for preventing neural tube  
40  
41  
42 14 dysplasia[17]. However, excessive folic acid intake may increase the risk of  
43  
44  
45 15 cancer[18], vitamin B12 deficiency[19], and autism spectrum disorder[20].  
46  
47  
48 16 The optimal dose of folic acid for preventing CHD warrants further  
49  
50  
51 17 investigation. In addition, most previous studies only focused on the  
52  
53  
54 18 supplement of folic acid or the serum folate level during or after pregnancy,  
55  
56  
57 19 which may not be the optimal time period and way to reflect the exposure  
58  
59  
60 20 level to risk of CHD.

21 To investigate the association between parental periconceptual key

1 nutritional factors such as folate with the development of CHD and to  
2 explore the cutoff biomarker levels, we conducted Shanghai PreConception  
3 Cohort (SPCC) and a nested case-control analysis.

4 The SPCC cohort was initiated primarily to study CHD. However, based  
5 on the strengths of its baseline data collection, it has received attention and  
6 support, with improved additional extensive outcomes for children that will  
7 be followed up longer term.

### 8 **Who is in the cohort?**

9 The SPCC cohort recruited parent-planning women and men who were  
10 permanent residents and who voluntarily presented at preconception clinical  
11 clinics at 28 maternity institutions in 10 districts of Shanghai (Minhang  
12 District, Huangpu District, Xuhui District, Changning District, Jing'an  
13 District, Putuo District, Yangpu District, Pudong District, Songjiang  
14 District, Qingpu District) from March 2016 to December 2018. The  
15 preconception examination policy in the city of Shanghai provides a unique  
16 opportunity and clinical resources to support recruitment of SPCC. Since  
17 2010, married couples in Shanghai have been encouraged to attend a free  
18 preconception health examination. In addition, these maternity institutions  
19 receive strong local administrative support and integrated maternal health  
20 care networking, providing service to 150 000–200 000 annual deliveries in  
21 Shanghai. Couples living in Shanghai who present at preconception clinics,

1 who are preparing for pregnancy within one year, who plan to receive  
2 antenatal care and deliver in Shanghai were eligible for the study. Written  
3 informed consent was obtained from all study participants before any data  
4 collection. In addition, we recruited early-pregnant women at their first  
5 antenatal examination who were at gestational week <14 weeks. These two  
6 groups of participants comprised a periconceptual baseline study  
7 population.

8 The first primary outcome of the SPCC cohort is CHD. The hypothesis is  
9 that maternal pre-conceptual serum or red blood cell (RBC) folate  
10 concentration is quantitatively associated with offspring CHD. The study  
11 design and protocol has been registered with Clinical Trials Registry (NCT  
12 02737644).

13 As shown in Figure 1, the baseline population will be followed up to  
14 delivery, and their babies will be followed up until 18 years old (Figure 1).

### 15 **Follow-up procedure**

16 At enrollment, the participants completed the questionnaire of key nutrient  
17 supplementation and blood sample collection. When participants were  
18 pregnant, the same investigations (questionnaire/blood sample collection)  
19 were conducted during early pregnancy (first antenatal visit at 16-20  
20 gestational weeks). Pregnancies were followed up along with routine  
21 maternal health care procedures. Blood samples were also collected at the



1 second (24-28 gestational weeks) and third trimester (32-34 gestational  
2 week). The follow-up of CHD outcome and birth data was obtained through  
3 Shanghai CHD screen platform (Figure 1).

4 As shown in Figure 1, outcomes at birth, during infant to childhood  
5 (preschool phase), and between 7 to 18 years (school ages) will be collected  
6 or extracted from multiple public platforms and data sources. Firstly,  
7 preconception clinical visit data from preconception care electronic data  
8 systems supported by national and local government, including height,  
9 weight, age, infections, sexually transmitted disease, and family history were  
10 collected. Secondly, the routine pregnant data were obtained in maternal  
11 clinic antenatal medical record systems, managed by Shanghai Center for  
12 Women and Children's Health, including height, gestational weight, last  
13 menstrual period, childbearing history, delivery outcomes, infections,  
14 hematocrit, coagulation function, liver and kidney function, and so on.  
15 Thirdly, the maternal and neonatal data at delivery came from Shanghai  
16 neonatal CHD screen platform including birth weight, CHD diagnosis, birth  
17 defects, and Apgar score, etc. In addition, we will work with the Shanghai  
18 Student Health and Fitness Surveillance Center to obtain outcome data. The  
19 personal national identification card number of participants are applied as  
20 index variables through the multiple data sources. The detailed variable list  
21 and codebook of data collection is presented in Appendix 1.

1  
2  
3  
4 1 During the first phase of the cohort, from preconception to delivery,  
5  
6  
7 2 comprehensive strategies were used to retain participants in the study. For  
8  
9  
10 3 mothers, we provided a variety of engagement activities including green  
11  
12 4 channel (fast track) to their antenatal care to provide convenience and save  
13  
14  
15 5 their time in hospitals. We also provided a contact number on the participant  
16  
17  
18 6 card to answer their calls or queries about the study procedures. Site  
19  
20  
21 7 investigators at early pregnant clinics in collaborative hospitals were  
22  
23 8 provided a smartphone APP to help identify recruited cohort participants  
24  
25  
26 9 timely and manage data and blood sample collection procedures. We also  
27  
28  
29 10 provided green channel echocardiography for diagnosing CHD for all site  
30  
31  
32 11 hospitals to enhance the compliancy of the participants. In addition, an  
33  
34 12 automated text message system is adopted to remind participants of  
35  
36  
37 13 schedules and appointment of follow-up.

## 39 14 **Study measures**

### 41 15 Personal characteristics questionnaires

42  
43  
44 16 As shown in Figure 1, Questionnaire 1 was administered during recruitment  
45  
46  
47 17 at pre-conception examination sites and Questionnaire 2 was administered at  
48  
49  
50 18 early pregnancy sites to collect information on consumption of folic acid  
51  
52  
53 19 supplement, vitamin supplement, the brand and content of nutrient  
54  
55  
56 20 supplement. Information of demographics, maternal education, socio-  
57  
58  
59 21 demographic status, occupation, smoking status, alcohol consumption, BMI,  
60

1 medication, and health status were also included. In addition to the content  
2 of Questionnaire 1, Questionnaire 2 added drug information, reproductive  
3 history, and health status. Questionnaire 1 for baseline and Questionnaire 2  
4 for the first antenatal visit at early pregnancy are presented in Appendix 2a  
5 and Appendix 2b.

### 6 Collection of blood samples

7 In this study, the rest blood samples for routine clinical examination were  
8 collected. The blood sample for routine clinical examination was usually 5  
9 ml and extracted in the morning. Routine clinical examination followed  
10 which was performed at room temperature. The rest blood samples (fasting  
11 serum and EDTA anticoagulation) of peripheral venous blood from routine  
12 laboratory examination were kept. These blood samples were temporarily  
13 stored in a 4°C refrigerator for dispensing within 6 hours and transferred to  
14 a -20 4°C. After completion of blood sample distribution the serum and the  
15 whole blood were stored at the site laboratory and then transported by three  
16 trained investigators to the central biobank for storage in -80 °C freezers  
17 within two weeks. During the collection and transfer process samples were  
18 labeled and recorded in the sample system. In order to detect chemicals  
19 (folate) that are sensitive to light sampling tubes were made of a light-proof  
20 material and the process of collecting blood samples were completely

1 protected from light.

2 Examination of key nutrition factors in blood samples

3 The examinations will be conducted in participants selected by nested case-  
4 control designs based on specific aims.

5 (1) *RBC folate, serum folate, serum homocysteine, vitamin D, vitamin B12*  
6 *and serum ferritin*

7 EDTA anticoagulation blood was collected to measure RBC folate, serum  
8 folate, serum homocysteine, vitamin D, vitamin B12 and serum ferritin  
9 assays. All six biomarkers were analyzed on an electrochemiluminescence  
10 assay (ARCHITECT i2000SR Analyzer, Abbott Laboratories, USA). A  
11 standard solution with known concentration (produced by Abbott  
12 Laboratories) was used daily to quality control before the measurement. If  
13 the quality control level was out of concentration range, the measurement  
14 would be suspended and adjusted. External quality control was carried out  
15 with the control lab data program from Abbott Laboratories (Abbott  
16 Laboratories, Shanghai, China). RBC folate concentrations were adjusted for  
17 hematocrit. If the RBC folate concentration is below 126.0 ng/ml or above  
18 651.1 ng/ml, adjustment was needed based on serum folate level. The  
19 hematocrit data were extracted from the hospital laboratory information  
20 system. Those examinations were performed in central laboratory of  
21 Children's Hospital of Fudan University.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 (2) *Vitamin A and vitamin E*

2 The serum concentration of vitamin A and vitamin E were quantitatively  
3 detected by liquid chromatography-tandem mass spectrometry in central  
4 laboratory of Children's Hospital of Fudan University. The testing  
5 instrument was triple quadrupole mass spectrometer LC/MS/MS System  
6 (NO: API 3200MDTM, ABSciex Pte.Ltd.). A standard solution of vitamin  
7 A-d6 and vitamin E-d6 were applied as internal standards.

8 (3) *Glycemic and lipid profiles*

9 Fasting serum cholesterol, high-density lipoprotein, low-density lipoprotein,  
10 triglyceride, and fasting glucose were performed on Beckman coulter AU  
11 chemistry analyzers (Beckman, USA) in central laboratory of Children's  
12 Hospital of Fudan University.

13 (4) *Metals*

14 Serum levels including Mg, Fe, Zn, Se, Mn, As, Cu and Ca, were analyzed  
15 by inductively coupled plasma mass spectrometry (ICP-MS) (Inductively  
16 Coupled Plasma Optical iCAP6300, Thermo®, USA) in standard mode [21].  
17 The metals examination was conducted in Instrumental Analysis Center of  
18 Shanghai Jiaotong University which is a national key laboratory.

19 (5) *Genomic DNA extraction*

20 Genomic DNA were extracted using a magnetic bead-based kit (TGuide  
21 M16 Automatic Nucleic Acid Extractor (OSE-M16), TIANGEN BIOTECH

1 (BEIJING) CO. LTD, China ) from 2 ml of EDTA anticoagulated whole  
2 blood sample after blood routine test and stored for future study. An average  
3 150 ng DNA are available. Similar to blood chemicals, future genetic  
4 variants genotyping will be performed in subjects that selected participants  
5 according to nested case-control design for specific aims. Currently, there  
6 are no candidate genes or variants that are listed. DNA was extracted from  
7 the EDTA anticoagulation blood samples.

#### 8 Outcomes -CHD in neonates

9 The diagnosis of CHD was the primary outcome of the study at this stage  
10 and obtained from Shanghai neonatal CHD screen network platform, which  
11 was initiated as routine screen for newborns in Shanghai since Jun 1st 2016.  
12 The standard protocol of CHD screening of the platform was previously  
13 described in detail [22]. All newborn babies received the screen by using  
14 double-index method (i.e. cardiac murmur auscultation and pulse oximetry)  
15 during 6-72 hours after delivery, and those screen-positive babies would  
16 receive a subsequent echocardiography for further confirmative diagnosis.

17 SPCC will also collect other birth defects as secondary outcomes,  
18 including Down's syndrome, neural tube defects, hydrocephalus, digestive  
19 tract malformations, urinary malformations, and behavioral cognitive  
20 developmental disorder. After delivery, the infants attended routine child  
21 care procedures organized by Shanghai child health care system which is

1 administered by Shanghai Center for Women and Children's Health. All  
2 birth defect records which were diagnosed in after birth, as well as routine  
3 neuro-development examinations and longitudinal anthropometric data were  
4 abstracted from the system by a professional clinical team from Children's  
5 Hospital of Fudan University (for details of the types of birth defect please  
6 see Appendix 3)

## 7 8 **Statistical methods**

9 To investigate the association of maternal pre-conception nutrition levels  
10 with offspring CHD risk, a nested case-control study will be conducted. The  
11 control will be matched by age and site.

12 The sample size for the nested case-control analysis was planned as 180  
13 cases and 720 matched controls to detect a maternal folate deficiency with  
14 prevalence of 50% in controls with odds ratio of 1.6 in association to achieve  
15 a power of 80% at alpha of 0.05. Based on CHD incidence above 8.94 per 1  
16 000 live births [4], 20 000 pregnancies will be needed. For a continuous  
17 nutrient variable with standard deviation 2.0, 50 matched-pairs (1:4) are  
18 required to achieve 90% power to detect an odds ratio of 1.3 calculated using  
19 conditional logistic regression with a 0.05 significance level [23, 24]. Once  
20 a sufficient number of CHD cases is achieved, the quantitative association

1  
2  
3  
4 1 of pre-conceptual RBC folate levels with CHD using nested case-control  
5  
6  
7 2 design will be investigated.  
8  
9

10 3 Conditional multivariate logistic regression will be used for association  
11  
12 4 analysis with offspring affected status of CHD being the dependent variable,  
13  
14  
15 5 nutrition factors levels as exposure and adjusted for all potential paternal and  
16  
17  
18 6 maternal covariates. Odds ratios (OR) and 95% confidence intervals (95%CI)  
19  
20  
21 7 will be reported. To explore a potential cutoff point of the nutrition levels  
22  
23  
24 8 that significantly increases the risk of CHD, a dummy variable will be set up  
25  
26  
27 9 by categorizing the maternal pre-conception nutrition levels based on the  
28  
29  
30 10 distribution of the control group. The does-response relationship will be also  
31  
32  
33 11 be analyzed. Sensitive analysis will include non-conditional logistic  
34  
35  
36 12 regression analysis, or generalized estimation equations (GEE) model, or  
37  
38  
39 13 generalized linear models when necessary.

#### 40 **FINDINGS TO DATE**

41  
42 15 The SPCC started recruitment in March 2016. As shown in Figure 2, by  
43  
44  
45 16 December 2018, we consecutively recruited 19 144/19 563 (97.9%)  
46  
47  
48 17 participants at preconception settings, including 8045 couples and 3054  
49  
50  
51 18 single women, and an additional 15 615/16 201 (96.4%) pregnant women at  
52  
53  
54 19 maternity hospitals with gestational age <16. Table 1 describes the basic  
55  
56  
57 20 demographic characteristics of the preparing-for-pregnant participants and  
58  
59  
60 21 pregnant women, respectively. The average age of the preconception



1 population was 29.9 (SD 3.9) years for females and 31.4 (SD 4.5) years for  
2 male, one-third of males and 2.4% of females were smokers, and two-thirds  
3 of males, and one-third of females had a habit of drinking alcohol. In  
4 pregnant women, the average age was 29.9 (SD 4.0) years, with half of them  
5 having a first pregnancy. Compared with the preconception females, they  
6 were similar in age but different in education levels and occupation, the  
7 prevalence of smoking and alcohol drinking were much lower (The  
8 descriptive data of Table 1 was partly included in another manuscript which  
9 is under review of Public Health Nutrition with Manuscript number of PHN-  
10 RES-2019-0914).

11 By the end of November 2018, the last participants recruited at early  
12 pregnancy were due for delivery, however, by now we have achieved birth  
13 records of 12 402 newborns. The follow-up of outcomes of the rest of the  
14 participants is ongoing (shown in Figure 2). A total of 151 cases of CHD  
15 were identified through the CHD screening platform, 131 cases of which  
16 were from the early pregnancy sample, the remaining 20 cases were from the  
17 preconception sample. The prevalence of CHD is 10.5% (131/12 402) based  
18 on the present available data.

19 We conducted a small pilot study in April 2017 to explore blood levels of  
20 nutrition factors, including serum folate, RBC folate, vitamin A, vitamin E,  
21 and vitamin D. The blood samples from 627 females were selected

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 consecutively from the preconception sample according to who was  
2 identified pregnant. In addition, 597 women who were consecutively  
3 recruited from the antenatal care clinics were selected. As shown in Table 2,  
4 the concentrations of RBC folate median level is 247.0 ng/ml (IQR: 184.8-  
5 340.5 ng/ml) in preconception women and 417.4 ng/ml (IQR: 308.6-544.2  
6 ng/ml) in early-pregnant women. Twenty percent of preconceptional  
7 participants and 44.9% of pregnant participants had a folate level over 400  
8 ng/ml, which was suggested as optimal level for preventing neural tube  
9 development defects [25, 26]. These results suggest that effort is urgently  
10 needed to improve the intake of folic acid supplementation in the prepare-  
11 for-pregnancy population, especially before pregnancy.

12 Based on SPCC, the possible scope of research questions, available types  
13 and number of biosamples and biomarkers that can be examined is shown in  
14 Table 3.

## 15 **FUTURE PLANS**

16 We have a complete plan to follow-up offspring to the age of 18 years old.  
17 The cohort will be financially supported by different grants. The current  
18 manuscript focuses on the first phase, the establishment of the baseline and  
19 our first main outcome, the CHD. The data collection plan for infants and  
20 children (from birth to 6 years old, pre-school stage), as well as school age  
21 (from 6 to 18 years old), are included (please see variable list of data

1  
2  
3  
4 1 collection plan: Appendix 4). Multiple outcomes for pediatrics, including  
5  
6  
7 2 growth, physical and neuro-developments, obesity, and common and rare  
8  
9  
10 3 diseases will be investigated. Nested case-control design will be used for rare  
11  
12 4 outcomes.  
13  
14  
15  
16  
17

## 18 **STRENGTHS AND LIMITATIONS**

19  
20 7 Compared with existing birth cohorts, there are three important strengths in  
21  
22  
23 8 our cohort. Firstly, the SPCC cohort is the first prospective birth cohort with  
24  
25  
26 9 CHD as primary outcome and recruitment starting from preconception.  
27  
28 10 Blood samples were collected and stored which allows for direct  
29  
30  
31 11 measurement of individual exposure levels before the development of CHD  
32  
33  
34 12 and make causal inference. Temporal sequence of exposures and outcomes  
35  
36  
37 13 can be achieved for causal inference of birth defects and other diseases that  
38  
39 14 occur during early stage of gestation. Up to date, no published studies have  
40  
41  
42 15 measured maternal blood folate levels before conception and link it to  
43  
44  
45 16 disease outcomes. Secondly, this cohort also allows for the investigation of  
46  
47  
48 17 associations between periconceptional maternal and paternal nutrition  
49  
50 18 exposures with other birth defects, early onset-diseases, and neuro-  
51  
52  
53 19 development outcomes. Preconception blood samples were appropriately  
54  
55  
56 20 collected and stored which allows for the examination of individual blood  
57  
58 21 levels of nutrition factors and other exposures. Thirdly, both paternal and  
59  
60

1  
2  
3  
4 1 maternal clinical data and blood samples before conception were collected,  
5  
6  
7 2 which will allow for testing effect of both maternal and paternal genetic and  
8  
9  
10 3 nutrition factors to fetal and children diseases.

11  
12  
13 4 Two limitations of this cohort study should be considered. Firstly, there  
14  
15  
16 5 are approximately 200 000 pregnant women giving birth every year in  
17  
18  
19 6 Shanghai, and approximately 20 000 of them will take part in the free  
20  
21  
22 7 preconceptional care in Shanghai, where participants were recruited  
23  
24  
25 8 consecutively. Although response rate was high (over 95%), pre-conception  
26  
27  
28 9 participants were recruited from a population voluntarily present in Shanghai  
29  
30  
31 10 city with pre-conception physical examination sites, who may have a  
32  
33  
34 11 stronger willingness for a healthy pregnancy. This may induce selection bias.  
35  
36  
37 12 Secondly, in this study, biological samples (cord blood, placenta) of the  
38  
39  
40 13 newborns are not collected. We plan to give new informed consent to the  
41  
42  
43 14 family who are willing to participate in future studies, to collect biological  
44  
45  
46 15 samples not mentioned before. In addition, electrochemiluminescence assay  
47  
48  
49 16 was used to examine serum and RBC folate concentrations, which is  
50  
51  
52 17 different from microbiologic assay that is used widely. This will not bias the  
53  
54  
55 18 association analysis but comparison with international populations needs  
56  
57  
58 19 caution.

## 20 21 **Collaboration**

1  
2  
3  
4 1 Investigators with an interest in hypotheses related to SPCC (and that meet  
5  
6  
7 2 the requirements of current approvals) are welcome to contact Dr. Guoying  
8  
9  
10 3 Huang or Weili Yan. A 'Research Collaboration application' should be send  
11  
12 4 to the corresponding author by Email. The application should include a brief  
13  
14  
15 5 description of the project.  
16  
17  
18 6  
19  
20 7  
21  
22  
23 8  
24  
25 9  
26  
27  
28 10  
29  
30 11  
31  
32  
33 12  
34  
35 13  
36  
37 14  
38  
39 15  
40  
41 16  
42  
43 17  
44  
45 18  
46  
47 19  
48  
49 20  
50  
51 21  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## 1 **Acknowledgements**

2 We are extremely grateful to all the participants who took part in this study,  
3 the doctors for their help in recruiting them, and the whole SPCC team,  
4 which includes interviewers, computer and laboratory technicians, clerical  
5 workers, research scientists, volunteers, managers, receptionists, and nurses.

## 7 **SPCC group**

8 Gouying Huang, Weili yan, Xiaojing Ma, Weifen Luo, Wei Sheng, Yi Zhang,  
9 Yuan Jiang, Yin Ye, Dingmei Wang, Xiaotian Chen, Mengru Li, Mi Ji,  
10 Yumei Liu, Gu Qing(s), Gu Qing(o), Linmei Zhu, De'ai Hou, Peiyu Sun.  
11 (Children's Hospital of Fudan University, Shanghai, China), Hongbing  
12 Wang, Li Meng, lin Zhang (Jingan Maternal and Child Health Center), Zifen  
13 Dai, Li fen (Shanghai First Maternity and Infant health Hospital), Shufang  
14 Chen, Zhenhua Tang, Jiahao Wu (International Peace Maternal and Child  
15 Health Hospital), Shuhua Wang, Dan li, Hui Wang (Xuhui Maternal and  
16 Child Health Center), Yu Ke, Weiping Cao, Baoren Zhang, Hong Huang  
17 (Shanghai Pudong New Area Health Care Hospital for Women & Children),  
18 Nailing Wang, Min Jiang, Jie Chen, Qiumin Xia (Shanghai Punan Hospital  
19 of Pudong New District), Hui Xu, Guoying Lao (Changning Maternity and  
20 Infant Health Hospital), HongMei Jin, Wenjuan Xie, Pin Yi (Qingpu  
21 Hospital, Zhongshan Hospital), Weiming Gong, JianXin Xu, Yingying Qian

1 (Shanghai Qingpu Maternal and Child Health Center), Mingjie Luo, Jingwei  
2 Xia, Dongmei Chen, Zhenyu Tang (Shanghai Huangpu Maternal and Child  
3 Health Center), Xuejing Zhu, Qing Liu, Huiling Yang (Shanghai Huangpu  
4 Maternal and Child Health Hospital), Xiaotian Li, Zhiyong Wu, Chuanmin  
5 Ying, Shan Shi (Obstetrics & Gynecology Hospital of Fudan University  
6 (Shanghai Red House Ob & Gyn Hospital)), Yanquan Zhang, Mingyi Yang  
7 (Wujing Hospital, Minhang District, Shanghai), Xiaohua Zhang, Lei Zhang,  
8 Lin Guan (Shanghai Minhang District Maternal and Child Health Care  
9 Hospital), Jinyu Xu, Honglin Wang, Fang Shen (The Fifth People's Hospital  
10 of Shanghai, Fudan University), Wenying Li, Xiaojing Teng, Jinling Zhao  
11 (Shanghai Minhang TCM Hospital), Cuili Zhu, Lan Wang, Hongwei Chen  
12 (Shanghai Songjiang District Central Hospital), Xiaoming Yuan, Meihua  
13 Zhang, Yaqiong Jin (Sijing Hospital, Songjiang District, Shanghai), Qing  
14 Yang, Hong Zhu, Min Feng (Songjiang Maternal and Child Health Center),  
15 Ying Wang, Yan Wu, Hong Tang (Songjiang Maternal and Child Health  
16 Hospital), Sa Guo (Tongji Hospital of Tongji University), Hongling Du  
17 (Shanghai Putuo District People's Hospital), Yuhuan Liu, Zhanyue Yi,  
18 Renhua Shi (Changhai Hospital, Second Military Medical University,  
19 Shanghai), Yu Gu, Qinfen Su, Yingying lv (Shanghai Zhabei District Central  
20 Hospital), Yun Sun, QiongPei Gu (Yangpu District Family Planning Service

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Center), Xixia Pang, Qingwu Zhang (Kong Jiang Hospital of Yangpu  
2 District, Shanghai), Songxiao Bai, Baoqiao Qi (Shanghai East City Hospital).

3  
4 **Contributors:** Substantial contributions to the conception or design of the  
5 work were made by GH and WY. YZ and DW prepared the original draft of  
6 the manuscript. YZ, DW, YY, JY, ML, MJ, YD and XC led study  
7 implementation at participating sites. DW and YZ were responsible for the  
8 day-to-day project management at each site. XM and WS were responsible  
9 for the biobank of the cohort. All authors provided critical review of the  
10 manuscript for important intellectual content and approved the final version.

11  
12 **Funding:** This work is supported by National key research and development  
13 program (Grant No: 2016YFC1000506) and Natural Science Foundation of  
14 China (Grant No: 81273168). Three-year Planning for Strengthening the  
15 Construction of Public Health System in Shanghai (GWIV-24).

16  
17 **Patient and public involvement:** No patient involved.

18  
19 **Conflict of interest:** The authors have no conflicts of interest.



1  
2  
3  
4 1 **Ethics approval:** This study was approved by Ethics Committee of  
5  
6  
7 2 Children's Hospital of Fudan University, Shanghai, China.  
8  
9

10 3  
11  
12 4 **Provenance and peer review** Not commissioned; externally peer reviewed.  
13  
14  
15 5

16  
17 6 **Data sharing statement:** The study data are not freely available due to  
18  
19 7 confidentiality reasons, but the research team welcomes potential  
20  
21 8 collaboration with other researchers. For further information, contact the  
22  
23 9 author GH (gyhuang@shmu.edu.cn)  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Mahle WT, Newburger JW, Matherne GP, Smith FC, Hoke TR, Koppel R, Gidding SS, Beekman RH, 3rd, Grosse SD, American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young CoCN *et al*: **Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics.** *Circulation* 2009, **120**(5):447-458.
2. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW: **Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis.** *J Am Coll Cardiol* 2011, **58**(21):2241-2247.
3. China MoPHo: **China's birth defects prevention report.** In. Edited by China MoPHo. Beijing; 2012.
4. Zhao QM, Ma XJ, Ge XL, Liu F, Yan WL, Wu L, Ye M, Liang XC, Zhang J, Gao Y *et al*: **Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study.** *Lancet* 2014, **384**(9945):747-754.
5. Bruneau BG: **The developmental genetics of congenital heart disease.** *Nature* 2008, **451**(7181):943-948.
6. Alverson CJ, Strickland MJ, Gilboa SM, Correa A: **Maternal smoking and congenital heart defects in the Baltimore-Washington Infant Study.** *Pediatrics* 2011, **127**(3):e647-653.
7. Lee LJ, Lupo PJ: **Maternal smoking during pregnancy and the risk of congenital heart defects in offspring: a systematic review and metaanalysis.** *Pediatr Cardiol* 2013, **34**(2):398-407.
8. Shi M, Wehby GL, Murray JC: **Review on genetic variants and maternal smoking in the etiology of oral clefts and other birth defects.** *Birth Defects Res C Embryo Today* 2008, **84**(1):16-29.
9. Kuciene R, Dulskiene V: **Selected environmental risk factors and congenital heart defects.** *Medicina (Kaunas)* 2008, **44**(11):827-832.
10. Carmichael SL, Shaw GM: **Maternal life event stress and congenital anomalies.** *Epidemiology* 2000, **11**(1):30-35.
11. Czeizel AE: **Periconceptional folic acid-containing multivitamin supplementation for the prevention of neural tube defects and cardiovascular malformations.** *Ann Nutr Metab* 2011, **59**(1):38-40.
12. Botto LD, Mulinare J, Erickson JD: **Occurrence of congenital heart defects in relation to maternal multivitamin use.** *Am J Epidemiol* 2000, **151**(9):878-884.
13. Ionescu-Ittu R, Marelli AJ, Mackie AS, Pilote L: **Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada.** *Brit Med J* 2009, **338**.
14. Liu SL, Joseph KS, Luo W, Leon JA, Lisonkova S, Van den Hof M, Evans J, Lim K, Little J, Sauve R *et al*: **Effect of Folic Acid Food Fortification in Canada on Congenital Heart Disease Subtypes.** *Circulation* 2016, **134**(9):647-655.
15. Czeizel AE, Dudas I: **Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation.** *N Engl J Med* 1992, **327**(26):1832-1835.
16. Liu S, Joseph KS, Luo W, Leon JA, Lisonkova S, Van den Hof M, Evans J, Lim K, Little J, Sauve R *et al*: **Effect of Folic Acid Food Fortification in Canada on Congenital Heart Disease Subtypes.** *Circulation* 2016, **134**(9):647-655.
17. Cordero AM, Crider KS, Rogers LM, Cannon MJ, Berry RJ: **Optimal serum and red blood cell folate concentrations in women of reproductive age for prevention of neural tube defects: World Health Organization guidelines.** *MMWR Morb Mortal Wkly Rep* 2015, **64**(15):421-423.
18. Kim YI: **Will mandatory folic acid fortification prevent or promote cancer?** *Am J Clin Nutr* 2004, **80**(5):1123-1128.
19. Selhub J, Rosenberg IH: **Excessive folic acid intake and relation to adverse health outcome.** *Biochimie* 2016, **126**:71-78.
20. Wiens D, DeSoto MC: **Is High Folic Acid Intake a Risk Factor for Autism?-A Review.** *Brain Sci* 2017, **7**(11).
21. Bolann BJ, Distant S, Morkrid L, Ulvik RJ: **Bloodletting therapy in hemochromatosis: Does it affect trace element homeostasis?** *J Trace Elem Med Biol* 2015, **31**:225-229.
22. Hu XJ, Ma XJ, Zhao QM, Yan WL, Ge XL, Jia B, Liu F, Wu L, Ye M, Liang XC *et al*: **Pulse Oximetry and Auscultation for Congenital Heart Disease Detection.** *Pediatrics* 2017, **140**(4).

- 1  
2  
3  
4 1 23. Lachin JM: **Sample size evaluation for a multiply matched case-control study using the score**  
5 2 **test from a conditional logistic (discrete Cox PH) regression model.** *Stat Med* 2008, **27**(14):2509-  
6 3 2523.  
7 4 24. Tang YQ: **Comments on 'Sample size evaluation for a multiply matched case-control study using**  
8 5 **the score test from a conditional logistic (discrete Cox PH) regression model'.** *Stat Med* 2009,  
9 6 **28**(1):175-177.  
10 7 25. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM: **Folate levels and neural tube defects.**  
11 8 **Implications for prevention.** *JAMA* 1995, **274**(21):1698-1702.  
12 9 26. Tam C, McKenna K, Goh YI, Klieger-Grossman C, O'Connor DL, Einarson A, Koren G:  
13 10 **Periconceptual folic acid supplementation: a new indication for therapeutic drug monitoring.**  
14 11 *Ther Drug Monit* 2009, **31**(3):319-326.  
15 12  
16 13  
17  
18  
19 14

For peer review only

**Table 1. Socio-demographics of participants including 6,573 couples (parents) and 15,203 pregnant women that were enrolled in the Shanghai PreConception Cohort (SPCC).**

Characteristics	Couples (parents) who completed preconception questionnaires				Additional pregnant women who completed both preconception and first-trimester questionnaires		P*
	Male (n=6573)		Female (n=9243)		Pregnant women (n=15203)		
Age (years), Mean±SD	6573	31.4±4.5	9243	29.9±3.9	15203	29.9±4.0	0.995
Ethnicity	6536		9188		15176		0.258
Han Nationality		6403 (98%)		8966 (97.6%)		15245 (97.8%)	
Other		133 (2%)		222 (2.4%)		342 (2.2%)	
Educational level	6530		9147		15143		<0.001
<College		514 (7.8%)		795 (8.7%)		2052 (13.6%)	
≥College		6016 (92.2%)		8352 (91.3%)		13091 (86.4%)	
Annual household income	6530		9147		NA		
< ¥10 000		1424 (21.8%)		2214 (24.2%)			
≥¥10 000		5106(78.2%)		6933 (75.8%)			
Occupation	6530		9147		14789		<0.001
Entrepreneur		157 (2.4%)		128 (1.4%)		171 (1.1%)	
Farmer		26 (0.4%)		46 (0.5%)		79 (0.5%)	
Self-employed		216 (3.3%)		274 (3%)		862 (5.6%)	
Manager		1410 (21.6%)		1765 (19.3%)		2650 (17.2%)	
Technician		2462 (37.7%)		1903 (20.8%)		3239 (20.6%)	

Company clerk		2259 (34.6%)		5031 (55%)		8451 (54.7%)	
Attending preconception pregnant examination	NA		NA		14996		—
Yes						3374 (22.5%)	
No						11622 (77.5%)	
Times of pregnancy	NA		NA		15162		
1						7569 (49.9%)	
2						4604 (30.4%)	
>=3						2989 (19.7%)	
Miscarriage or stillbirth	NA		NA		15159		
Yes						4838 (31.2%)	
No						10385 (68.7%)	
Smoking history	6552		9212		15159		<0.001
Yes		2073 (31.6%)		218 (2.4%)		153 (1.0%)	
No		4479 (68.4%)		8994 (97.6%)		15006 (99%)	
Alcohol Drinking history	6448		9075		15164		<0.001
Yes		3962 (61.5%)		2865 (31.6%)		1556 (10.3%)	
No		2486 (38.5%)		6210 (68.4%)		13608 (89.7%)	
Location of home	6573		9243		NA		
Developed districts		3034 (46.2%)		5452 (59.0%)			
Developing districts		3539 (53.8%)		3791 (41.0%)			

\* Comparisons between pre-conception females and pregnant women.

**Table 2. Distributions of biomarkers in women before and at early gestation (pilot study)**

Biomarker	PreConception		Early pregnancy	
	n	level	n	level
Serum folate, ng/ mL	620	9.7(6.5, 13.8)	577	14.5(11.2, 16.4)
RBC folate, ng/ mL	570	247.0(184.8, 340.5)	587	417.4(308.6, 544.2)
Homocysteine, $\mu$ mol/L	624	6.5(5.2, 8.6)	599	4.2(3.5, 5.2)
Vitamin B12, pg/mL	625	495.2(394.2, 639.0)	600	388.5(289.4, 511.4)
Vitamin D, ng/ mL	607	16.3 $\pm$ 6.0	578	15.5 $\pm$ 6.1

**Table 3. Biosample collected and biomarkers that can be examined in the SPCC cohort**

Biosample Available in participants	Available Sample type and volume	Time		
		Preconception+early pregnancy (Baseline)	24-28 weeks	32-36 weeks
<b>Mother</b>		(n=25487)	(n=8668)	(n=7522)
	Serum, 200 ul*3	Yes	Yes	Yes
	Whole blood	Yes	Yes	Yes
	Genomic DNA, 150 ng	Yes	Yes	Yes
<b>Father</b>		(n= 7151)	-	-
	Serum, 200 ul*3	Yes	NA	NA
	Whole blood	Yes	NA	NA
	Genomic DNA, 150 ng	Yes	NA	NA
<b>Child</b>	NA			

**Scope of research questions:**

1. Quantitative association of pre-conceptual key nutrition levels (such as serum and RBC folates and related biomarkers, such as homocysteine and vitamin B12) with CHD, currently, and other folate sensitive birth defects.
2. Quantitative association of periconceptual maternal and paternal key nutrition levels (preconception levels, and dynamic levels during gestation) with important maternal and neonatal gestational complications, neuro-development of infants, childhood obesity, and clinical pediatric diseases.
3. Periconceptual maternal and paternal folate concentration with Autism spectrum disorder, allergy and asthma in children.

**Biomarkers that will be examined in different types of biosamples:**

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
1. Biomarkers based on serum sample:
    - a) Folate and related markers: serum folate, homocysteine
    - b) Other Vitamins: vitamin A, vitamin B12, vitamin E, and vitamin D
    - c) Macro and micro metals: Mg, Fe, Zn, Se, Mn, As, Cu, Ca, etc., mg/L
    - d) Serum ferritin
    - e) Fasting glycaemic and lipid profiles: fasting glucose, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein
  2. Whole blood sample: RBC folate
  3. Genomic DNA sample: candidate genetic variants or genome-wide variants are all possible to be examined



1  
2  
3  
4  
5 Figure 1 Diagram of the protocol and follow-up of Shanghai PreConceptional Cohort (SPCC)  
6

7  
8 Frame of SPCC cohort protocol. The baseline population of SPCC cohort were females and males at periconception  
9  
10 stage: couples who are prepare-for-pregnancy, and pregnant women at early gestation stage. The cohort includes three  
11  
12 phases, from periconception to birth (peri-natal phase), from newborns to 6 years old (birth to pre-school age), and  
13  
14 from 7-18 years (school age). The current manuscript focuses on the first phase, with congenital heart disease as the  
15  
16 primary outcome, and will cover other folate sensitive birth defects.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## Figure 2 Flow chart diagram

By December 2018, we consecutively recruited 19 144/19 563 (97.9%) participants at preconception settings, including 8045 couples and 3054 single women at pre-pregnancy sites, and an additional 15 615/16 201 (96.4%) pregnant women at maternity hospitals with gestational age <16 were recruited. By the end of November 2018, the last participants recruited at early pregnancy were due for delivery, by now we have achieved birth records of 12402 newborns. The follow-up of outcomes of the rest of participants is ongoing (shown in Figure 2). A total of 151 cases of CHD were identified through the CHD screening platform, 131 cases of which were from the early pregnancy sample, the remaining 20 cases were from preconception sample. The prevalence of CHD is 10.5 ‰ (131/12 402) based on the present available data.




Figure 1 Diagram of the protocol and follow-up of Shanghai PreConceptional Cohort (SPCC) Frame of SPCC cohort protocol. The baseline population of SPCC cohort were females and males at periconception stage: couples who are prepare-for-pregnancy, and pregnant women at early gestation stage. The cohort includes three phases, from periconception to birth (peri-natal phase), from newborns to 6 years old (birth to pre-school age), and from 7-18 years (school age). The current manuscript focuses on the first phase, with congenital heart disease as the primary outcome, and will cover other folate sensitive birth defects.




Figure 2 Flow chart diagram

By December 2018, we consecutively recruited 19 144/19 563 (97.9%) participants at preconception settings, including 8045 couples and 3054 single women at pre-pregnancy sites, and an additional 15 615/16 201 (96.4%) pregnant women at maternity hospitals with gestational age <16 were recruited. By the end of November 2018, the last participants recruited at early pregnancy were due for delivery, by now we have achieved birth records of 12402 newborns. The follow-up of outcomes of the rest of participants is ongoing (shown in Figure 2). A total of 151 cases of CHD were identified through the CHD screening platform, 131 cases of which were from the early pregnancy sample, the remaining 20 cases were from preconception sample. The prevalence of CHD is 10.5 ‰ (131/12 402) based on the present available data.

## Appendix 1 Variable list

<b>Pre-pregnant variable list</b>		
No	Variables	Data type
	<b>General information</b>	
1	Wife id	Text
2	Husband nation	Text
3	Husband age	N
4	Husband education	Text
5	Husband id	Text
6	Husband occupation	Text
7	Wife nation	Text
8	Wife age	N
9	Wife education	Text
10	Wife occupation	Text
11	Tel No	Text
12	Mobile phone No	Text
	<b>Medical history</b>	
13	Female anemia	Category
14	Female EH	Category
15	Female heart disease	Category
16	Female DM	Category
17	Female epilepsy	Category
18	Female thyroid disease	Category
19	Female CGN	Category
20	Female mental disease	Category
21	Female tumour	Category
22	Female TB	Category
23	Female HBV	Category
24	Female VD	Category
25	Male anemia	Category
26	Male EH	Category
27	Male heart disease	Category
28	Male DM	Category
29	Male epilepsy	Category
30	Male thyroid disease	Category
31	Male CGN	Category
32	Male mental disease	Category
33	Male tumour	Category
34	Male TB	Category
35	Male HBV	Category
36	Male VD	Category

	<b>Vaccine</b>	
37	Female rubella vaccine	Category
38	Female hepB vaccine	Category
39	Male hepB vaccine	Category
	<b>Drug use</b>	
40	Female current medicine	Category
41	Female medicine name	Category
42	Male current medicine	Category
43	Male medicine name	Category
	<b>Childbearing history</b>	
44	Birth history	Category
45	Pregnancy times	Category
46	Live birth	Category
47	Dead fetus	Category
48	Dead birth	Category
49	Term delivery	Category
50	Premature delivery	Category
51	Natural abortion	Category
52	Abactio	Category
53	Children number	Category
54	Birth defect	Category
55	Defect type	Category
56	Menarche age	Category
57	Period menstruation	Category
58	Menstrual cycle	Category
59	Menstrual quantity	Category
60	LMP	Date
	<b>Family history of disease</b>	
61	Female family history thalassemia	Category
62	Female family history albinism	Category
63	Female family history favism	Category
64	Female family history hemophilia	Category
65	Female family history CHD	Category
66	Female family history DS	Category
67	Female family history openNTDs	Category
68	Female family history DM	Category
69	Female family history dysnoesia	Category
70	Female family history daysaudia	Category
71	Female family history viual disorder	Category
72	Female family history neuropsychiatric	Category
73	Female family history other birth defects	Category
74	Female family history fetal death	Category
75	Female family history intermarry	Category

76	Female family history relations	Category
77	Male family history thalassemia	Category
78	Male family history albinism	Category
79	Male family history favism	Category
80	Male family history hemophilia	Category
81	Male family history CHD	Category
82	Male family history DS	Category
83	Male family history openNTDs	Category
84	Male family history DM	Category
85	Male family history dysnoesia	Category
86	Male family history dysaudia	Category
87	Male family history vidual disorder	Category
88	Male family history neuropsychiatric	Category
89	Male family history other birth defects	Category
90	Male family history fetal death	Category
91	Male family history intermarry	Category
92	Male family history relations	Category
	<b>Anthroposomatology</b>	
93	Female height	Numeric
94	Female weight	Numeric
95	Female BMI	Numeric
96	Female heart rate	Numeric
97	Female SBP	Numeric
98	Female SDP	Numeric
99	Male height	Numeric
100	Male weight	Numeric
101	Male BMI	Numeric
102	Male heart rate	Numeric
103	Male SBP	Numeric
104	Male SDP	Numeric
	<b>Lab data</b>	
105	Leucorrhoea check	Numeric
106	Clue cell	Numeric
107	Monilia infection	Numeric
108	Trichomomas	Numeric
109	Cleanness	Numeric
110	Whiff test	Numeric
111	PH	Numeric
112	Wom blood analysis	Numeric
113	Female hb	Numeric
114	Female wbc	Numeric
115	Female rbc	Numeric
116	Wom urine test	Numeric

117	Female ABO	Numeric
118	Female Rh	Numeric
119	Female GLU	Numeric
120	Female GLU levels	Numeric
121	Female NG	Numeric
122	Female chlamydia	Numeric
123	Female syphilis	Numeric
124	Female HIV	Numeric
125	Female ALT	Numeric
126	Female ALT levels	Numeric
127	Female HBs-Ag	Numeric
128	Female HBs-Ab	Numeric
129	Female HBe-Ag	Numeric
130	Female HBe-Ab	Numeric
131	Female HBc-Ab	Numeric
132	Female HCV-Ab	Numeric
133	Female CMV IgM	Numeric
134	Female CMV IgG	Numeric
135	Female RV IgM	Numeric
136	Female RV IgG	Numeric
137	Female TOX IgM	Numeric
138	Female TOX IgG	Numeric
139	Male blood analysis	Numeric
140	Male hb	Numeric
141	Male wbc	Numeric
142	Male rbc	Numeric
<b>During-pregnancy variable list</b>		
	<b>Basic information</b>	
1	Hospital card number	Text
2	Inpatient number	Text
3	Name	Text
4	Age	Numeric
5	Pregnant times	Numeric
6	Delivery times	Numeric
7	Last menstrual period	Date
8	Gestational week at the first visit	Numeric
9	The first visit date	Date
10	Height	Numeric
11	Weight	Numeric
12	Systolic blood pressure at the first visit	Numeric
13	Diastolic blood pressure at the first visit	Numeric



14	Occupation	Text
15	Education	Text
	<b>Antenatal care record</b>	
16	Weight at each antenatal care	Numeric
17	Systolic blood pressure at each antenatal care	Numeric
18	Diastolic blood pressure at each antenatal care	Numeric
19	Gestational week at each antenatal care	Numeric
20	Antenatal care date	Date
	<b>Lab data</b>	
21	Cytomegalovirus	Numeric
22	Cytomegalovirus examination date	Date
23	Rubella virus	Numeric
24	Rubella virus examination date	Date
25	Toxoplasmosis	Numeric
26	Toxoplasmosis examination date	Date
27	Syphilis screening	Numeric
28	Syphilis screening examination date	Date
29	Fasting blood-glucose	Numeric
30	Fasting blood-glucose examination date	Date
31	HCT(hematokrit)	Numeric
32	HCT(hematokrit) examination date	Date
33	Serum folate	Numeric
34	Serum folate examination date	Date
35	HCY(homocysteine)	Numeric
36	HCY(homocysteine) examination date	Date
37	OGTT 0 hours	Numeric
38	OGTT 1 hours	Numeric
39	OGTT 2 hours	Numeric
40	OGTT examination date	Date
41	Triglyceride	Numeric
42	Triglyceride examination date	Date
43	Total cholesterol	Numeric
44	Total cholesterol examination date	Date
45	Hemoglobin	Numeric
46	Hemoglobin examination date	Date
	<b>Delivery date</b>	
47	Gestational week at delivery	Numeric
48	Delivery mode	Text
49	Birth weight	Numeric
50	Birth weight(second baby)	Numeric
51	Systolic blood pressure at delivery	Numeric
52	Diastolic blood pressure at delivery	Numeric
53	Apgar scoring	Numeric

54	Delivery date	Date
55	Birth defect records	Text
56	Weight blood pressure at delivery	Numeric
<b>Offspring variable list</b>		
	<b>0 - 6 years (6 weeks, 6 months, 12 months, 36 months, 60 months)</b>	
1	Name	Text
2	ID number	Text
3	Weight	Numeric
4	Height/ Length	Numeric
5	Vision detection	Numeric
6	DDST: Denver developmental screening test	Numeric
	<b>6 - 18 years (each year)</b>	
7	Weight	Numeric
8	Height	Numeric
9	Diastolic blood pressure	Numeric
10	Systolic blood pressure	Numeric
11	Vision detection	Numeric
12	Vital capacity	Numeric
13	Physical fitness measurement (running, jumping, solid balls, etc)	Text
The clinical diagnosis during 0 – 18 years will be extracted from the routine medical system each year.		

1  
2  
3 姓名 Name : \_\_\_\_\_

4 身份证号 ID no : □□□□□□□□□□□□□□□□□□□□

5  
6 医院代码 Hospital No : \_\_\_\_\_ ( 到时打印到问卷上 )

7  
8 填表日期 Date : \_\_\_\_\_年\_\_\_\_月\_\_\_\_日

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 孕前膳食补充剂调查表

# Pre-pregnancy nutrition supplement questionnaire

( 男女共用 )

## A 一般情况

A1 联系电话（请您认真填写，有助于医生和您联系） Contact number: _____ (手机) _____ (固定电话) _____ (Email)
A2 家庭住址 Address: _____ 区/县 _____ 街道/小区 _____ 门牌号码/村
A3 您的出生日期是 Birth date _____ 年 _____ 月 _____ 日
A4 民族 Nationality <input type="checkbox"/> 1 汉族 <input type="checkbox"/> 2 其他（请注明） _____
A5 您的最高学历 Education <input type="checkbox"/> 1 初高中以下 <input type="checkbox"/> 2 大专本科 <input type="checkbox"/> 3 硕士研究生以上及以上
A6 您现在的主要职业 Occupation <input type="checkbox"/> 1 管理人员/干部 <input type="checkbox"/> 2 技术人员 <input type="checkbox"/> 3. 企业主 <input type="checkbox"/> 4 工人 <input type="checkbox"/> 5 农民 <input type="checkbox"/> 6 个体户 <input type="checkbox"/> 7 其它 _____
A7 上一年您的家庭年收入是： Income of a year <input type="checkbox"/> 1. <2 万元 <input type="checkbox"/> 2. (2~3.9)万 <input type="checkbox"/> 3.(5.9)万 <input type="checkbox"/> 4.(6~9.9)万 <input type="checkbox"/> 5.(10~14.9)万 <input type="checkbox"/> 6.15 万及以上 <input type="checkbox"/> 9.不详
A8 填表日期 Date _____ 年 _____ 月 _____ 日

## B 营养补充剂使用情况

营养补充剂种类 Nutritional supplement types	叶酸 Folic acid	复合维生素 multi-vitamins	单一维生素 Single vitamin
您在近三个月是否服用 Have you taken it in the last three months?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂？（如果没有对应选项请在其他处写明） Brand name	<input type="checkbox"/> 1、创盈金斯利安多维片 <input type="checkbox"/> 2、福施福胶囊营养素 <input type="checkbox"/> 3、汤臣倍健 <input type="checkbox"/> 4、安利纽崔莱铁 <input type="checkbox"/> 5、其他 _____	<input type="checkbox"/> 1、爱乐维 <input type="checkbox"/> 2、汤臣倍健孕妇专用 <input type="checkbox"/> 3、惠氏玛特纳 <input type="checkbox"/> 4、21 金维他 <input type="checkbox"/> 5、其他 _____	<input type="checkbox"/> V <sub>C</sub> <input type="checkbox"/> V <sub>E</sub> <input type="checkbox"/> V <sub>B1</sub> <input type="checkbox"/> V <sub>B2</sub> <input type="checkbox"/> 其他 _____
您这三个月的服用频率？（如果食用频率小于每天/周一次，请填写每周/月食用几次，并勾出周/月） How often did you take in	_____次/□天 □周 □月	_____次/□天□周□月	_____次/□天 □周 □月

营养补充剂种类 Nutritional supplement types	铁 Fe	钙 Ca	锌 Zn
您在近三个月是否服用 Have you taken it in the last three months?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂？（如果没有，选项请在其他处写明） Brand name	<input type="checkbox"/> 1、汤臣倍健叶酸亚铁片 <input type="checkbox"/> 2、安利纽崔莱铁片 <input type="checkbox"/> 3、金康倍叶酸铁片 <input type="checkbox"/> 4、其他_____	<input type="checkbox"/> 1、惠氏金钙尔奇 <input type="checkbox"/> 2、君宝康孕妇钙片 <input type="checkbox"/> 3、十月妈咪维生素 AD 钙锌咀嚼片 <input type="checkbox"/> 4、安利钙镁片 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、美康利健 MK 硒金牡蛎锌片 <input type="checkbox"/> 2、汤臣倍健 锌咀嚼片 <input type="checkbox"/> 3、宫诺肽片 <input type="checkbox"/> 4、其他_____

您这三个月的服用频率？（如果食用频率小于每天/周一次，请填写每周/月食用几次，并勾出周/月） How often did you take in	____次/□天 □周 □月	____次/□天□周□月	____次/□天 □周 □月
---	----------------	--------------	----------------

## B 营养补充剂使用情况

<b>C 吸烟情况</b>	
C1 您有吸烟史吗？ Have you smoked cigarettes ever before?	□ 1 是                      □ 0 否 ( <b>跳至 F6</b> )
C2 在您最近的 3 个月内，您是否吸烟？ Did you smoke cigarettes in 3 month	□ 1 是                      □ 0 否
C3 如果是，您平均每天吸多少支烟？ On average, how many cigarettes did you smoke each day in the month after your last menstrual period?	_____ 支
C4 如果您曾经戒过烟，您戒了多少次？ How many times did you stop smoking?	_____
C5 在您生活的大多数时间里，您是否暴露于他人烟草烟雾中？ On most days during your pregnancy, were you exposed to someone else's cigarette smoke?	□ 1 是                      □ 0 否 ( <b>跳至 G1</b> )
C6 您在哪里暴露与烟草烟雾中 Where were you exposed to the smoke?	□ 1 仅在家中      □ 2 仅在工作单位      □ 3 在家和在工作单位均暴露
<b>D 酒精</b>	
D1 您最近三个月的饮酒情况？ During the 3 months before or during your pregnancy, did you ever drink any alcoholic beverages?	
□ 0.从未饮酒；	
□ 1.尝试饮酒（曾饮至少半瓶或一听啤酒，一小盅白酒等）；	
□ 2.现在饮酒（过去 30 天，至少有一天喝过一杯酒）；	
□ 3.重度饮酒（过去 30 天，至少有一天在 2 小时内喝过五杯酒）；	
□ 4.醉酒（过去 12 个月内，因喝酒太多而感到头晕/头疼/嗜睡等醉酒症状）。	

核查人员签名：\_\_\_\_\_

Name of pregnancy : \_\_\_\_\_

ID no : \_\_\_\_\_

## 孕期危险因素暴露调查表

## Pregnancy risk factor exposure questionnaire

For peer review only

**A 一般情况 General information**

A1 您的出生日期是 Birth date	_____年_____月_____日
A2 民族 Nationality	<input type="checkbox"/> 1 汉族 Han <input type="checkbox"/> 2 其他 other_____
A3 您的最高学历 Education	<input type="checkbox"/> 1 初高中以下 Mid <input type="checkbox"/> 2 大专本科 High <input type="checkbox"/> 3 硕士研究生以上及以上 College
A4 您现在的主要职业 Occupation	<input type="checkbox"/> 1 管理人员/干部 <input type="checkbox"/> 2 技术人员 <input type="checkbox"/> 3. 企业主 <input type="checkbox"/> 4 工人 <input type="checkbox"/> 5 农民 <input type="checkbox"/> 6 个体户 <input type="checkbox"/> 7 其它_____
A6 家庭住址: Address	_____区/县_____街道/小区_____门牌号码/村
A7 联系电话 (请您认真填写, 以助于医生和您联系): Contact number	_____(手机) _____(固定电话) _____(Email) _____(微信号)

**B 本次妊娠情况**

B1 您孕前体重通常为? Current weight	_____ (公斤 Kg)
B2 您身高是? Height	_____ (厘米 cm)
B3 您的腰围是? Waist	_____ (厘米 cm)
B4 您此次怀孕的末次月经时间? What was the first day of the menstrual period that came right before this pregnancy (LMP)?	_____年_____月_____日
B5 孕期是否发生过重大负性生活事件而使您的精神受到刺激? Have you ever experienced the negative events which irritate you and generate some negative emotion?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
B6 生这个孩子是您第几次怀孕? How many times have you been pregnant?	_____次
B7 是否有不良生育史? Did you have the adverse reproductive history?	<input type="checkbox"/> 1 有 (继续回答 B6.1) <input type="checkbox"/> 0 无 (跳至 B7)
B6.1 流产史 Abortion	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B6.2 早产史 Preterm	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B6.3 死产史 Stillbirth	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B8 您是否有糖尿病和高血压疾病? Do you have hypertension or diabetes	<input type="checkbox"/> 1 是 (继续回答 B8) <input type="checkbox"/> 0 否 (跳至 C1) <input type="checkbox"/> 999 不知道 (跳至 C1)
B9 您的直系亲属中是否患有糖尿病、高血压疾病? Is there the family history of hypertension or diabetes in children's immediate family members	<input type="checkbox"/> 1 是 (继续回答 B8) <input type="checkbox"/> 0 否 (跳至 C1) <input type="checkbox"/> 999 不知道 (跳至 C1)
B10 若有, 请选择出该亲属与您的关系 (可多选) If so, please choose the relationship with the child	



1. 父亲    2. 母亲    3. 爷爷    4. 奶奶    5. 兄弟    6. 姐妹

### C 叶酸使用

C1 在您末次月经前三个月内，您是否服用过叶酸？ Did you take folic acid in the month before your last period?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否		
C2 在您末次月经之后至今，您是否服用过叶酸？ Did you take any folic acid after your last period and during pregnancy ?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否		
	叶酸 1	叶酸 2	叶酸 3
C3 药物名称(商品名) Brand name			
C4 使用时间 When did you take it?	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always
C5 是否在怀孕期间一直使用？ Did you take it during the rest of your pregnancy?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C6 是否停止使用过？ Did you stop taking it?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C7 使用频率？ How often did you take it?	____次/□天 □周 □月	____次/□天 □周 □月	____次/□天 □周 □月
C8 每次的使用量 What is the usage per time?	一次____片	一次____片	一次____片

### D 维生素使用

D1 在您末次月经的前三个月内，您是否服用过维生素？ Did you take any vitamins in the three months before your last period ?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否		
D2 在您末次月经之后至今，您是否服用过维生素？ Did you take any vitamins after your last period and during pregnancy?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 (跳至 E1)		
	维生素 1	维生素 2	维生素 3
D3 维生素名称 Vitamin name			
D4 维生素商品名称 Brand name			

D5 是否是医生给药? Did your doctor give it to you?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
D6 是否包括叶酸? Does it contain folic acid?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道
D7 使用时间 When did you take it?	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always
D8 是否停止使用过? Did you stop taking it?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
D9 使用频率? How often did you take it?	____次/□天 □周 □月	____次/□天 □周 □月	____次/□天 □周 □月
D10 每次的使用量 What is the usage per time?	一次____片	一次____片	一次____片

### E 其他营养补充剂使用情况 Other nutritional supplement use

营养补充剂种类 Nutritional supplement types	铁 Fe	钙 Ca	锌 Zn
您在近三个月是否服用 Did you take it around the time you became pregnant?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂? (如果没有, 选项请在其他处写明) Brand name	<input type="checkbox"/> 1、汤臣倍健叶酸亚铁片 <input type="checkbox"/> 2、安利纽崔莱铁片 <input type="checkbox"/> 3、金康倍叶酸铁片 <input type="checkbox"/> 4、其他_____	<input type="checkbox"/> 1、惠氏金钙尔奇 <input type="checkbox"/> 2、君宝康孕妇钙片 <input type="checkbox"/> 3、十月妈咪维生素 AD 钙锌咀嚼片 <input type="checkbox"/> 4、安利钙镁片 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、美康利健 MK 硒金牡蛎锌片 <input type="checkbox"/> 2、汤臣倍健 锌咀嚼片 <input type="checkbox"/> 3、宫诺肽片 <input type="checkbox"/> 4、其他_____
您这三个月的服用频率? (如果食用频率小于每天/周一一次, 请填写每周/月食用几次, 并勾出周/月) How often did you take it?	____次/□天 □周 □月	____次/□天□周□月	____次/□天 □周 □月

**F 草本药物使用**

F1 在您末次月经前三个月内，您是否使用过任何一种草本药物/传统医学药物？ Did you take any herbal supplements/traditional Chinese medicine in the three months before your last period □ 1 是      □ 0 否			
F2 在您末次月经之后，您是否使用过任何一种草本药物/传统医学药物 Did you take any herbal supplements/traditional Chinese medicine after your last period and during pregnancy? ? □ 1 是      □ 0 否 (跳至 F1)			
	草本药物 1 Herbal 1	草本药物 2 Herbal 2	草本药物 3 Herbal 3
F3 草本药物类型 Name of herb	□ 1 中成药 □ 2 中医草药	□ 1 中成药 □ 2 中医草药	□ 1 中成药 □ 2 中医草药
F4 药物名称(如果选择中医草药，请填写中药功效) The use of traditional Chinese medicine			
F5 用药持续多少天 How long did you take in?	_____天	_____天	_____天

**G 吸烟情况**

G1 您在怀孕前或者怀孕期间吸烟吗？ Did you smoke cigarettes before or during your pregnancy with the baby?	□ 1 是      □ 0 否(跳至 F9)
G2 在您末次月经的当月，您是否吸烟？ Did you smoke during the month before your last menstrual period ?	□ 1 是      □ 0 否
G3 在您末次月经的一个月后（末次月经结束直至一个月后），您是否吸烟？ (跳至 5) Did you smoke during the month after your last menstrual period, that is between LMP and LMP+1 month	□ 1 是      □ 0 否
G4 如果是，您平均每天吸多少支烟？ On average, how many cigarettes did you smoke each day in the month after your last menstrual period ? 支	
G5 在您怀孕期间，您是否吸烟？ Did you smoke during your pregnancy?	□ 1 是      □ 0 否(跳至 F7)
G6 在您怀孕期间，您平均每天吸多少支烟？ On average how many cigarettes did you smoke each	_____ 支

G7 在您末次月经期间至今，您是否戒过吸烟？ Did you stop smoking at any time between your last menstrual period and the end of your pregnancy?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否 (跳至F9)
G8 您戒烟有多少次？ How many times did you stop? _____ 次		
G9 在您怀孕的大多数时间里，您是否暴露于他人烟草烟雾中？ On most days during your pregnancy, were you exposed to someone else's cigarette smoke?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否 (跳至G1)
G10 您在哪里暴露与烟草烟雾中？ Where were you exposed to the smoke?	<input type="checkbox"/> 1 仅在家中 <input type="checkbox"/> 2 仅在工作单位 <input type="checkbox"/> 3 在家和在工作单位均暴露	

## H 酒精

H1 在您怀孕前三个月至今，您是否饮用过任何含有酒精的饮料？ During the 3 months before or during your pregnancy, did you ever drink any alcoholic beverages?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否
H2 在这三个月内，您通常每次饮几杯酒？ On those days that you drank, how many drinks did you have?	_____ 杯	

## I 环境暴露情况

I1 怀孕前三个月到现走，您是否染烫发？ Did you dye perm in the first three months of pregnancy?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否
I2 怀孕前三个月到现在，后您工作的地点或家里是否装修过？ Did you exposed to formaldehyde in the first three months of pregnancy?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否
I3 怀孕前后您是否接触过下列物质？ Have you been exposed to the following substances before and after pregnancy? (Toxic chemicals)	<input type="checkbox"/> 1 除草剂 <input type="checkbox"/> 2 杀虫剂 <input type="checkbox"/> 3 灭鼠剂 <input type="checkbox"/> 4 有机溶剂 <input type="checkbox"/> 5 消毒剂 <input type="checkbox"/> 6 金属制剂 <input type="checkbox"/> 7 有害气体 <input type="checkbox"/> 8 有害固体	

## J 药物使用情况

以下问题是有关于您在末次月经之前三个月内至今期间的用药情况

	治疗高血压 药物 Medication for hypertension	胰岛素 Insulin for diabetes	口服降血糖 药物 Oral hypoglycemic for diabetes	抗癫痫药物 Medications for epilepsy	每天都要服用 的药物 Medications at least once a day
1 您是否使用过？ Did you take?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否

2 您使用的药物名称? What did you take?	_____	_____	_____	_____	_____	_____
<b>如果下一个问题令您感到不安且不愿意回答, 请在“拒答”上打√, 我们将对您所有回答进行严格保密!</b>						
	安定\有助于您放松药物 Valium\drugs to help you relax	使您感觉良好\精力旺盛 Make you feel good\have more energy	美沙酮\氧可酮\其他止痛药 Methadone oxymoron\other pain killers	可卡因 Cocaine or crack cocaine	海洛因 Heroin	大麻 Marijuana
1 您是否使用过? Did you take?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚
2 您使用的药物名称? What did you take?	_____	_____	_____	_____	_____	_____

### I 您在怀孕期间是否患过以下疾病?

I.3 发热性疾病及呼吸道感染 Febrile illness and respiratory infections	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
I.3.1 您发烧时的最高温度是多少? What was the highest temperature of your fever during your illness?	_____ °C
I.3.2 您发烧有几天? How long did you have a fever?	_____ 天
I.6 其他 _____	

**调查结束, 谢谢您的配合!**

调查员姓名 \_\_\_\_\_

调查日期 \_\_\_\_/\_\_\_\_/\_\_\_\_  
年 月 日

1  
2  
3 Types of fetus defects and birth defects  
4

---

5 **Diagnosis**  
6

7 Anencephalus  
8

9 Spina bifida  
10

11 Encephalocele  
12

13 Congenital Hydrocephalus  
14

15 Cleft Palate  
16

17 Cleft Lip  
18

19 Cleft Lip with Cleft Palate  
20

21 Microtia (including Anotia)  
22

23 Deformity of external ear(s) (except Microtia and Anotia)  
24

25 Esophageal atresia or stenosis  
26

27 Anorectal atresia (including Congenital Anorectal Malformations)  
28

29 Hypospadias  
30

31 Ectopocystis  
32

33 Pes Equinovarus  
34

35 Polydactylism  
36

37 Syndactylia  
38

39 Limb shortening  
40

41 Congenital Diaphragmatic Hernia  
42

43 Pcomphalus  
44

45 Celoschisis  
46

47 Conjoined Twins  
48

49 Trisomy 21 syndrome  
50

51 Congenital heart disease  
52

53 Others  
54  
55

---

56  
57 **Note:** Down's syndrome, neural tube defects, congenital heart defects, hydrocephalus, digestive tract  
58 malformations and urinary malformations are most common defects in China. Defects were detected by  
59  
60

1  
2  
3 prenatal Down's syndrome screening, NT examination and Ultrasound image examination during the  
4 second trimester; and the number and type of birth defects after childbirth are diagnosed by professional  
5 clinical team. Down syndrome (DS), caused by the trisomy, translocation, or partial trisomy of  
6 chromosome 21, is the most common genetic cause of intellectual disability. DS is diagnosed by  
7 neonatologist. Neural tube defects including spina bifida and hypospadias, were diagnosed by ultrasound  
8 examination and pediatric neurosurgeon. Congenital heart disease was diagnosis by Doppler ultrasound  
9 and CHD screening (pulse oximetry plus cardiac murmurs). Hydrocephalus, digestive tract malformations,  
10 urinary malformations and other defects also were also diagnosed either by ultrasound or some other  
11 specific diagnosis methods.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Future Plan of Shanghai PreConception Cohort, Shanghai, China (SPCC)**

The Shanghai PreConception Cohort (SPCC) is a long-term cohort and meets the “Cohort profile” requirement. We have a complete plan to follow-up offspring to the age of 18 years old. The cohort will be financially supported by different grants. The current manuscript focuses on the first phase, the establishment of the baseline and our first main outcome, the congenital heart disease (CHD).

The second phase of this cohort study is from birth to 6 years old. Follow-up work will rely on Shanghai Community health care centers-child care. The third phase is from 6 to the age of 18 (school age). We will cooperate with Shanghai Student Health and Fitness Surveillance Center for the follow-up of the school age children.

Multiple outcomes for pediatrics, including growth, physical and neuro-developments, obesity, common and rare diseases will be investigated. Nested case-control design will be used for rare outcomes.



## The data collection plan for infants and children

	At birth	6 weeks	6 months	12 months	36 months	60 months	6 – 18 years*
General information (gender, ID number, Home Address, etc)	√	√					
Delivery outcome (Congenital malformation, preterm birth, miscarriage, stillbirth)	√						
Body measurement (weight, height, waistline, hipline)	√	√	√	√	√	√	√
Diet investigation (questionnaire)	√	√	√	√	√	√	√
Neurobehavioral developmental assessment (DDST <sup>\$</sup> )		√	√	√	√	√	
Anthropometrics data (Shanghai Community health care centers-child care and Shanghai Student Health and Fitness Surveillance Center) weight, height, waist circumference	√	√	√	√	√	√	√
Physical fitness measurement (running, jumping, solid balls, etc)							√
Blood pressure measurement, annually							√
Hemachrome (anemia)							√
Renal functions, at grade 9 and 12							√
Cardiovascular-related chronic diseases (Hypertension, Obesity, Diabetes/Pre-diabetes and Dyslipidemia)							√
Venous blood <sup>#</sup>							√

Note: \* Shanghai Student Health and Fitness Surveillance Center routinely conducts all-round physical examinations for students in the school as a health care policy for Shanghai students. It is usually in September-November of each year.

\$ DDST: Denver developmental screening test.

# Venous blood will be collected at 12, 15 and 18 years of age.

# BMJ Open

## Cohort profile: Shanghai PreConception Cohort (SPCC) for association of periconceptional parental key nutrition factors with health outcomes of children: I -congenital heart disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031076.R2
Article Type:	Cohort profile
Date Submitted by the Author:	14-Sep-2019
Complete List of Authors:	Wang, Dingmei; Children's Hospital of Fudan University Zhang, Yi; Children's Hospital of Fudan University Jiang, Yuang; Children's Hospital of Fudan University Ye, Ying; Clinical Epidemiology Ji, Mi; Children's Hospital of Fudan University Dou, Yalan; Children's Hospital of Fudan University, Dermatology Chen, Xiaotian; Children's Hospital of Fudan University Li, Mengru; Children's Hospital of Fudan University Ma, Xiaojing ; Children's Hospital of Fudan University Sheng, Wei; Children's Hospital of Fudan University Huang, Guoying; Children's Hospital of Fudan University, Pediatric Heart Center Yan, Weili; Children's Hospital of Fudan University,
<b>Primary Subject Heading</b>:	Research methods
Secondary Subject Heading:	Public health, Obstetrics and gynaecology, Nutrition and metabolism
Keywords:	red blood cell folate, vitamin, congenital heart diseases, periconceptional health care

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1           **Cohort profile: Shanghai PreConception Cohort (SPCC) for**  
2           **association of periconceptional parental key nutrition factors with**  
3           **health outcomes of children: I -congenital heart disease**

4           Dingmei Wang\*<sup>1,2</sup>, Yi Zhang\*<sup>1,2</sup>, Yuan Jiang<sup>1,2</sup>, Ying Ye<sup>1</sup>, Mi Ji<sup>1</sup>, Yalan  
5           Dou<sup>1</sup>, Xiaotian Chen<sup>1,2</sup>, Mengru Li<sup>2</sup>, Xiaojing Ma<sup>2</sup>, Wei Sheng<sup>2</sup>, Guoying  
6           Huang<sup>2</sup>#, Weili Yan<sup>1,2</sup>#; SPCC group

7           1 Department of Clinical Epidemiology & Clinical Trial Unit (CTU),  
8           Children's Hospital of Fudan University, Shanghai, China.

9           2 Shanghai Key Lab of Birth Defect, Children's Hospital of Fudan  
10          University, Shanghai, China.

11  
12          \* Contributed equally to this work.

13          # Co-corresponding author.

14          A full list of SPCC group can be found after Acknowledgements.

15          Weili Yan, PhD

16          86-21-64931215

17          Email: yanwl@fudan.edu.cn

18          Guoying Huang, MD PhD

19          86-21-64931913

20          Email: gyhuang@shmu.edu.cn

## 1 ABSTRACT (293)

2 **Purpose:** The Shanghai PreConception Cohort (SPCC) was established  
3 initially to investigate associations of parental peri-conception nutritional  
4 factors with congenital heart disease (CHD), and has extended to children  
5 growth, development and pediatric diseases.

6 **Participants** Prepare-for-pregnant couples who presented at Shanghai  
7 preconception examination clinics and early-pregnant women before 14  
8 gestational weeks were enrolled to comprise a peri-conception baseline  
9 study population. General characteristics, routine clinical data,  
10 consumption of diet supplements, such as folic acid and multivitamins,  
11 were collected. Blood samples were collected at preconception, early,  
12 middle and late gestation respectively by standard procedures. Multiple  
13 nutrition factors in blood sample of participants that were selected by  
14 case-control design will be examined, including folates, homocysteine,  
15 vitamin A, vitamin D, vitamin E and metals. Genomic DNA was extracted.

16 **Findings to date** The baseline population included 8045 preconception  
17 couples, 3054 single women, and 15 615 early-pregnant women,  
18 respectively. Birth data from 12 402 births were collected and follow-up of  
19 the cohort for more outcomes is ongoing. Currently, 151 CHDs were  
20 identified after birth. Pilot analysis in a small subgroup showed that only  
21 about 15% of 656 preconceptional women and 49% of early-pregnant  
22 women had red blood cell folate concentration meeting the international  
23 recommendation for preventing neural tube defects.

### 24 **Future plans**

25 Once a sufficient number of CHD cases is achieved, we will investigate  
26 quantitative association of preconceptional red blood cell folate levels with  
27 CHD using nested case-control design. The SPCC cohort will be followed  
28 up for 18 years to investigate extensive outcomes of growth, development,  
29 obesity, and common and rare diseases during childhood and adolescence  
30 according to our plan. Blood nutrition factors will be examined in  
31 participants selected for specific aims. The SPCC cohort will also allow for  
32 prospective cohort studies on extensive research questions.

33 **Trial registration number:** NCT 02737644.

34 **Key Messages:** red blood cell folate, vitamin, congenital heart diseases,  
35 peri-conception health care

### Strengths and limitations of this study

- The SPCC cohort is the first prospective birth cohort with CHD as primary outcome with recruitment starting from preconception stage. Temporal sequence of exposures and outcomes can be achieved for causal inference of birth defects and other diseases that occur during early stage of gestation.
- Preconception blood samples were appropriately collected and stored which allow examination of individual blood levels for nutrition factors and other exposures.
- Clinical data and blood samples from both father and mother from before conception were collected, which will allow for testing the effect of both maternal and paternal genetic and nutrition factors on fetal and children diseases.
- Although response rate was high (over 95%), pre-conception participants were recruited from the population who voluntarily presented at Shanghai city preconception physical examination sites. They may have a stronger willingness for a healthy pregnancy, which may induce selection bias.
- Biological samples (cord blood, placenta) of the newborns were not collected.

view only

## 1 Introduction

2 Congenital heart disease (CHD) is a common congenital malformation,  
3 which seriously affects quality of children's life [1]. CHD is a leading  
4 cause of infant death in high-income countries affecting eight of 1000 live  
5 births [2]. According to the report from National Health and Family  
6 Planning Commission of the People's Republic of China, CHD accounts  
7 for about a quarter of the birth defects of newborns in China, ranking the  
8 first among birth defects [3]. In a prospective, nation-wide large-scale  
9 study in more than 120 000 newborns in China in 2013, the prevalence of  
10 CHD in live births was identified 8.94 ‰; the rate of severe CHD was  
11 2.9 ‰ [4].

12 The cause of CHD is multifactorial. With the development of genetic  
13 engineering technology, the genetic factors have been better understood in  
14 the past decade [5]. Multiple environmental risk factors have been reported  
15 in epidemiological studies, the maternal social variables such as  
16 occupation, educational background, health status, unhealthy life style,  
17 maternal medical history and emotional status, family history of disease,  
18 consanguineous marriages and so on [6-10]. In addition, maternal key  
19 nutrients related to the risk of offspring's CHD as a modifiable  
20 environmental factor during peri-conception [11, 12]. The peri-conception  
21 intake of folic acid supplement has been shown to reduce the risk of CHD

1 [13, 14] and women worldwide have been recommended to take folic acid  
2 supplements before conception and in the beginning of pregnancy.  
3 Awareness of the relationship between folic acid deficiency and CHD is  
4 actually a by-product finding from the well-known Hungarian RCT study  
5 of folic acid supplementation to prevent neural tube defects. The study  
6 found that prenatal supplementation with a vitamin complex containing 0.8  
7 mg of folic acid daily reduced the incidence of congenital neural tube  
8 defects. At the same time, the incidence of various heart defects have also  
9 been reduced by nearly half [15]. Longitudinal data from more than one  
10 million births in Canada over a total of 22 years from 1990 to 2011 also  
11 show that food fortification with folic acid reduced risk of CHD by 20-30%  
12 [16]. The current folic acid supplementation recommends that all women of  
13 childbearing potential be supplemented with at least 0.4 mg folic acid daily  
14 prior to conception and during pregnancy, which is designed for preventing  
15 neural tube defects [17]. However, excessive folic acid intake may increase  
16 the risk of cancer [18], vitamin B12 deficiency [19], and autism spectrum  
17 disorder [20]. The optimal dose of folic acid for preventing CHD warrants  
18 further investigation. In addition, most previous studies only focused on the  
19 supplement of folic acid or the serum folate level during or after pregnancy,  
20 which may not be the optimal period and way to reflect the exposure level  
21 to risk of CHD.

1 To investigate the association between parental peri-conception key  
2 nutritional factors such as folate with the development of CHD and to  
3 explore the cutoff biomarker levels, we conducted Shanghai PreConception  
4 Cohort (SPCC) and a nested case-control analysis.

5 The SPCC cohort was initiated primarily to study CHD. However, based  
6 on the strengths of its baseline data collection, it has received attention and  
7 support, with improved additional extensive outcomes for children that will  
8 be followed up longer term.

### 9 **Who is in the cohort?**

10 The SPCC cohort recruited parent-planning women and men who were  
11 permanent residents and who voluntarily presented at preconception  
12 clinical clinics at 28 maternity institutions in 10 districts of Shanghai  
13 (Minhang District, Huangpu District, Xuhui District, Changning District,  
14 Jing'an District, Putuo District, Yangpu District, Pudong District ,  
15 Songjiang District, Qingpu District) from March 2016 to December 2018.

16 The preconception examination policy in the city of Shanghai provides a  
17 unique opportunity and clinical resources to support recruitment of SPCC.

18 Since 2010, married couples in Shanghai have been encouraged to attend a  
19 free preconception health examination. In addition, these maternity  
20 institutions receive strong local administrative support and integrated  
21 maternal health care networking, providing service to 150 000–200 000



1  
2  
3  
4 1 annual deliveries in Shanghai. Couples who were present at preconception  
5  
6  
7 2 clinics, living in Shanghai, preparing for pregnancy within one year, and  
8  
9  
10 3 planning to receive antenatal care and to delivering in Shanghai, were  
11  
12 4 eligible for the study. Written informed consents were obtained from all  
13  
14  
15 5 participants before any data collection. In addition, we recruited  
16  
17  
18 6 early-pregnant women at their first antenatal examination who were at  
19  
20  
21 7 gestational week <14 weeks. These two groups of participants comprised a  
22  
23  
24 8 peri-conception baseline study population.

25  
26 9 The first primary outcome of the SPCC cohort is CHD. The hypothesis is  
27  
28  
29 10 that maternal preconception serum or red blood cell (RBC) folate  
30  
31  
32 11 concentration is quantitatively associated with offspring CHD. The study  
33  
34  
35 12 design and protocol has been registered with Clinical Trials Registry (NCT  
36  
37  
38 13 02737644).

39  
40 14 As shown in Figure 1, the baseline population will be followed up to  
41  
42  
43 15 delivery, and their babies will be followed up until 18 years old (Figure 1).

#### 44 45 16 **Follow-up procedure**

46  
47 17 At enrollment, the participants completed the questionnaire of key nutrient  
48  
49  
50 18 supplementation and blood sample collection. When participants got  
51  
52  
53 19 pregnant, the same investigations (questionnaire/blood sample collection)  
54  
55  
56 20 were conducted during early pregnancy (first antenatal visit at 16-20  
57  
58  
59 21 gestational weeks). Pregnancies were followed up along with routine  
60

1 maternal health care procedures. Blood samples were also collected at the  
2 second (24-28 gestational weeks) and third trimester (32-34 gestational  
3 week). The follow-up of CHD outcome and birth data was obtained  
4 through Shanghai Neonatal CHD Screen Platform (Figure 1).

5 As shown in Figure 1, outcomes at birth, during infant to childhood  
6 (preschool phase), and between 7 to 18 years (school ages) will be  
7 collected or extracted from multiple public platforms and data sources.  
8 Firstly, preconception clinical visit data from Preconception Care  
9 Electronic Data System supported by national and local government,  
10 including height, weight, age, infections, sexually transmitted disease, and  
11 family history were collected. Secondly, the routine pregnant data were  
12 obtained in Maternal Clinic Antenatal Medical Record System, managed  
13 by Shanghai Center for Women and Children's Health, including height,  
14 gestational weight, last menstrual period, childbearing history, delivery  
15 outcomes, infections, hematocrit, coagulation function, liver and kidney  
16 function, and so on. Thirdly, the maternal and neonatal data at delivery  
17 came from Shanghai Neonatal CHD Screen Platform including birth  
18 weight, CHD diagnosis, birth defects, and Apgar score, etc. In addition, we  
19 will work with the Shanghai Student Health and Fitness Surveillance  
20 Center to obtain outcome data. The personal national identification card  
21 number of participants are applied as index variables through the multiple

1  
2  
3  
4 1 data sources. The detailed variable list and codebook of data collection is  
5  
6  
7 2 presented in Appendix 1.  
8  
9

10 3 During the first phase of the cohort, from preconception to delivery,  
11  
12 4 comprehensive strategies were used to retain participants in the study. For  
13  
14  
15 5 mothers, we provided a variety of engagement activities including green  
16  
17  
18 6 channel (fast track) to their antenatal care to provide convenience and save  
19  
20  
21 7 their time in hospitals. We also provided a contact number on the  
22  
23  
24 8 participant card to answer their calls or queries about the study procedures.  
25  
26  
27 9 Site investigators at early pregnant clinics in collaborative hospitals were  
28  
29  
30 10 provided a smartphone APP to help identify recruited cohort participants  
31  
32  
33 11 timely and manage data and blood sample collection procedures. We also  
34  
35  
36 12 provided green channel echocardiography for diagnosing CHD for all site  
37  
38  
39 13 hospitals to enhance the compliancy of the participants. In addition, an  
40  
41  
42 14 automated text message system is adopted to remind participants of  
43  
44  
45 15 schedules and appointment of follow-up.

## 16 **Study measures**

### 17 Personal characteristics questionnaires

18 18 As shown in Figure 1, Questionnaire 1 was administered during  
19  
20  
21 19 recruitment at preconception examination sites and Questionnaire 2 was  
22  
23  
24 20 administered at early pregnancy sites to collect information on  
25  
26  
27 21 consumption of folic acid supplement, vitamin supplement, the brand and  
28  
29  
30

1 content of nutrient supplement. Information of demographics, maternal  
2 education, socio-demographic status, occupation, smoking status, alcohol  
3 consumption, BMI, medication, and health status were also included. In  
4 addition to the content of Questionnaire 1, Questionnaire 2 added drug  
5 information, reproductive history, and health status. Questionnaire 1 for  
6 baseline and Questionnaire 2 for the first antenatal visit at early pregnancy  
7 are presented in Appendix 2a and Appendix 2b.

### 8 Collection of blood samples

9 In this study, the rest blood samples for routine clinical blood test were  
10 collected. The blood sample for routine clinical examination was usually 5  
11 ml and extracted in the morning. Routine clinical blood test was performed  
12 at room temperature. The rest blood samples (fasting serum and EDTA  
13 anticoagulation) of peripheral venous blood from routine laboratory clinical  
14 blood test were kept. These blood samples were temporarily stored in a 4°C  
15 refrigerator for dispensing within 6 hours and transferred to a -20 4 °C .  
16 After completion of blood sample distribution the serum and the whole  
17 blood were stored at the site laboratory, and then transported by three  
18 trained investigators to the central laboratory for storage in -80 °C freezers  
19 within two weeks. Sampling tubes were made of a light-proof material and  
20 the process of collecting blood samples were completely protected from

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 light.

2 Examination of key nutrition factors in blood samples

3 The examinations will be conducted in participants selected by nested  
4 case-control designs based on specific aims.

5 (1) *RBC folate, serum folate, serum homocysteine, vitamin D, vitamin B12*  
6 *and serum ferritin*

7 EDTA anticoagulation blood was collected to measure RBC folate, serum  
8 folate, serum homocysteine, vitamin D, vitamin B12 and serum ferritin  
9 assays. All six biomarkers were analyzed on an electrochemiluminescence  
10 assay (ARCHITECT i2000SR Analyzer, Abbott Laboratories, USA). A  
11 standard solution with known concentration (produced by Abbott  
12 Laboratories) was used daily to quality control before the measurement. If  
13 the quality control level was out of concentration range, the measurement  
14 would be suspended and adjusted. External quality control was carried out  
15 with the control lab data program from Abbott Laboratories (Abbott  
16 Laboratories, Shanghai, China). RBC folate concentrations were adjusted  
17 for hematocrit. If the RBC folate concentration is below 126.0 ng/ml or  
18 above 651.1 ng/ml, adjustment was needed based on serum folate level.  
19 The hematocrit data were extracted from the hospital laboratory  
20 information system. Those examinations were performed in central  
21 laboratory of Children's Hospital of Fudan University.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 (2) *Vitamin A and vitamin E*

2 The serum concentration of vitamin A and vitamin E were quantitatively  
3 detected by liquid chromatography-tandem mass spectrometry in central  
4 laboratory of Children's Hospital of Fudan University. The testing  
5 instrument was triple quadrupole mass spectrometer LC/MS/MS System  
6 (NO: API 3200MDTM, ABSciex Pte.Ltd.). A standard solution of vitamin  
7 A-d6 and vitamin E-d6 were applied as internal standards.

8 (3) *Glycemic and lipid profiles*

9 Fasting serum cholesterol, high-density lipoprotein, low-density  
10 lipoprotein, triglyceride, and fasting glucose were performed on Beckman  
11 coulter AU chemistry analyzers (Beckman, USA) in central laboratory of  
12 Children's Hospital of Fudan University.

13 (4) *Metals*

14 Serum levels including Mg, Fe, Zn, Se, Mn, As, Cu and Ca, were analyzed  
15 by inductively coupled plasma mass spectrometry (ICP-MS) (Inductively  
16 Coupled Plasma Optical iCAP6300, Thermo®, USA) in standard mode  
17 [21]. The metals examination was conducted in Instrumental Analysis  
18 Center of Shanghai Jiaotong University which is a national key laboratory.

19 (5) *Genomic DNA extraction*

20 Genomic DNA of all participants were extracted using a magnetic  
21 bead-based kit (TGuide M16 Automatic Nucleic Acid Extractor

1 (OSE-M16), TIANGEN BIOTECH (BEIJING) CO. LTD, China ) from 2  
2 ml of EDTA anticoagulated whole blood sample after routine blood test.  
3 Genomic DNA samples were stored for future study. An average 150 ng  
4 DNA were available. Similar to blood chemicals, future genetic variants  
5 genotyping will be performed in selected participants according to nested  
6 case-control design for specific aims. Currently, there are no candidate  
7 genes or variants that are listed.

#### 8 Outcomes -CHD in neonates

9 The diagnosis of CHD was the primary outcome of the study at this stage  
10 and obtained from Shanghai Neonatal CHD Screen Platform, which was  
11 initiated as routine screen for newborns in Shanghai since Jun 1st 2016.  
12 The standard protocol of CHD screening of the platform was previously  
13 described in detail [22]. All newborn babies received the screen by using  
14 double-index method (i.e. cardiac murmur auscultation and pulse oximetry)  
15 during 6-72 hours after delivery, and those screen-positive babies would  
16 receive a subsequent echocardiography for further confirmative diagnosis.

17 SPCC will also collect other birth defects as secondary outcomes,  
18 including Down's syndrome, neural tube defects, hydrocephalus, digestive  
19 tract malformations, urinary malformations, and behavioral cognitive  
20 developmental disorder. After delivery, the infants attended routine  
21 childcare procedures organized by Shanghai Child Health Care System,

1  
2  
3  
4 1 which is administered by Shanghai Center for Women and Children's  
5  
6  
7 2 Health. All birth defects records, which were diagnosed after birth, as well  
8  
9  
10 3 as routine neuro-development examinations and longitudinal  
11  
12 4 anthropometric data, were abstracted from the system by a professional  
13  
14  
15 5 clinical team from Children's Hospital of Fudan University (for details of  
16  
17  
18 6 the types of birth defect please see Appendix 3)

### 7 **Statistical methods**

8 To investigate the association of maternal preconception nutrition levels  
9 with offspring CHD risk, a nested case-control study will be conducted.  
10 The control will be matched by age and site.

11 The sample size for the nested case-control analysis was planned as 180  
12 CHD cases and 720 matched controls to detect a maternal folate deficiency  
13 with prevalence of 50% in controls with odds ratio of 1.6 in association to  
14 achieve a power of 80% at alpha of 0.05. Based on CHD incidence above  
15 8.94 per 1 000 live births [4], 20 000 pregnancies will be needed. For a  
16 continuous nutrient variable with standard deviation 2.0, 50 matched-pairs  
17 (1:4) are required to achieve 90% power to detect an odds ratio of 1.3  
18 calculated using conditional logistic regression with a 0.05 significance  
19 level [23, 24]. Once a sufficient number of CHD cases is achieved, the  
20 quantitative association of preconception RBC folate levels with CHD  
21 using nested case-control design will be investigated.



1  
2  
3  
4 1 Conditional multivariate logistic regression will be used for association  
5  
6  
7 2 analysis with offspring affected status of CHD being the dependent  
8  
9  
10 3 variable, nutrition factors levels as exposure and adjusted for all potential  
11  
12 4 paternal and maternal covariates. Odds ratios (OR) and 95% confidence  
13  
14  
15 5 intervals (95%CI) will be reported. To explore a potential cutoff point of  
16  
17  
18 6 the nutrition levels that significantly increases the risk of CHD, a dummy  
19  
20  
21 7 variable will be set up by categorizing the maternal preconception nutrition  
22  
23  
24 8 levels based on the distribution of the control group. The does-response  
25  
26  
27 9 relationship will be also be analyzed. Sensitive analysis will include  
28  
29  
30 10 non-conditional logistic regression analysis, or generalized estimation  
31  
32  
33 11 equations (GEE) model, or generalized linear models when necessary.

## 34 12 **FINDINGS TO DATE**

35  
36  
37 13 The SPCC started recruitment in March 2016. As shown in Figure 2, by  
38  
39  
40 14 December 2018, we consecutively recruited 19 144/19 563 (97.9%)  
41  
42  
43 15 participants at preconception settings, including 8045 couples and 3054  
44  
45  
46 16 single women, and an additional 15 615/16 201 (96.4%) pregnant women  
47  
48  
49 17 at maternity hospitals with gestational age <14 weeks. Table 1 describes  
50  
51  
52 18 the basic demographic characteristics of the preparing-for-pregnant  
53  
54  
55 19 participants and pregnant women, respectively. The average age of the  
56  
57  
58 20 preconception population was 29.9 (SD 3.9) years for females and 31.4  
59  
60 21 (SD 4.5) years for male, one-third of males and 2.4% of females were

1 smokers, and two-thirds of males, and one-third of females had a habit of  
2 drinking alcohol. In pregnant women, the average age was 29.9 (SD 4.0)  
3 years, with half of them having a first pregnancy. Compared with the  
4 preconception females, they were similar in age but different in education  
5 levels and occupation, the prevalence of smoking and alcohol drinking  
6 were much lower. (The descriptive data of Table 1 was partly included in  
7 another manuscript, which is under review of Maternal & Child Nutrition  
8 with Manuscript number of MCN-08-19-OA-4056).

9 By the end of December 2018, the last participants recruited at early  
10 pregnancy were due for delivery, however, we have achieved birth records  
11 of 12 402 newborns. The follow-up of outcomes of the rest of the  
12 participants is ongoing (shown in Figure 2). A total of 151 cases of CHD  
13 were identified through the CHD screening platform, 131 cases from the  
14 early pregnancy sample, and the remaining 20 cases were from the  
15 preconception sample. The prevalence of CHD in live births is 10.5 %  
16 (131/12 402) based on the present available data.

17 We conducted a small pilot study in April 2017 to explore blood levels  
18 of nutrition factors, including serum folate, RBC folate, vitamin A, vitamin  
19 E, and vitamin D. The blood samples from 627 females were selected  
20 consecutively from the preconception sample according to who was  
21 identified pregnant. In addition, 597 women who were consecutively

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 recruited from the antenatal care clinics were selected. As shown in Table  
2 2, the concentrations of RBC folate median level is 247.0 ng/ml (IQR:  
3 184.8-340.5 ng/ml) in preconception women and 417.4 ng/ml (IQR:  
4 308.6-544.2 ng/ml) in early-pregnant women. Twenty percent of  
5 preconceptional participants and 44.9% of pregnant participants had a  
6 folate level over 400 ng/ml, which was suggested as optimal level for  
7 preventing neural tube development defects [25, 26]. These results suggest  
8 that effort is urgently needed to improve the intake of folic acid  
9 supplementation in the prepare-for-pregnancy population, especially before  
10 pregnancy.

11 Based on SPCC, the possible scope of research questions, available types  
12 and number of bio-samples and biomarkers that can be examined is shown  
13 in Table 3.

#### 14 **FUTURE PLANS**

15 We have a complete plan to follow-up offspring to the age of 18 years old.  
16 The cohort will be financially supported by different grants. The current  
17 manuscript focuses on the first phase, the establishment of the baseline and  
18 our first main outcome, the CHD. The data collection plan for infants and  
19 children (from birth to 6 years old, pre-school stage), as well as school age  
20 (from 6 to 18 years old), are included. During the stage of 0 to 6 years old,  
21 the data of neurodevelopment will be collected from routine childcare

1 clinical visit at birth, 6 weeks, 6 months, 12 months, 36 months, and 60  
2 months through the cooperating medical institutions. Physical  
3 measurements data and dietary intake information also can be collected at  
4 this stage. During the stage of 6 to 18 years old, we plan to follow up their  
5 growth (height, weight, blood pressure, et al.) mainly relying on the annual  
6 physical examination of Shanghai Student Health and Fitness Surveillance  
7 Center System. Multiple outcomes for children, including growth and  
8 development, cardiovascular diseases, neurodevelopment, metabolic  
9 diseases, obesity, and hypertension will be investigated. Please see  
10 Appendix 4 for details.

## 11 **STRENGTHS AND LIMITATIONS**

12 Compared with existing birth cohorts, there are three important strengths in  
13 our cohort. Firstly, the SPCC cohort is the first prospective birth cohort  
14 with CHD as primary outcome and recruitment starting from preconception.  
15 Blood samples were collected and stored which allows for direct  
16 measurement of individual exposure levels before the development of CHD  
17 and make causal inference. Temporal sequence of exposures and outcomes  
18 can be achieved for causal inference of birth defects and other diseases that  
19 occur during early stage of gestation. Up to date, no published studies have  
20 measured maternal blood folate levels before conception and link it to  
21 disease outcomes. Secondly, this cohort also allows for the investigation of

1  
2  
3  
4 1 associations between peri-conception maternal and paternal nutrition  
5  
6  
7 2 exposures with other birth defects, early onset-diseases, and  
8  
9  
10 3 neuro-development outcomes. Preconception blood samples were  
11  
12 4 appropriately collected and stored which allows for the examination of  
13  
14  
15 5 individual blood levels of nutrition factors and other exposures. Thirdly,  
16  
17  
18 6 both paternal and maternal clinical data and blood samples before  
19  
20  
21 7 conception were collected, which will allow for testing effect of both  
22  
23  
24 8 maternal and paternal genetic and nutrition factors to fetal and children  
25  
26  
27 9 diseases.

28  
29 10 Two limitations of this cohort study should be considered. Firstly, there  
30  
31  
32 11 are approximately 200 000 pregnant women giving birth every year in  
33  
34  
35 12 Shanghai, and approximately 20 000 of them will take part in the free  
36  
37  
38 13 preconception care in Shanghai, where participants were recruited  
39  
40  
41 14 consecutively. Although response rate was high (over 95%), preconception  
42  
43  
44 15 participants were recruited from a population voluntarily present in  
45  
46  
47 16 Shanghai city with preconception physical examination sites, who may  
48  
49  
50 17 have a stronger willingness for a healthy pregnancy. This may induce  
51  
52  
53 18 selection bias. Secondly, in this study, biological samples (cord blood,  
54  
55  
56 19 placenta) of the newborns are not collected. We plan to give new informed  
57  
58  
59 20 consent to the family who are willing to participate in future studies, to  
60  
21 collect biological samples not mentioned before. In addition,

1  
2  
3  
4 1 electrochemiluminescence assay was used to examine serum and RBC  
5  
6  
7 2 folate concentrations, which is different from microbiologic assay that is  
8  
9  
10 3 used widely. This will not bias the association analysis but comparison  
11  
12 4 with international populations needs caution.

### 5 **Collaboration**

6 Investigators with an interest in hypotheses related to SPCC (and that meet  
7 the requirements of current approvals) are welcome to contact Dr. Guoying  
8 Huang or Weili Yan. A 'Research Collaboration application' should be  
9 send to the corresponding author by Email. The application should include  
10 a brief description of the project.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 **Acknowledgements**

2 We are extremely grateful to all the participants who took part in this study,  
3 the doctors for their help in recruiting them, and the whole SPCC team,  
4 which includes interviewers, computer and laboratory technicians, clerical  
5 workers, research scientists, volunteers, managers, receptionists, and  
6 nurses.

## 8 **SPCC group**

9 Gouying Huang, Weili yan, Xiaojing Ma, Weifen Luo, Wei Sheng, Yi  
10 Zhang, Yuan Jiang, Yin Ye, Dingmei Wang, Xiaotian Chen, Mengru Li,  
11 Mi Ji, Yumei Liu, Gu Qing(s), Gu Qing(o), Linmei Zhu, De'ai Hou, Peiyu  
12 Sun. (Children's Hospital of Fudan University, Shanghai, China),  
13 Hongbing Wang, Li Meng, lin Zhang (Jingan Maternal and Child Health  
14 Center), Zifen Dai, Li fen (Shanghai First Maternity and Infant health  
15 Hospital), Shufang Chen, Zhenhua Tang, Jiahao Wu (International Peace  
16 Maternal and Child Health Hospital), Shuhua Wang, Dan li, Hui Wang  
17 (Xuhui Maternal and Child Health Center), Yu Ke, Weiping Cao, Baoren  
18 Zhang, Hong Huang (Shanghai Pudong New Area Health Care Hospital for  
19 Women & Children),  
20 Nailing Wang, Min Jiang, Jie Chen, Qiumin Xia (Shanghai Punan Hospital  
21 of Pudong New District), Hui Xu, Guoying Lao (Changning Maternity and

1  
2  
3  
4 1 Infant Health Hospital), HongMei Jin, Wenjuan Xie, Pin Yi (Qingpu  
5  
6  
7 2 Hospital, Zhongshan Hospital), Weiming Gong, JianXin Xu, Yingying  
8  
9  
10 3 Qian (Shanghai Qingpu Maternal and Child Health Center), Mingjie Luo,  
11  
12 4 Jingwei Xia, Dongmei Chen, Zhenyu Tang (Shanghai Huangpu Maternal  
13  
14  
15 5 and Child Health Center), Xuejing Zhu, Qing Liu, Huiling Yang (Shanghai  
16  
17  
18 6 Huangpu Maternal and Child Health Hospital), Xiaotian Li, Zhiyong Wu,  
19  
20  
21 7 Chuanmin Ying, Shan Shi (Obstetrics & Gynecology Hospital of Fudan  
22  
23  
24 8 University (Shanghai Red House Ob & Gyn Hospital)), Yanquan Zhang,  
25  
26  
27 9 Mingyi Yang (Wujing Hospital, Minhang District, Shanghai), Xiaohua  
28  
29  
30 10 Zhang, Lei Zhang, Lin Guan (Shanghai Minhang District Maternal and  
31  
32  
33 11 Child Health Care Hospital), Jinyu Xu, Honglin Wang, Fang Shen (The  
34  
35  
36 12 Fifth People's Hospital of Shanghai, Fudan University), Wenying Li,  
37  
38  
39 13 Xiaojing Teng, Jinling Zhao (Shanghai Minhang TCM Hospital), Cuili  
40  
41  
42 14 Zhu, Lan Wang, Hongwei Chen (Shanghai Songjiang District Central  
43  
44  
45 15 Hospital), Xiaoming Yuan, Meihua Zhang, Yaqiong Jin (Sijing Hospital,  
46  
47  
48 16 Songjiang District, Shanghai), Qing Yang, Hong Zhu, Min Feng  
49  
50  
51 17 (Songjiang Maternal and Child Health Center), Ying Wang, Yan Wu, Hong  
52  
53  
54 18 Tang (Songjiang Maternal and Child Health Hospital), Sa Guo (Tongji  
55  
56  
57 19 Hospital of Tongji University), Hongling Du (Shanghai Putuo District  
58  
59  
60 20 People's Hospital), Yuhuan Liu, Zhanyue Yi, Renhua Shi (Changhai  
21  
Hospital, Second Military Medical University, Shanghai), Yu Gu, Qinfen



1  
2  
3  
4 1 Su, Yingying lv (Shanghai Zhabei District Central Hospital), Yun Sun,  
5  
6  
7 2 Qiongpei Gu (Yangpu District Family Planning Service Center), Xixia  
8  
9  
10 3 Pang, Qingwu Zhang (Kong Jiang Hospital of Yangpu District, Shanghai),  
11  
12 4 Songxiao Bai, Baoqiao Qi (Shanghai East City Hospital).  
13  
14  
15  
16  
17

18 **Contributors:** Substantial contributions to the conception or design of the  
19  
20 7 work were made by GH and WY. YZ and DW prepared the original draft  
21  
22  
23 8 of the manuscript. YZ, DW, YY, JY, ML, MJ, YD and XC led study  
24  
25  
26 9 implementation at participating sites. DW and YZ were responsible for the  
27  
28  
29 10 day-to-day project management at each site. XM and WS were responsible  
30  
31  
32 11 for the biobank of the cohort. All authors provided critical review of the  
33  
34 12 manuscript for important intellectual content and approved the final  
35  
36  
37 13 version.  
38  
39  
40  
41

42 **Funding:** This work is supported by National key research and  
43  
44 16 development program (Grant No: 2016YFC1000506) and Natural Science  
45  
46  
47 17 Foundation of China (Grant No: 81273168). Three-year Planning for  
48  
49  
50 18 Strengthening the Construction of Public Health System in Shanghai  
51  
52  
53 19 (GWIV-24).  
54  
55  
56  
57

58 **Patient and public involvement:** No patient involved.  
59  
60

1

2 **Conflict of interest:** The authors have no conflicts of interest.

3

4 **Ethics approval:** This study was approved by Ethics Committee of  
5 Children's Hospital of Fudan University, Shanghai, China.

6

7 **Provenance and peer review** Not commissioned; externally peer  
8 reviewed.

9

10 **Data sharing statement:** The study data are not freely available due to  
11 confidentiality reasons, but the research team welcomes potential  
12 collaboration with other researchers. For further information, contact the  
13 author GH (gyhuang@shmu.edu.cn)

## REFERENCES

1. Mahle WT, Newburger JW, Matherne GP, Smith FC, Hoke TR, Koppel R, Gidding SS, Beekman RH, 3rd, Grosse SD, American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young CoCN *et al*: **Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics.** *Circulation* 2009, **120**(5):447-458.
2. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW: **Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis.** *J Am Coll Cardiol* 2011, **58**(21):2241-2247.
3. China MoPHo: **China's birth defects prevention report.** In. Edited by China MoPHo. Beijing; 2012.
4. Zhao QM, Ma XJ, Ge XL, Liu F, Yan WL, Wu L, Ye M, Liang XC, Zhang J, Gao Y *et al*: **Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study.** *Lancet* 2014, **384**(9945):747-754.
5. Bruneau BG: **The developmental genetics of congenital heart disease.** *Nature* 2008, **451**(7181):943-948.
6. Alverson CJ, Strickland MJ, Gilboa SM, Correa A: **Maternal smoking and congenital heart defects in the Baltimore-Washington Infant Study.** *Pediatrics* 2011, **127**(3):e647-653.
7. Lee LJ, Lupo PJ: **Maternal smoking during pregnancy and the risk of congenital heart defects in offspring: a systematic review and metaanalysis.** *Pediatr Cardiol* 2013, **34**(2):398-407.
8. Shi M, Wehby GL, Murray JC: **Review on genetic variants and maternal smoking in the etiology of oral clefts and other birth defects.** *Birth Defects Res C Embryo Today* 2008, **84**(1):16-29.
9. Kuciene R, Dulskiene V: **Selected environmental risk factors and congenital heart defects.** *Medicina (Kaunas)* 2008, **44**(11):827-832.
10. Carmichael SL, Shaw GM: **Maternal life event stress and congenital anomalies.** *Epidemiology* 2000, **11**(1):30-35.
11. Czeizel AE: **Periconceptional folic acid-containing multivitamin supplementation for the prevention of neural tube defects and cardiovascular malformations.** *Ann Nutr Metab* 2011, **59**(1):38-40.
12. Botto LD, Mulinare J, Erickson JD: **Occurrence of congenital heart defects in relation to maternal multivitamin use.** *Am J Epidemiol* 2000, **151**(9):878-884.
13. Ionescu-Ittu R, Marelli AJ, Mackie AS, Pilote L: **Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada.** *Brit Med J* 2009, **338**.
14. Liu SL, Joseph KS, Luo W, Leon JA, Lisonkova S, Van den Hof M, Evans J, Lim K, Little J, Sauve R *et al*: **Effect of Folic Acid Food Fortification in Canada on Congenital Heart Disease Subtypes.** *Circulation* 2016, **134**(9):647-655.
15. Czeizel AE, Dudas I: **Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation.** *N Engl J Med* 1992, **327**(26):1832-1835.
16. Liu S, Joseph KS, Luo W, Leon JA, Lisonkova S, Van den Hof M, Evans J, Lim K, Little J, Sauve R *et al*: **Effect of Folic Acid Food Fortification in Canada on Congenital Heart Disease Subtypes.** *Circulation* 2016, **134**(9):647-655.
17. Cordero AM, Crider KS, Rogers LM, Cannon MJ, Berry RJ: **Optimal serum and red blood cell folate concentrations in women of reproductive age for prevention of neural tube defects: World Health Organization guidelines.** *MMWR Morb Mortal Wkly Rep* 2015, **64**(15):421-423.
18. Kim YI: **Will mandatory folic acid fortification prevent or promote cancer?** *Am J Clin Nutr* 2004, **80**(5):1123-1128.
19. Selhub J, Rosenberg IH: **Excessive folic acid intake and relation to adverse health outcome.** *Biochimie* 2016, **126**:71-78.
20. Wiens D, DeSoto MC: **Is High Folic Acid Intake a Risk Factor for Autism?-A Review.** *Brain Sci* 2017, **7**(11).
21. Bolann BJ, Distant S, Morkrid L, Ulvik RJ: **Bloodletting therapy in hemochromatosis: Does it affect trace element homeostasis?** *J Trace Elem Med Biol* 2015, **31**:225-229.
22. Hu XJ, Ma XJ, Zhao QM, Yan WL, Ge XL, Jia B, Liu F, Wu L, Ye M, Liang XC *et al*: **Pulse Oximetry**

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 1      **and Auscultation for Congenital Heart Disease Detection.** *Pediatrics* 2017, **140**(4).
- 2      23. Lachin JM: **Sample size evaluation for a multiply matched case-control study using the score**
- 3      **test from a conditional logistic (discrete Cox PH) regression model.** *Stat Med* 2008,
- 4      **27**(14):2509-2523.
- 5      24. Tang YQ: **Comments on 'Sample size evaluation for a multiply matched case-control study**
- 6      **using the score test from a conditional logistic (discrete Cox PH) regression model'.** *Stat Med*
- 7      2009, **28**(1):175-177.
- 8      25. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM: **Folate levels and neural tube defects.**
- 9      **Implications for prevention.** *JAMA* 1995, **274**(21):1698-1702.
- 10     26. Tam C, McKenna K, Goh YI, Klieger-Grossman C, O'Connor DL, Einarson A, Koren G:
- 11     **Periconceptional folic acid supplementation: a new indication for therapeutic drug**
- 12     **monitoring.** *Ther Drug Monit* 2009, **31**(3):319-326.
- 13
- 14
- 15

For peer review only

**Table 1. Socio-demographics of participants including 6,573 couples (parents) and 15,203 pregnant women that were enrolled in the Shanghai PreConception Cohort (SPCC).**

Characteristics	Couples (parents) who completed preconception questionnaires		Additional pregnant women who completed both preconception and first-trimester questionnaires		<i>P</i> *		
	Male (n=6573)	Female (n=9243)	Pregnant women (n=15203)				
Age (years), Mean±SD	6573	31.4±4.5	9243	29.9±3.9	15203	29.9±4.0	0.995
Ethnicity	6536		9188		15176		0.258
Han Nationality		6403 (98%)		8966 (97.6%)		15245 (97.8%)	
Other		133 (2%)		222 (2.4%)		342 (2.2%)	
Educational level	6530		9147		15143		<0.001
<College		514 (7.8%)		795 (8.7%)		2052 (13.6%)	
≥College		6016 (92.2%)		8352 (91.3%)		13091 (86.4%)	
Annual household income	6530		9147		NA		
< ¥10 000		1424 (21.8%)		2214 (24.2%)			
≥¥10 000		5106(78.2%)		6933 (75.8%)			
Occupation	6530		9147		14789		<0.001
Entrepreneur		157 (2.4%)		128 (1.4%)		171 (1.1%)	
Farmer		26 (0.4%)		46 (0.5%)		79 (0.5%)	
Self-employed		216 (3.3%)		274 (3%)		862 (5.6%)	
Manager		1410 (21.6%)		1765 (19.3%)		2650 (17.2%)	
Technician		2462 (37.7%)		1903 (20.8%)		3239 (20.6%)	

Company clerk		2259 (34.6%)		5031 (55%)		8451 (54.7%)	
Attending preconception pregnant examination	NA		NA		14996		—
Yes						3374 (22.5%)	
No						11622 (77.5%)	
Times of pregnancy	NA		NA		15162		
1						7569 (49.9%)	
2						4604 (30.4%)	
≥3						2989 (19.7%)	
Miscarriage or stillbirth	NA		NA		15159		
Yes						4838 (31.2%)	
No						10385 (68.7%)	
Smoking	6552		9212		15159		<0.001
Yes		2073 (31.6%)		218 (2.4%)		153 (1.0%)	
No		4479 (68.4%)		8994 (97.6%)		15006 (99%)	
Alcohol drinking	6448		9075		15164		<0.001
Yes		3962 (61.5%)		2865 (31.6%)		1556 (10.3%)	
No		2486 (38.5%)		6210 (68.4%)		13608 (89.7%)	
Location of home	6573		9243		NA		
Developed districts		3034 (46.2%)		5452 (59.0%)			
Developing districts		3539 (53.8%)		3791 (41.0%)			

\* Comparisons between preconception females and pregnant women. *t* tests were used to compare numerical variable (age). Chi-square tests were used to compare categorical variables (ethnicity, educational level occupation, smoking and alcohol drinking).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

**Table 2. Distributions of biomarkers in women before and at early gestation (pilot study)**

Biomarker	Preconception		Early pregnancy	
	n	level	n	level
Serum folate, Median (IQR), ng/ mL	620	9.7 (6.5, 13.8)	577	14.5 (11.2, 16.4)
RBC folate, Median (IQR), ng/ mL	570	247.0 (184.8, 340.5)	587	417.4 (308.6, 544.2)
Homocysteine, Median (IQR), µmol/L	624	6.5 (5.2, 8.6)	599	4.2 (3.5, 5.2)
Vitamin B12, Median (IQR), pg/mL	625	495.2 (394.2, 639.0)	600	388.5 (289.4, 511.4)
Vitamin D, Mean ±SD, ng/ mL	607	16.3 ±6.0	578	15.5 ±6.1

**Table 3. Bio-samples collected and biomarkers that can be examined in the SPCC cohort**

Bio-samples Available in participants	Available sample type and volume	Time		
		Preconception+early pregnancy (Baseline)	24-28 weeks	32-36 weeks
<b>Mother</b>		(n=25487)	(n=8668)	(n=7522)
	Serum, 200 ul*3	Yes	Yes	Yes
	Whole blood	Yes	Yes	Yes
	Genomic DNA, 150 ng	Yes	Yes	Yes
<b>Father</b>		(n= 7151)	-	-
	Serum, 200 ul*3	Yes	NA	NA
	Whole blood	Yes	NA	NA
	Genomic DNA, 150 ng	Yes	NA	NA
<b>Child</b>	NA			

**Scope of research questions:**

1. Quantitative association of preconceptional key nutrition levels (such as serum and RBC folates and related biomarkers, such as homocysteine and vitamin B12) with CHD, currently, and other folate sensitive birth defects.
2. Quantitative association of peri-conceptional maternal and paternal key nutrition levels (preconception levels, and dynamic levels during gestation) with important maternal and neonatal gestational complications, neuro-development of infants, childhood obesity, and clinical pediatric diseases.
3. Peri-conceptional maternal and paternal folate concentration with Autism spectrum disorder, allergy and asthma in children.

**Biomarkers that will be examined in different types of bio-samples:**



- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
1. Biomarkers based on serum sample:
    - a) Folate and related markers: serum folate, homocysteine
    - b) Other Vitamins: vitamin A, vitamin B12, vitamin E, and vitamin D
    - c) Macro and micro metals: Mg, Fe, Zn, Se, Mn, As, Cu, Ca, etc., mg/L
    - d) Serum ferritin
    - e) Fasting glycaemic and lipid profiles: fasting glucose, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein
  2. Whole blood sample: RBC folate
  3. Genomic DNA sample: candidate genetic variants or genome-wide variants are all possible to be examined

1  
2  
3  
4  
5 Figure 1 Diagram of the protocol and follow-up of Shanghai PreConceptional Cohort (SPCC)  
6

7  
8 The baseline population of SPCC cohort was females and males at peri-conception stage (couples who are  
9  
10 prepare-for-pregnancy) and pregnant women at early gestation stage. The cohort includes three phases, from  
11  
12 peri-conception to birth (Phase I, peri-natal phase), from birth to 6 years old (Phase II, infant and pre-school age), and  
13  
14 from 7 to 18 years (Phase III, school age). The current manuscript focuses on the first phase, with congenital heart  
15  
16 disease as the primary outcome, and will cover other folate sensitive birth defects.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## Figure 2 Flow chart diagram

By December 2018, we consecutively recruited 19 144/19 563 (97.9%) participants at preconception settings, including 8045 couples and 3054 single women at pre-pregnancy sites, and an additional 15 615/16 201 (96.4%) pregnant women at maternity hospitals with gestational age <14 weeks were recruited. By the end of December 2018, the last participants recruited at early pregnancy were due for delivery, we have achieved birth records of 12 402 newborns in Maternal Clinic Antenatal Medical Record System. The follow-up of outcomes of the rest of participants is ongoing (shown in Figure 2). A total of 151 cases of CHD were identified through Shanghai Neonatal CHD Screen Platform, 131 cases were from the early pregnancy sample, the remaining 20 cases were from the preconception sample. The prevalence of CHD in liver births is 10.5 ‰ (131/12 402) based on the present available data. In the preconception sample, from March 2016 to May 2018 (the latest data extraction in Maternal Clinic Antenatal Medical Record System), the number of pregnancies and delivers were 1538 and 975 respectively.




Figure 1 Diagram of the protocol and follow-up of Shanghai PreConceptional Cohort (SPCC)  
 The baseline population of SPCC cohort was females and males at peri-conception stage (couples who are prepare-for-pregnancy) and pregnant women at early gestation stage. The cohort includes three phases, from peri-conception to birth (Phase I, peri-natal phase), from birth to 6 years old (Phase II, infant and pre-school age), and from 7 to 18 years (Phase III, school age). The current manuscript focuses on the first phase, with congenital heart disease as the primary outcome, and will cover other folate sensitive birth defects.




Figure 2 Flow chart diagram

45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

By December 2018, we consecutively recruited 19 144/19 563 (97.9%) participants at preconception settings, including 8045 couples and 3054 single women at pre-pregnancy sites, and an additional 15 615/16 201 (96.4%) pregnant women at maternity hospitals with gestational age <14 weeks were recruited. By the end of December 2018, the last participants recruited at early pregnancy were due for delivery, we have achieved birth records of 12 402 newborns in Maternal Clinic Antenatal Medical Record System. The follow-up of outcomes of the rest of participants is ongoing (shown in Figure 2). A total of 151 cases of CHD were identified through Shanghai Neonatal CHD Screen Platform, 131 cases were from the early pregnancy sample, the remaining 20 cases were from the preconception sample. The prevalence of CHD in liver births is 10.5 ‰ (131/12 402) based on the present available data. In the preconception sample, from March 2016 to May 2018 (the latest data extraction in Maternal Clinic Antenatal Medical Record System), the number of pregnancies and delivers were 1538 and 975 respectively.

## Appendix 1 Variable list

<b>Pre-pregnant variable list</b>		
No	Variables	Data type
	<b>General information</b>	
1	Wife id	Text
2	Husband nation	Text
3	Husband age	N
4	Husband education	Text
5	Husband id	Text
6	Husband occupation	Text
7	Wife nation	Text
8	Wife age	N
9	Wife education	Text
10	Wife occupation	Text
11	Tel No	Text
12	Mobile phone No	Text
	<b>Medical history</b>	
13	Female anemia	Category
14	Female EH	Category
15	Female heart disease	Category
16	Female DM	Category
17	Female epilepsy	Category
18	Female thyroid disease	Category
19	Female CGN	Category
20	Female mental disease	Category
21	Female tumour	Category
22	Female TB	Category
23	Female HBV	Category
24	Female VD	Category
25	Male anemia	Category
26	Male EH	Category
27	Male heart disease	Category
28	Male DM	Category
29	Male epilepsy	Category
30	Male thyroid disease	Category
31	Male CGN	Category
32	Male mental disease	Category
33	Male tumour	Category
34	Male TB	Category
35	Male HBV	Category
36	Male VD	Category

	<b>Vaccine</b>	
37	Female rubella vaccine	Category
38	Female hepB vaccine	Category
39	Male hepB vaccine	Category
	<b>Drug use</b>	
40	Female current medicine	Category
41	Female medicine name	Category
42	Male current medicine	Category
43	Male medicine name	Category
	<b>Childbearing history</b>	
44	Birth history	Category
45	Pregnancy times	Category
46	Live birth	Category
47	Dead fetus	Category
48	Dead birth	Category
49	Term delivery	Category
50	Premature delivery	Category
51	Natural abortion	Category
52	Abactio	Category
53	Children number	Category
54	Birth defect	Category
55	Defect type	Category
56	Menarche age	Category
57	Period menstruation	Category
58	Menstrual cycle	Category
59	Menstrual quantity	Category
60	LMP	Date
	<b>Family history of disease</b>	
61	Female family history thalassemia	Category
62	Female family history albinism	Category
63	Female family history favism	Category
64	Female family history hemophilia	Category
65	Female family history CHD	Category
66	Female family history DS	Category
67	Female family history openNTDs	Category
68	Female family history DM	Category
69	Female family history dysnoesia	Category
70	Female family history daysaudia	Category
71	Female family history viual disorder	Category
72	Female family history neuropsychiatric	Category
73	Female family history other birth defects	Category
74	Female family history fetal death	Category
75	Female family history intermarry	Category

76	Female family history relations	Category
77	Male family history thalassemia	Category
78	Male family history albinism	Category
79	Male family history favism	Category
80	Male family history hemophilia	Category
81	Male family history CHD	Category
82	Male family history DS	Category
83	Male family history openNTDs	Category
84	Male family history DM	Category
85	Male family history dysnoesia	Category
86	Male family history dysaudia	Category
87	Male family history vidual disorder	Category
88	Male family history neuropsychiatric	Category
89	Male family history other birth defects	Category
90	Male family history fetal death	Category
91	Male family history intermarry	Category
92	Male family history relations	Category
	<b>Anthroposomatology</b>	
93	Female height	Numeric
94	Female weight	Numeric
95	Female BMI	Numeric
96	Female heart rate	Numeric
97	Female SBP	Numeric
98	Female SDP	Numeric
99	Male height	Numeric
100	Male weight	Numeric
101	Male BMI	Numeric
102	Male heart rate	Numeric
103	Male SBP	Numeric
104	Male SDP	Numeric
	<b>Lab data</b>	
105	Leucorrhoea check	Numeric
106	Clue cell	Numeric
107	Monilia infection	Numeric
108	Trichomomas	Numeric
109	Cleanness	Numeric
110	Whiff test	Numeric
111	PH	Numeric
112	Wom blood analysis	Numeric
113	Female hb	Numeric
114	Female wbc	Numeric
115	Female rbc	Numeric
116	Wom urine test	Numeric



117	Female ABO	Numeric
118	Female Rh	Numeric
119	Female GLU	Numeric
120	Female GLU levels	Numeric
121	Female NG	Numeric
122	Female chlamydia	Numeric
123	Female syphilis	Numeric
124	Female HIV	Numeric
125	Female ALT	Numeric
126	Female ALT levels	Numeric
127	Female HBs-Ag	Numeric
128	Female HBs-Ab	Numeric
129	Female HBe-Ag	Numeric
130	Female HBe-Ab	Numeric
131	Female HBc-Ab	Numeric
132	Female HCV-Ab	Numeric
133	Female CMV IgM	Numeric
134	Female CMV IgG	Numeric
135	Female RV IgM	Numeric
136	Female RV IgG	Numeric
137	Female TOX IgM	Numeric
138	Female TOX IgG	Numeric
139	Male blood analysis	Numeric
140	Male hb	Numeric
141	Male wbc	Numeric
142	Male rbc	Numeric
<b>During-pregnancy variable list</b>		
	<b>Basic information</b>	
1	Hospital card number	Text
2	Inpatient number	Text
3	Name	Text
4	Age	Numeric
5	Pregnant times	Numeric
6	Delivery times	Numeric
7	Last menstrual period	Date
8	Gestational week at the first visit	Numeric
9	The first visit date	Date
10	Height	Numeric
11	Weight	Numeric
12	Systolic blood pressure at the first visit	Numeric
13	Diastolic blood pressure at the first visit	Numeric

14	Occupation	Text
15	Education	Text
	<b>Antenatal care record</b>	
16	Weight at each antenatal care	Numeric
17	Systolic blood pressure at each antenatal care	Numeric
18	Diastolic blood pressure at each antenatal care	Numeric
19	Gestational week at each antenatal care	Numeric
20	Antenatal care date	Date
	<b>Lab data</b>	
21	Cytomegalovirus	Numeric
22	Cytomegalovirus examination date	Date
23	Rubella virus	Numeric
24	Rubella virus examination date	Date
25	Toxoplasmosis	Numeric
26	Toxoplasmosis examination date	Date
27	Syphilis screening	Numeric
28	Syphilis screening examination date	Date
29	Fasting blood-glucose	Numeric
30	Fasting blood-glucose examination date	Date
31	HCT(hematokrit)	Numeric
32	HCT(hematokrit) examination date	Date
33	Serum folate	Numeric
34	Serum folate examination date	Date
35	HCY(homocysteine)	Numeric
36	HCY(homocysteine) examination date	Date
37	OGTT 0 hours	Numeric
38	OGTT 1 hours	Numeric
39	OGTT 2 hours	Numeric
40	OGTT examination date	Date
41	Triglyceride	Numeric
42	Triglyceride examination date	Date
43	Total cholesterol	Numeric
44	Total cholesterol examination date	Date
45	Hemoglobin	Numeric
46	Hemoglobin examination date	Date
	<b>Delivery date</b>	
47	Gestational week at delivery	Numeric
48	Delivery mode	Text
49	Birth weight	Numeric
50	Birth weight(second baby)	Numeric
51	Systolic blood pressure at delivery	Numeric
52	Diastolic blood pressure at delivery	Numeric
53	Apgar scoring	Numeric

54	Delivery date	Date
55	Birth defect records	Text
56	Weight blood pressure at delivery	Numeric
<b>Offspring variable list</b>		
	<b>0 - 6 years (6 weeks, 6 months, 12 months, 36 months, 60 months)</b>	
1	Name	Text
2	ID number	Text
3	Weight	Numeric
4	Height/ Length	Numeric
5	Vision detection	Numeric
6	DDST: Denver developmental screening test	Numeric
	<b>6 - 18 years (each year)</b>	
7	Weight	Numeric
8	Height	Numeric
9	Diastolic blood pressure	Numeric
10	Systolic blood pressure	Numeric
11	Vision detection	Numeric
12	Vital capacity	Numeric
13	Physical fitness measurement (running, jumping, solid balls, etc)	Text
The clinical diagnosis during 0 – 18 years will be extracted from the routine medical system each year.		

1  
2  
3 姓名 Name : \_\_\_\_\_

4 身份证号 ID no : □□□□□□□□□□□□□□□□□□□□

5  
6 医院代码 Hospital No : \_\_\_\_\_ ( 到时打印到问卷上 )

7  
8 填表日期 Date : \_\_\_\_\_年\_\_\_\_月\_\_\_\_日

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 孕前膳食补充剂调查表

# Pre-pregnancy nutrition supplement questionnaire

( 男女共用 )

## A 一般情况

A1 联系电话（请您认真填写，以助于医生和您联系） Contact number: _____ (手机) _____ (固定电话) _____ (Email)
A2 家庭住址 Address: _____ 区/县 _____ 街道/小区 _____ 门牌号码/村
A3 您的出生日期是 Birth date _____ 年 _____ 月 _____ 日
A4 民族 Nationality <input type="checkbox"/> 1 汉族 <input type="checkbox"/> 2 其他（请注明） _____
A5 您的最高学历 Education <input type="checkbox"/> 1 初高中以下 <input type="checkbox"/> 2 大专本科 <input type="checkbox"/> 3 硕士研究生以上及以上
A6 您现在的主要职业 Occupation <input type="checkbox"/> 1 管理人员/干部 <input type="checkbox"/> 2 技术人员 <input type="checkbox"/> 3. 企业主 <input type="checkbox"/> 4 工人 <input type="checkbox"/> 5 农民 <input type="checkbox"/> 6 个体户 <input type="checkbox"/> 7 其它 _____
A7 上一年您的家庭年收入是： Income of a year <input type="checkbox"/> 1. <2 万元 <input type="checkbox"/> 2. (2~3.9)万 <input type="checkbox"/> 3.(5.9)万 <input type="checkbox"/> 4.(6~9.9)万 <input type="checkbox"/> 5.(10~14.9)万 <input type="checkbox"/> 6.15 万及以上 <input type="checkbox"/> 9.不详
A8 填表日期 Date _____ 年 _____ 月 _____ 日

## B 营养补充剂使用情况

营养补充剂种类 Nutritional supplement types	叶酸 Folic acid	复合维生素 multi-vitamins	单一维生素 Single vitamin
您在近三个月是否服用 Have you taken it in the last three months?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂？（如果没有对应选项请在其他处写明） Brand name	<input type="checkbox"/> 1、创盈金斯利安多维片 <input type="checkbox"/> 2、福施福胶囊营养素 <input type="checkbox"/> 3、汤臣倍健 <input type="checkbox"/> 4、安利纽崔莱铁 <input type="checkbox"/> 5、其他 _____	<input type="checkbox"/> 1、爱乐维 <input type="checkbox"/> 2、汤臣倍健孕妇专用 <input type="checkbox"/> 3、惠氏玛特纳 <input type="checkbox"/> 4、21 金维他 <input type="checkbox"/> 5、其他 _____	<input type="checkbox"/> V <sub>C</sub> <input type="checkbox"/> V <sub>E</sub> <input type="checkbox"/> V <sub>B1</sub> <input type="checkbox"/> V <sub>B2</sub> <input type="checkbox"/> 其他 _____
您这三个月的服用频率？（如果食用频率小于每天/周一次，请填写每周/月食用几次，并勾出周/月） How often did you take in	_____次/□天 □周 □月	_____次/□天□周□月	_____次/□天 □周 □月

营养补充剂种类 Nutritional supplement types	铁 Fe	钙 Ca	锌 Zn
您在近三个月是否服用 Have you taken it in the last three months?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂？（如果没有，选项请在其他处写明） Brand name	<input type="checkbox"/> 1、汤臣倍健叶酸亚铁片 <input type="checkbox"/> 2、安利纽崔莱铁片 <input type="checkbox"/> 3、金康倍叶酸铁片 <input type="checkbox"/> 4、其他_____	<input type="checkbox"/> 1、惠氏金钙尔奇 <input type="checkbox"/> 2、君宝康孕妇钙片 <input type="checkbox"/> 3、十月妈咪维生素 AD 钙锌咀嚼片 <input type="checkbox"/> 4、安利钙镁片 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、美康利健 MK 硒金牡蛎锌片 <input type="checkbox"/> 2、汤臣倍健 锌咀嚼片 <input type="checkbox"/> 3、宫诺肽片 <input type="checkbox"/> 4、其他_____

您这三个月的服用频率？（如果食用频率小于每天/周一次，请填写每周/月食用几次，并勾出周/月） How often did you take in	____次/□天 □周 □月	____次/□天□周□月	____次/□天 □周 □月
---	----------------	--------------	----------------

### B 营养补充剂使用情况

<b>C 吸烟情况</b>	
C1 您有吸烟史吗？ Have you smoked cigarettes ever before?	□ 1 是                      □ 0 否 ( <b>跳至 F6</b> )
C2 在您最近的 3 个月内，您是否吸烟？ Did you smoke cigarettes in 3 month	□ 1 是                      □ 0 否
C3 如果是，您平均每天吸多少支烟？ On average, how many cigarettes did you smoke each day in the month after your last menstrual period?	_____ 支
C4 如果您曾经戒过烟，您戒了多少次？ How many times did you stop smoking?	_____
C5 在您生活的大多数时间里，您是否暴露于他人烟草烟雾中？ On most days during your pregnancy, were you exposed to someone else's cigarette smoke?	□ 1 是                      □ 0 否 ( <b>跳至 G1</b> )
C6 您在哪里暴露与烟草烟雾中 Where were you exposed to the smoke?	□ 1 仅在家中      □ 2 仅在工作单位      □ 3 在家和在工作单位均暴露
<b>D 酒精</b>	
D1 您最近三个月的饮酒情况？ During the 3 months before or during your pregnancy, did you ever drink any alcoholic beverages?	
<input type="checkbox"/> 0.从未饮酒； <input type="checkbox"/> 1.尝试饮酒（曾饮至少半瓶或一听啤酒，一小盅白酒等）； <input type="checkbox"/> 2.现在饮酒（过去 30 天，至少有一天喝过一杯酒）； <input type="checkbox"/> 3.重度饮酒（过去 30 天，至少有一天在 2 小时内喝过五杯酒）； <input type="checkbox"/> 4.醉酒（过去 12 个月内，因喝酒太多而感到头晕/头疼/嗜睡等醉酒症状）。	

核查人员签名：\_\_\_\_\_

Name of pregnancy : \_\_\_\_\_

ID no : \_\_\_\_\_

## 孕期危险因素暴露调查表

## Pregnancy risk factor exposure questionnaire

For peer review only



**A 一般情况 General information**

A1 您的出生日期是 Birth date	_____年_____月_____日
A2 民族 Nationality	<input type="checkbox"/> 1 汉族 Han <input type="checkbox"/> 2 其他 other_____
A3 您的最高学历 Education	<input type="checkbox"/> 1 初高中以下 Mid <input type="checkbox"/> 2 大专本科 High <input type="checkbox"/> 3 硕士研究生以上及以上 College
A4 您现在的主要职业 Occupation	<input type="checkbox"/> 1 管理人员/干部 <input type="checkbox"/> 2 技术人员 <input type="checkbox"/> 3. 企业主 <input type="checkbox"/> 4 工人 <input type="checkbox"/> 5 农民 <input type="checkbox"/> 6 个体户 <input type="checkbox"/> 7 其它_____
A6 家庭住址: Address	_____区/县_____街道/小区_____门牌号码/村
A7 联系电话 (请您认真填写, 以助于医生和您联系): Contact number	_____(手机) _____(固定电话) _____(Email) _____(微信号)

**B 本次妊娠情况**

B1 您孕前体重通常为? Current weight	_____ (公斤 Kg)
B2 您身高是? Height	_____ (厘米 cm)
B3 您的腰围是? Waist	_____ (厘米 cm)
B4 您此次怀孕的末次月经时间? What was the first day of the menstrual period that came right before this pregnancy (LMP)?	_____年_____月_____日
B5 孕期是否发生过重大负性生活事件而使您的精神受到刺激? Have you ever experienced the negative events which irritate you and generate some negative emotion?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
B6 生这个孩子是您第几次怀孕? How many times have you been pregnant?	_____次
B7 是否有不良生育史? Did you have the adverse reproductive history?	<input type="checkbox"/> 1 有 (继续回答 B6.1) <input type="checkbox"/> 0 无 (跳至 B7)
B6.1 流产史 Abortion	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B6.2 早产史 Preterm	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B6.3 死产史 Stillbirth	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B8 您是否有糖尿病和高血压疾病? Do you have hypertension or diabetes	<input type="checkbox"/> 1 是 (继续回答 B8) <input type="checkbox"/> 0 否 (跳至 C1) <input type="checkbox"/> 999 不知道 (跳至 C1)
B9 您的直系亲属中是否患有糖尿病、高血压疾病? Is there the family history of hypertension or diabetes in children's immediate family members	<input type="checkbox"/> 1 是 (继续回答 B8) <input type="checkbox"/> 0 否 (跳至 C1) <input type="checkbox"/> 999 不知道 (跳至 C1)
B10 若有, 请选择出该亲属与您的关系 (可多选) If so, please choose the relationship with the child	

1. 父亲    2. 母亲    3. 爷爷    4. 奶奶    5. 兄弟    6. 姐妹

### C 叶酸使用

C1 在您末次月经前三个月内，您是否服用过叶酸？ Did you take folic acid in the month before your last period?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否		
C2 在您末次月经之后至今，您是否服用过叶酸？ Did you take any folic acid after your last period and during pregnancy ?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否		
	叶酸 1	叶酸 2	叶酸 3
C3 药物名称(商品名) Brand name			
C4 使用时间 When did you take it?	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always
C5 是否在怀孕期间一直使用？ Did you take it during the rest of your pregnancy?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C6 是否停止使用过？ Did you stop taking it?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C7 使用频率？ How often did you take it?	____次/□天 □周 □月	____次/□天 □周 □月	____次/□天 □周 □月
C8 每次的使用量 What is the usage per time?	一次____片	一次____片	一次____片

### D 维生素使用

D1 在您末次月经的前三个月内，您是否服用过维生素？ Did you take any vitamins in the three months before your last period ?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否		
D2 在您末次月经之后至今，您是否服用过维生素？ Did you take any vitamins after your last period and during pregnancy?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 (跳至 E1)		
	维生素 1	维生素 2	维生素 3
D3 维生素名称 Vitamin name			
D4 维生素商品名称 Brand name			

D5 是否是医生给药? Did your doctor give it to you?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
D6 是否包括叶酸? Does it contain folic acid?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道
D7 使用时间 When did you take it?	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always
D8 是否停止使用过? Did you stop taking it?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
D9 使用频率? How often did you take it?	____次/□天 □周 □月	____次/□天 □周 □月	____次/□天 □周 □月
D10 每次的使用量 What is the usage per time?	一次____片	一次____片	一次____片

### E 其他营养补充剂使用情况 Other nutritional supplement use

营养补充剂种类 Nutritional supplement types	铁 Fe	钙 Ca	锌 Zn
您在近三个月是否服用 Did you take it around the time you became pregnant?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂? (如果没有, 选项请在其他处写明) Brand name	<input type="checkbox"/> 1、汤臣倍健叶酸亚铁片 <input type="checkbox"/> 2、安利纽崔莱铁片 <input type="checkbox"/> 3、金康倍叶酸铁片 <input type="checkbox"/> 4、其他_____	<input type="checkbox"/> 1、惠氏金钙尔奇 <input type="checkbox"/> 2、君宝康孕妇钙片 <input type="checkbox"/> 3、十月妈咪维生素 AD 钙锌咀嚼片 <input type="checkbox"/> 4、安利钙镁片 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、美康利健 MK 硒金牡蛎锌片 <input type="checkbox"/> 2、汤臣倍健 锌咀嚼片 <input type="checkbox"/> 3、宫诺肽片 <input type="checkbox"/> 4、其他_____
您这三个月的服用频率? (如果食用频率小于每天/周一一次, 请填写每周/月食用几次, 并勾出周/月) How often did you take it?	____次/□天 □周 □月	____次/□天□周□月	____次/□天 □周 □月

**F 草本药物使用**

F1 在您末次月经前三个月内，您是否使用过任何一种草本药物/传统医学药物？ Did you take any herbal supplements/traditional Chinese medicine in the three months before your last period □ 1 是      □ 0 否			
F2 在您末次月经之后，您是否使用过任何一种草本药物/传统医学药物 Did you take any herbal supplements/traditional Chinese medicine after your last period and during pregnancy? ? □ 1 是      □ 0 否 (跳至 F1)			
	草本药物 1 Herbal 1	草本药物 2 Herbal 2	草本药物 3 Herbal 3
F3 草本药物类型 Name of herb	□ 1 中成药 □ 2 中医草药	□ 1 中成药 □ 2 中医草药	□ 1 中成药 □ 2 中医草药
F4 药物名称(如果选择中医草药，请填写中药功效) The use of traditional Chinese medicine			
F5 用药持续多少天 How long did you take in?	_____天	_____天	_____天

**G 吸烟情况**

G1 您在怀孕前或者怀孕期间吸烟吗？ Did you smoke cigarettes before or during your pregnancy with the baby?	□ 1 是      □ 0 否(跳至 F9)
G2 在您末次月经的当月，您是否吸烟？ Did you smoke during the month before your last menstrual period ?	□ 1 是      □ 0 否
G3 在您末次月经的一个月后（末次月经结束直至一个月后），您是否吸烟？ (跳至 5) Did you smoke during the month after your last menstrual period, that is between LMP and LMP+1 month	□ 1 是      □ 0 否
G4 如果是，您平均每天吸多少支烟？ On average, how many cigarettes did you smoke each day in the month after your last menstrual period ? 支	
G5 在您怀孕期间，您是否吸烟？ Did you smoke during your pregnancy?	□ 1 是      □ 0 否(跳至 F7)
G6 在您怀孕期间，您平均每天吸多少支烟？ On average how many cigarettes did you smoke each	_____ 支

G7 在您末次月经期间至今，您是否戒过吸烟？ Did you stop smoking at any time between your last menstrual period and the end of your pregnancy?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否 (跳至F9)
G8 您戒烟有多少次？ How many times did you stop? _____ 次		
G9 在您怀孕的大多数时间里，您是否暴露于他人烟草烟雾中？ On most days during your pregnancy, were you exposed to someone else's cigarette smoke?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否 (跳至G1)
G10 您在哪里暴露与烟草烟雾中？ Where were you exposed to the smoke?	<input type="checkbox"/> 1 仅在家中 <input type="checkbox"/> 2 仅在工作单位 <input type="checkbox"/> 3 在家和在工作单位均暴露	

## H 酒精

H1 在您怀孕前三个月至今，您是否饮用过任何含有酒精的饮料？ During the 3 months before or during your pregnancy, did you ever drink any alcoholic beverages?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否
H2 在这三个月内，您通常每次饮几杯酒？ On those days that you drank, how many drinks did you have?	_____ 杯	

## I 环境暴露情况

I1 怀孕前三个月到现在，您是否染烫发？ Did you dye perm in the first three months of pregnancy?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否
I2 怀孕前三个月到现在，后您工作的地点或家里是否装修过？ Did you exposed to formaldehyde in the first three months of pregnancy?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否
I3 怀孕前后您是否接触过下列物质？ Have you been exposed to the following substances before and after pregnancy? (Toxic chemicals)	<input type="checkbox"/> 1 除草剂 <input type="checkbox"/> 2 杀虫剂 <input type="checkbox"/> 3 灭鼠剂 <input type="checkbox"/> 4 有机溶剂 <input type="checkbox"/> 5 消毒剂 <input type="checkbox"/> 6 金属制剂 <input type="checkbox"/> 7 有害气体 <input type="checkbox"/> 8 有害固体	

## J 药物使用情况

以下问题是有关于您在末次月经之前三个月内至今期间的用药情况

	治疗高血压 药物 Medication for hypertension	胰岛素 Insulin for diabetes	口服降血糖 药物 Oral hypoglycemic for diabetes	抗癫痫药物 Medications for epilepsy	每天都要服用 的药物 Medications at least once a day
1 您是否使用过？ Did you take?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否

2 您使用的药物名称? What did you take?	_____	_____	_____	_____	_____	_____
<b>如果下一个问题令您感到不安且不愿意回答, 请在“拒答”上打√, 我们将对您所有回答进行严格保密!</b>						
	安定\有助于您放松药物 Valium\drugs to help you relax	使您感觉良好\精力旺盛 Make you feel good\have more energy	美沙酮\氧可酮\其他止痛药 Methadone oxymoron\other pain killers	可卡因 Cocaine or crack cocaine	海洛因 Heroin	大麻 Marijuana
1 您是否使用过? Did you take?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚
2 您使用的药物名称? What did you take?	_____	_____	_____	_____	_____	_____

### I 您在怀孕期间是否患过以下疾病?

I.3 发热性疾病及呼吸道感染 Febrile illness and respiratory infections	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
I.3.1 您发烧时的最高温度是多少? What was the highest temperature of your fever during your illness?	_____ °C
I.3.2 您发烧有几天? How long did you have a fever?	_____ 天
I.6 其他 _____	

**调查结束, 谢谢您的配合!**

调查员姓名 \_\_\_\_\_

调查日期 \_\_\_\_/\_\_\_\_/\_\_\_\_  
年 月 日

1  
2  
3 Types of fetus defects and birth defects  
4

---

5 **Diagnosis**  
6

7 Anencephalus  
8

9 Spina bifida  
10

11 Encephalocele  
12

13 Congenital Hydrocephalus  
14

15 Cleft Palate  
16

17 Cleft Lip  
18

19 Cleft Lip with Cleft Palate  
20

21 Microtia (including Anotia)  
22

23 Deformity of external ear(s) (except Microtia and Anotia)  
24

25 Esophageal atresia or stenosis  
26

27 Anorectal atresia (including Congenital Anorectal Malformations)  
28

29 Hypospadias  
30

31 Ectopocystis  
32

33 Pes Equinovarus  
34

35 Polydactylism  
36

37 Syndactylia  
38

39 Limb shortening  
40

41 Congenital Diaphragmatic Hernia  
42

43 Pcomphalus  
44

45 Celoschisis  
46

47 Conjoined Twins  
48

49 Trisomy 21 syndrome  
50

51 Congenital heart disease  
52

53 Others  
54  
55

---

56  
57 **Note:** Down's syndrome, neural tube defects, congenital heart defects, hydrocephalus, digestive tract  
58 malformations and urinary malformations are most common defects in China. Defects were detected by  
59  
60

1  
2  
3 prenatal Down's syndrome screening, NT examination and Ultrasound image examination during the  
4 second trimester; and the number and type of birth defects after childbirth are diagnosed by professional  
5 clinical team. Down syndrome (DS), caused by the trisomy, translocation, or partial trisomy of  
6 chromosome 21, is the most common genetic cause of intellectual disability. DS is diagnosed by  
7 neonatologist. Neural tube defects including spina bifida and hypospadias, were diagnosed by ultrasound  
8 examination and pediatric neurosurgeon. Congenital heart disease was diagnosis by Doppler ultrasound  
9 and CHD screening (pulse oximetry plus cardiac murmurs). Hydrocephalus, digestive tract malformations,  
10 urinary malformations and other defects also were also diagnosed either by ultrasound or some other  
11 specific diagnosis methods.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## **Future Plan of Shanghai PreConception Cohort, Shanghai, China (SPCC)**

The Shanghai PreConception Cohort (SPCC) is a long-term cohort and meets the “Cohort profile” requirement. We have a complete plan to follow-up offspring to the age of 18 years old. The cohort will be financially supported by different grants. The current manuscript focuses on the first phase, the establishment of the baseline and our first main outcome, the congenital heart disease (CHD).

The second phase of this cohort study is from birth to 6 years old. Follow-up work will rely on Shanghai Community health care centers-child care. The third phase is from 6 to the age of 18 (school age). We will cooperate with Shanghai Student Health and Fitness Surveillance Center for the follow-up of the school age children.

Multiple outcomes for pediatrics, including growth, physical and neuro-developments, obesity, common and rare diseases will be investigated. Nested case-control design will be used for rare outcomes.

## The data collection plan for infants and children

	At birth	6 weeks	6 months	12 months	36 months	60 months	6 – 18 years*
General information (gender, ID number, Home Address, etc)	√	√					
Delivery outcome (Congenital malformation, preterm birth, miscarriage, stillbirth)	√						
Body measurement (weight, height, waistline, hipline)	√	√	√	√	√	√	√
Diet investigation (questionnaire)	√	√	√	√	√	√	√
Neurobehavioral developmental assessment (DDST <sup>\$</sup> )		√	√	√	√	√	
Anthropometrics data (Shanghai Community health care centers-child care and Shanghai Student Health and Fitness Surveillance Center) weight, height, waist circumference	√	√	√	√	√	√	√
Physical fitness measurement (running, jumping, solid balls, etc)							√
Blood pressure measurement, annually							√
Hemachrome (anemia)							√
Renal functions, at grade 9 and 12							√
Cardiovascular-related chronic diseases (Hypertension, Obesity, Diabetes/Pre-diabetes and Dyslipidemia)							√
Venous blood <sup>#</sup>							√

Note: \* Shanghai Student Health and Fitness Surveillance Center routinely conducts all-round physical examinations for students in the school as a health care policy for Shanghai students. It is usually in September-November of each year.

\$ DDST: Denver developmental screening test.

# Venous blood will be collected at 12, 15 and 18 years of age.

# BMJ Open

## Cohort profile: Shanghai PreConception Cohort (SPCC) for association of periconceptional parental key nutrition factors with health outcomes of children: I -congenital heart disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031076.R3
Article Type:	Cohort profile
Date Submitted by the Author:	28-Sep-2019
Complete List of Authors:	Wang, Dingmei; Children's Hospital of Fudan University Zhang, Yi; Children's Hospital of Fudan University Jiang, Yuang; Children's Hospital of Fudan University Ye, Ying; Clinical Epidemiology Ji, Mi; Children's Hospital of Fudan University Dou, Yalan; Children's Hospital of Fudan University, Dermatology Chen, Xiaotian; Children's Hospital of Fudan University Li, Mengru; Children's Hospital of Fudan University Ma, Xiaojing ; Children's Hospital of Fudan University Sheng, Wei; Children's Hospital of Fudan University Huang, Guoying; Children's Hospital of Fudan University, Pediatric Heart Center Yan, Weili; Children's Hospital of Fudan University,
<b>Primary Subject Heading</b>:	Research methods
Secondary Subject Heading:	Public health, Obstetrics and gynaecology, Nutrition and metabolism
Keywords:	red blood cell folate, vitamin, congenital heart diseases, periconceptional health care

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1           **Cohort profile: Shanghai PreConception Cohort (SPCC) for**  
2           **association of periconceptual parental key nutrition factors with**  
3           **health outcomes of children: I -congenital heart disease**

4           Dingmei Wang\*<sup>1,2</sup>, Yi Zhang\*<sup>1,2</sup>, Yuan Jiang<sup>1,2</sup>, Ying Ye<sup>1</sup>, Mi Ji<sup>1</sup>, Yalan  
5           Dou<sup>1</sup>, Xiaotian Chen<sup>1,2</sup>, Mengru Li<sup>2</sup>, Xiaojing Ma<sup>2</sup>, Wei Sheng<sup>2</sup>, Guoying  
6           Huang<sup>2</sup>#, Weili Yan<sup>1,2</sup>#; SPCC group

7           1 Department of Clinical Epidemiology & Clinical Trial Unit (CTU),  
8           Children's Hospital of Fudan University, Shanghai, China.

9           2 Shanghai Key Lab of Birth Defect, Children's Hospital of Fudan  
10          University, Shanghai, China.

11  
12          \* Contributed equally to this work.

13          # Co-corresponding author.

14          A full list of SPCC group can be found after Acknowledgements.

15          Weili Yan, PhD

16          86-21-64931215

17          Email: yanwl@fudan.edu.cn

18          Guoying Huang, MD PhD

19          86-21-64931913

20          Email: gyhuang@shmu.edu.cn

## 1 ABSTRACT (290)

2 **Purpose:** The Shanghai PreConception Cohort (SPCC) was established  
3 initially to investigate associations of parental periconception nutritional  
4 factors with congenital heart disease (CHD), and has extended to children  
5 growth, development and pediatric diseases.

6 **Participants** Prepare-for-pregnant couples who presented at Shanghai  
7 preconception examination clinics and early-pregnant women before 14  
8 gestational weeks were enrolled to comprise a periconception baseline  
9 study population. General characteristics, routine clinical data,  
10 consumption of diet supplements, such as folic acid and multivitamins,  
11 were collected. Blood samples were collected at preconception, early,  
12 middle and late gestation respectively by standard procedures. Multiple  
13 nutrition factors in blood sample of participants that were selected by  
14 case-control design will be examined, including folates, homocysteine,  
15 vitamin A, vitamin D, vitamin E and metals. Genomic DNA was extracted.

16 **Findings to date** The baseline population included 8045 preconception  
17 couples, 3054 single women, and 15 615 early-pregnant women,  
18 respectively. Birth data from 12 402 births were collected and follow-up of  
19 the cohort for more outcomes is ongoing. Currently, 151 CHDs were  
20 identified after birth. Pilot analysis in a small subgroup showed that only  
21 about 15% of 656 preconceptional women and 49% of early-pregnant  
22 women had red blood cell folate concentration meeting the international  
23 recommendation for preventing neural tube defects.

24 **Future plans** Once a sufficient number of CHD cases is achieved, we will  
25 investigate quantitative association of preconceptional red blood cell folate  
26 levels with CHD using nested case-control design. The SPCC cohort will  
27 be followed up for 18 years to investigate extensive outcomes of growth,  
28 development, obesity, and common and rare diseases during childhood and  
29 adolescence according to our plan. Blood nutrition factors will be examined  
30 in participants selected for specific aims. The SPCC cohort will also allow  
31 for prospective cohort studies on extensive research questions.

32 **Registration:** NCT 02737644.

33 **Key Messages:** red blood cell folate, vitamin, congenital heart diseases,  
34 periconception health care

### Strengths and limitations of this study

- The SPCC cohort is the first prospective birth cohort with CHD as primary outcome with recruitment starting from preconception stage. Temporal sequence of exposures and outcomes can be achieved for causal inference of birth defects and other diseases that occur during early stage of gestation.
- Preconception blood samples were appropriately collected and stored which allow examination of individual blood levels for nutrition factors and other exposures.
- Clinical data and blood samples from both father and mother from before conception were collected, which will allow for testing the effect of both maternal and paternal genetic and nutrition factors on fetal and children diseases.
- Although response rate was high (over 95%), preconception participants were recruited from the population who voluntarily presented at Shanghai city preconception physical examination sites. They may have a stronger willingness for a healthy pregnancy, which may induce selection bias.
- Biological samples (cord blood, placenta) of the newborns were not collected.

view only

## 1 INTRODUCTION

2 Congenital heart disease (CHD) is a common congenital malformation,  
3 which seriously affects quality of children's life [1]. CHD is a leading  
4 cause of infant death in high-income countries affecting eight of 1000 live  
5 births [2]. According to the report from National Health and Family  
6 Planning Commission of the People's Republic of China, CHD accounts  
7 for about a quarter of the birth defects of newborns in China, ranking the  
8 first among birth defects [3]. In a prospective, nation-wide large-scale  
9 study in more than 120 000 newborns in China in 2013, the prevalence of  
10 CHD in live births was identified 8.94 ‰; the rate of severe CHD was  
11 2.9 ‰ [4].

12 The cause of CHD is multifactorial. With the development of genetic  
13 engineering technology, the genetic factors have been better understood in  
14 the past decade [5]. Multiple environmental risk factors have been reported  
15 in epidemiological studies, the maternal social variables such as  
16 occupation, educational background, health status, unhealthy life style,  
17 maternal medical history and emotional status, family history of disease,  
18 consanguineous marriages and so on [6-10]. In addition, maternal key  
19 nutrients related to the risk of offspring's CHD as a modifiable  
20 environmental factor during periconception [11, 12]. The periconception  
21 intake of folic acid supplement has been shown to reduce the risk of CHD

1 [13, 14] and women worldwide have been recommended to take folic acid  
2 supplements before conception and in the beginning of pregnancy.  
3 Awareness of the relationship between folic acid deficiency and CHD is  
4 actually a by-product finding from the well-known Hungarian RCT study  
5 of folic acid supplementation to prevent neural tube defects. The study  
6 found that prenatal supplementation with a vitamin complex containing 0.8  
7 mg of folic acid daily reduced the incidence of congenital neural tube  
8 defects. At the same time, the incidence of various heart defects have also  
9 been reduced by nearly half [15]. Longitudinal data from more than one  
10 million births in Canada over a total of 22 years from 1990 to 2011 also  
11 show that food fortification with folic acid reduced risk of CHD by 20-30%  
12 [16]. The current folic acid supplementation recommends that all women of  
13 childbearing potential be supplemented with at least 0.4 mg folic acid daily  
14 prior to conception and during pregnancy, which is designed for preventing  
15 neural tube defects [17]. However, excessive folic acid intake may increase  
16 the risk of cancer [18], vitamin B12 deficiency [19], and autism spectrum  
17 disorder [20]. The optimal dose of folic acid for preventing CHD warrants  
18 further investigation. In addition, most previous studies only focused on the  
19 supplement of folic acid or the serum folate level during or after pregnancy,  
20 which may not be the optimal period and way to reflect the exposure level  
21 to risk of CHD.



1 To investigate the association between parental periconception key  
2 nutritional factors such as folate with the development of CHD and to  
3 explore the biomarker cutoff levels, we conducted Shanghai PreConception  
4 Cohort (SPCC) and a nested case-control analysis.

5 The SPCC cohort was initiated to study CHD as the primary outcome.  
6 Based on the strengths of its baseline data collection, it has received  
7 attention and support, with improved additional extensive outcomes for  
8 children that will be followed up longer term.

## 10 **Cohort description**

### 11 ***Setting and participants***

12 The SPCC cohort recruited parent-planning women and men who were  
13 permanent residents and who voluntarily presented at preconception  
14 clinical clinics at 28 maternity institutions in 10 districts of Shanghai  
15 (Minhang District, Huangpu District, Xuhui District, Changning District,  
16 Jing'an District, Putuo District, Yangpu District, Pudong District,  
17 Songjiang District, Qingpu District) from March 2016 to December 2018.

18 The preconception examination policy in the city of Shanghai provides a  
19 unique opportunity and clinical resources to support recruitment of SPCC.  
20 Since 2010, married couples in Shanghai have been encouraged to attend a  
21 free preconception health examination. In addition, these maternity

1  
2  
3  
4 1 institutions receive strong local administrative support and integrated  
5  
6 2 maternal health care networking, providing service to 150 000–200 000  
7  
8  
9 3 annual deliveries in Shanghai. Couples who were present at preconception  
10  
11 4 clinics, living in Shanghai, preparing for pregnancy within one year, and  
12  
13 5 planning to receive antenatal care and to delivering in Shanghai, were  
14  
15 6 eligible for the study. Written informed consents were obtained from all  
16  
17 7 participants before any data collection. In addition, we recruited  
18  
19 8 early-pregnant women at their first antenatal examination who were at  
20  
21 9 gestational week <14 weeks. These two groups of participants comprised a  
22  
23 10 periconceptual baseline study population.  
24  
25  
26  
27  
28  
29

### 30 ***Baseline data collection and antenatal visits***

31  
32  
33 12 Baseline data collection was designed according to the hypothesis that  
34  
35 13 maternal preconception serum or red blood cell (RBC) folate concentration  
36  
37 14 is quantitatively associated with offspring CHD. As shown in Figure 1, the  
38  
39 15 baseline population will be followed up to delivery, and their babies will be  
40  
41 16 followed up until 18 years old. At enrollment, the participants completed a  
42  
43 17 questionnaire (Questionnaire 1) of key nutrients supplementation and blood  
44  
45 18 sample collection. When participants got pregnant, as well as the  
46  
47 19 participants recruited at early gestation, investigations included  
48  
49 20 administration of Questionnaire 2 and blood sample collection at the first  
50  
51 21 antenatal visit <14 gestational weeks. Pregnancies were followed up till  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 birth along with routine maternal health care procedures. Blood samples  
2 were also collected at the second (24-28 gestational weeks) and third  
3 trimester (32-34 gestational week). The study design and protocol has been  
4 registered with Clinical Trials Registry (NCT 02737644).

#### 5 ***Outcomes -CHD in neonates***

6 The diagnosis of CHD was the primary outcome of the study at this stage  
7 and obtained from Shanghai Neonatal CHD Screen Platform, which was  
8 initiated as routine screen for newborns in Shanghai since Jun 1st 2016.  
9 The standard protocol of CHD screening of the platform was previously  
10 described in detail [21]. All newborn babies received the screen by using  
11 double-index method (i.e. cardiac murmur auscultation and pulse oximetry)  
12 during 6-72 hours after delivery, and those screen-positive babies would  
13 receive a subsequent echocardiography for further confirmative diagnosis.

14 SPCC will also collect other birth defects as secondary outcomes,  
15 including Down's syndrome, neural tube defects, hydrocephalus, digestive  
16 tract malformations, urinary malformations, and behavioral cognitive  
17 developmental disorder. After delivery, the infants attended routine  
18 childcare procedures organized by Shanghai Child Health Care System,  
19 which is administered by Shanghai Center for Women and Children's  
20 Health. All birth defects records, which were diagnosed after birth, as well  
21 as routine neuro-development examinations and longitudinal

1 anthropometric data, were abstracted from the system by a professional  
2 clinical team from Children's Hospital of Fudan University (for details of  
3 the types of birth defects please see Appendix 1)

4 ***Questionnaire 1 and 2 (Demographics, disease history and diet***  
5 ***supplements)***

6 As shown in Figure 1, Questionnaire 1 was administered during  
7 recruitment at preconception examination sites for collecting information  
8 of demographics, maternal education, socio-economic status, occupation,  
9 smoking status, alcohol consumption, BMI, medication, and health status  
10 were also included. Questionnaire 2 was administered at early pregnancy  
11 sites to collect information on consumption of folic acid supplement,  
12 vitamin supplement, the brand and content of nutrient supplement. Besides  
13 the content of Questionnaire 1, Questionnaire 2 added drug information,  
14 reproductive history, and health status. The structure of Questionnaire 1  
15 and Questionnaire 2 are presented in Appendix 2a and Appendix 2b.

16 ***Specimens***

17 In this study, the rest blood samples for routine clinical blood test were  
18 collected. The blood sample for routine clinical examination was usually 5  
19 ml and extracted in the morning. Routine clinical blood test was performed  
20 at room temperature. The rest blood samples (fasting serum and EDTA  
21 anticoagulation) of peripheral venous blood from routine laboratory clinical

1 blood test were kept. These blood samples were temporarily stored in a 4 °C  
2 refrigerator for dispensing within 6 hours and transferred to a -20 °C .  
3 After completion of blood sample distribution the serum and the whole  
4 blood were stored at the site laboratory, and then transported by three  
5 trained investigators to the central laboratory for storage in -80 °C freezers  
6 within two weeks. Sampling tubes were made of a light-proof material and  
7 the process of collecting blood samples were completely protected from  
8 light.

### 9 ***Laboratory examinations of key nutrition factors***

10 The examinations will be conducted in participants selected by nested  
11 case-control designs based on specific aims.

12 *(1) RBC folate, serum folate, serum homocysteine, vitamin D, vitamin B12*  
13 *and serum ferritin*

14 EDTA anticoagulation blood was collected to examine RBC folate, serum  
15 folate, serum homocysteine, vitamin D, vitamin B12 and serum ferritin  
16 assays. All six biomarkers were analyzed on an electrochemiluminescence  
17 assay (ARCHITECT i2000SR Analyzer, Abbott Laboratories, USA). A  
18 standard solution with known concentration (produced by Abbott  
19 Laboratories) was used daily to quality control before the measurement. If  
20 the quality control level was out of concentration range, the measurement

1  
2  
3  
4 1 would be suspended and adjusted. External quality control was carried out  
5  
6  
7 2 with the control lab data program from Abbott Laboratories (Abbott  
8  
9  
10 3 Laboratories, Shanghai, China). RBC folate concentrations were adjusted  
11  
12 4 for hematocrit. If the RBC folate concentration is below 126.0 ng/ml or  
13  
14  
15 5 above 651.1 ng/ml, adjustment was needed based on serum folate level.  
16  
17  
18 6 The hematocrit data were extracted from the hospital laboratory  
19  
20 7 information system. Those examinations were performed in central  
21  
22  
23 8 laboratory of Children's Hospital of Fudan University.

#### 24 25 26 9 *(2) Vitamin A and vitamin E*

27  
28  
29 10 The serum concentration of vitamin A and vitamin E were quantitatively  
30  
31 11 detected by liquid chromatography-tandem mass spectrometry in central  
32  
33  
34 12 laboratory of Children's Hospital of Fudan University. The testing  
35  
36  
37 13 instrument was triple quadrupole mass spectrometer LC/MS/MS System  
38  
39 14 (NO: API 3200MDTM, ABSciex Pte.Ltd.). A standard solution of vitamin  
40  
41  
42 15 A-d6 and vitamin E-d6 were applied as internal standards.

#### 43 44 45 16 *(3) Glycemic and lipid profiles*

46  
47 17 Fasting serum cholesterol, high-density lipoprotein, low-density  
48  
49  
50 18 lipoprotein, triglyceride, and fasting glucose were performed on Beckman  
51  
52  
53 19 coulter AU chemistry analyzers (Beckman, USA) in central laboratory of  
54  
55  
56 20 Children's Hospital of Fudan University.

#### 57 58 21 *(4) Metals*

1  
2  
3  
4 1 Serum levels including Mg, Fe, Zn, Se, Mn, As, Cu and Ca, were analyzed  
5  
6  
7 2 by inductively coupled plasma mass spectrometry (ICP-MS) (Inductively  
8  
9  
10 3 Coupled Plasma Optical iCAP6300, Thermo®, USA) in standard mode  
11  
12 4 [22]. The metals examination was conducted in Instrumental Analysis  
13  
14  
15 5 Center of Shanghai Jiaotong University which is a national key laboratory.

#### 16 17 18 6 *(5) Genomic DNA extraction*

19  
20 7 Genomic DNA of all participants were extracted using a magnetic  
21  
22  
23 8 bead-based kit (TGuide M16 Automatic Nucleic Acid Extractor  
24  
25  
26 9 (OSE-M16), TIANGEN BIOTECH (BEIJING) CO. LTD, China ) from 2  
27  
28  
29 10 ml of EDTA anticoagulated whole blood sample after routine blood test.  
30  
31 11 Genomic DNA samples were stored for future study. An average 150 ng  
32  
33  
34 12 DNA were available. Similar to blood chemicals, future genetic variants  
35  
36  
37 13 genotyping will be performed in selected participants according to nested  
38  
39  
40 14 case-control design for specific aims. Currently, there are no candidate  
41  
42  
43 15 genes or variants that are listed.

#### 44 45 16 *Procedures for routine data extraction and cohort retention*

46  
47 17 As shown in Figure 1, outcomes at birth, during infant to childhood  
48  
49  
50 18 (preschool phase), and between 7 to 18 years (school ages) will be  
51  
52  
53 19 collected or extracted from multiple public platforms and data sources.  
54  
55  
56 20 Firstly, preconception clinical visit data (height, weight, age, infections,  
57  
58  
59 21 sexually transmitted disease, and family history) was collected from  
60

1  
2  
3  
4 1 Preconception Care Electronic Data System, supported by national and  
5  
6  
7 2 local government. Secondly, the routine pregnant data was obtained in  
8  
9  
10 3 Maternal Clinic Antenatal Medical Record System, managed by Shanghai  
11  
12 4 Center for Women and Children's Health, including height, gestational  
13  
14  
15 5 weight, last menstrual period, childbearing history, delivery outcomes,  
16  
17  
18 6 infections, hematocrit, coagulation function, liver and kidney function, and  
19  
20  
21 7 so on. Thirdly, the maternal and neonatal data at delivery came from  
22  
23 8 Shanghai Neonatal CHD Screen Platform including birth weight, CHD  
24  
25  
26 9 diagnosis, birth defects, and Apgar score, etc. In addition, we will work  
27  
28  
29 10 with the Shanghai Student Health and Fitness Surveillance Center to obtain  
30  
31  
32 11 outcome data. The personal national identification card numbers of  
33  
34  
35 12 participants are applied as index variables through the multiple data  
36  
37  
38 13 sources. The detailed variables list and codebook of data collection are  
39  
40  
41 14 presented in Appendix 3.

42 15 During the first phase of the cohort, from preconception to delivery,  
43  
44  
45 16 comprehensive strategies were used to retain participants in the study. For  
46  
47  
48 17 mothers, we provided a variety of engagement activities including green  
49  
50  
51 18 channel (fast track) to their antenatal care to provide convenience and save  
52  
53  
54 19 their time in hospitals. We also provided a contact number on the  
55  
56  
57 20 participant card to answer their calls or queries about the study procedures.  
58  
59  
60 21 Site investigators at early pregnant clinics in collaborative hospitals were



1 provided a smartphone APP to help identify recruited cohort participants  
2 timely and manage data and blood sample collection procedures. We also  
3 provided green channel echocardiography for diagnosing CHD for all site  
4 hospitals to enhance the compliancy of the participants. In addition, an  
5 automated text message system was adopted to remind participants of  
6 schedules and appointment of follow-up.

### 7 ***Characteristics of study participants***

8 The SPCC started recruitment in March 2016. As shown in Figure 2, by  
9 December 2018, we consecutively recruited 19 144/19 563 (97.9%)  
10 participants at preconception settings, including 8045 couples and 3054  
11 single women, and an additional 15 615/16 201 (96.4%) pregnant women  
12 at maternity hospitals with gestational age <14 weeks. Table 1 describes  
13 the basic demographic characteristics of the preparing-for-pregnant  
14 participants and pregnant women, respectively. The average age of the  
15 preconception population was 29.9 (SD 3.9) years for females and 31.4  
16 (SD 4.5) years for male, one-third of males and 2.4% of females were  
17 smokers, and two-thirds of males, and one-third of females had a habit of  
18 drinking alcohol. In pregnant women, the average age was 29.9 (SD 4.0)  
19 years, with half of them having a first pregnancy. Compared with the  
20 preconception females, they were similar in age but different in education  
21 levels and occupation, the prevalence of smoking and alcohol drinking

1  
2  
3  
4 1 were much lower. (Table 1 was partly included in another manuscript,  
5  
6  
7 2 which is under review of Maternal & Child Nutrition with Manuscript  
8  
9  
10 3 number of MCN-08-19-OA-4056).

#### 11 12 4 *Statistical methods*

13  
14  
15 5 To investigate the association of maternal preconception nutrition levels  
16  
17  
18 6 with offspring CHD risk, a nested case-control study will be conducted.  
19  
20  
21 7 The control will be matched by age and site.

22  
23 8 The sample size for the nested case-control analysis was planned as 180  
24  
25  
26 9 CHD cases and 720 matched controls to detect a maternal folate deficiency  
27  
28  
29 10 with prevalence of 50% in controls with odds ratio of 1.6 in association to  
30  
31  
32 11 achieve a power of 80% at alpha of 0.05. Based on CHD incidence above  
33  
34  
35 12 8.94 per 1 000 live births [4], 20 000 pregnancies will be needed. For a  
36  
37  
38 13 continuous nutrient variable with standard deviation 2.0, 50 matched-pairs  
39  
40  
41 14 (1:4) are required to achieve 90% power to detect an odds ratio of 1.3  
42  
43  
44 15 calculated using conditional logistic regression with a 0.05 significance  
45  
46  
47 16 level [23, 24]. Once a sufficient number of CHD cases is achieved, the  
48  
49  
50 17 quantitative association of preconception RBC folate levels with CHD  
51  
52  
53 18 using nested case-control design will be investigated.

54  
55  
56 19 Conditional multivariate logistic regression will be used for association  
57  
58  
59 20 analysis with offspring affected status of CHD being the dependent  
60  
61  
62 21 variable, nutrition factors levels as exposure and adjusted for all potential

1 paternal and maternal covariates. Odds ratios (OR) and 95% confidence  
2 intervals (95%CI) will be reported. To explore a potential cutoff point of  
3 the nutrition levels that significantly increases the risk of CHD, a dummy  
4 variable will be set up by categorizing the maternal preconception nutrition  
5 levels based on the distribution of the control group. The does-response  
6 relationship will be also be analyzed. Sensitive analysis will include  
7 non-conditional logistic regression analysis, or generalized estimation  
8 equations (GEE) model, or generalized linear models when necessary.

### 9 ***Future plan***

10 We have a complete plan to follow-up offspring of SPCC population to the  
11 age of 18 years old. The cohort will be financially supported by different  
12 grants. The current manuscript focuses on the first phase, the establishment  
13 of the baseline and our first main outcome, the CHD. The data collection  
14 plan for infants and children (from birth to 6 years old, pre-school stage), as  
15 well as school age (from 6 to 18 years old), are included. During the stage  
16 of 0 to 6 years old, the data of neurodevelopment will be collected from  
17 routine childcare clinical visit at birth, 6 weeks, 6 months, 12 months, 36  
18 months, and 60 months through the cooperating medical institutions.  
19 Physical measurements data and dietary intake information also can be  
20 collected at this stage. During the stage of 6 to 18 years old, we plan to  
21 follow up their growth (height, weight, blood pressure, etc.) mainly relying

1  
2  
3  
4 1 on the annual physical examination of Shanghai Student Health and Fitness  
5  
6  
7 2 Surveillance Center System. Multiple outcomes for children, including  
8  
9  
10 3 growth and development, cardiovascular diseases, neurodevelopment,  
11  
12 4 metabolic diseases, obesity status, and hypertension will be investigated.  
13  
14  
15 5 Please see Appendix 4 for details.  
16  
17

### 18 **Patient and public involvement**

19  
20 7 Patients and public were not involved in the design or conduct of this  
21  
22  
23 8 study.  
24  
25  
26  
27  
28

### 29 **Findings to date**

30  
31 11 By the end of December 2018, the last participants recruited at early  
32  
33  
34 12 pregnancy were due for delivery, however, we have achieved birth records  
35  
36  
37 13 of 12 402 newborns. The follow-up of outcomes of the rest of the  
38  
39  
40 14 participants is ongoing (shown in Figure 2). A total of 151 cases of CHD  
41  
42  
43 15 were identified through the CHD screening platform, 131 cases from the  
44  
45  
46 16 early pregnancy sample, and the remaining 20 cases were from the  
47  
48  
49 17 preconception sample. The prevalence of CHD in live births is 10.5 %  
50  
51  
52 18 (131/12 402) based on the present available data.

53 19 We conducted a small pilot study in April 2017 to explore blood levels  
54  
55  
56 20 of nutrition factors, including serum folate, RBC folate, vitamin A, vitamin  
57  
58  
59 21 E, and vitamin D. The blood samples from 627 females were selected  
60

1  
2  
3  
4 1 consecutively from the preconception sample according to who was  
5  
6  
7 2 identified pregnant. In addition, 597 women who were consecutively  
8  
9  
10 3 recruited from the antenatal care clinics were selected. As shown in Table  
11  
12 4 2, the concentrations of RBC folate median level is 247.0 ng/ml (IQR:  
13  
14 5 184.8-340.5 ng/ml) in preconception women and 417.4 ng/ml (IQR:  
15  
16 6 308.6-544.2 ng/ml) in early-pregnant women. Twenty percent of  
17  
18 7 preconceptional participants and 44.9% of pregnant participants had a  
19  
20 8 folate level over 400 ng/ml, which was suggested as optimal level for  
21  
22 9 preventing neural tube development defects [25, 26]. These results suggest  
23  
24 10 that effort is urgently needed to improve the intake of folic acid  
25  
26 11 supplementation in the prepare-for-pregnancy population, especially before  
27  
28 12 pregnancy.

29  
30  
31  
32  
33  
34  
35  
36 13 Based on SPCC, the possible scope of research questions, available types  
37  
38 14 and number of bio-samples and biomarkers that can be examined is shown  
39  
40 15 in Table 3.  
41  
42  
43  
44  
45  
46

### 47 **Strengths and limitations**

48  
49 18 Compared with existing birth cohorts, there are three important strengths in  
50  
51 19 our cohort. Firstly, the SPCC cohort is the first prospective birth cohort  
52  
53 20 with CHD as primary outcome and recruitment starting from preconception.  
54  
55 21 Blood samples were collected and stored which allows for direct  
56  
57  
58  
59  
60

1 measurement of individual exposure levels before the development of CHD  
2 and make causal inference. Temporal sequence of exposures and outcomes  
3 can be achieved for causal inference of birth defects and other diseases that  
4 occur during early stage of gestation. Up to date, no published studies have  
5 measured maternal blood folate levels before conception and link it to  
6 disease outcomes. Secondly, this cohort also allows for the investigation of  
7 associations between periconception maternal and paternal nutrition  
8 exposures with other birth defects, early onset-diseases, and  
9 neuro-development outcomes. Preconception blood samples were  
10 appropriately collected and stored which allows for the examination of  
11 individual blood levels of nutrition factors and other exposures. Thirdly,  
12 both paternal and maternal clinical data and blood samples before  
13 conception were collected, which will allow for testing effect of both  
14 maternal and paternal genetic and nutrition factors to fetal and children  
15 diseases.

16 Two limitations of this cohort study should be considered. Firstly, there  
17 are approximately 200 000 pregnant women giving birth every year in  
18 Shanghai, and approximately 20 000 of them will take part in the free  
19 preconception care in Shanghai, where participants were recruited  
20 consecutively. Although response rate was high (over 95%), preconception  
21 participants were recruited from a population voluntarily present in

1  
2  
3  
4 1 Shanghai city with preconception physical examination sites, who may  
5  
6  
7 2 have a stronger willingness for a healthy pregnancy. This may induce  
8  
9  
10 3 selection bias. Secondly, in this study, biological samples (cord blood,  
11  
12 4 placenta) of the newborns are not collected. We plan to give new informed  
13  
14  
15 5 consent to the family who are willing to participate in future studies, to  
16  
17  
18 6 collect biological samples not mentioned before. In addition,  
19  
20 7 electrochemiluminescence assay was used to examine serum and RBC  
21  
22  
23 8 folate concentrations, which is different from microbiologic assay that is  
24  
25  
26 9 used widely. This will not bias the association analysis but comparison  
27  
28  
29 10 with international populations needs caution.  
30  
31  
32  
33

## 34 **Collaboration**

35  
36  
37 13 Investigators with an interest in hypotheses related to SPCC (and that meet  
38  
39  
40 14 the requirements of current approvals) are welcome to contact Dr. Guoying  
41  
42  
43 15 Huang or Weili Yan. A 'Research Collaboration application' should be  
44  
45  
46 16 send to the corresponding author by Email. The application should include  
47  
48  
49 17 a brief description of the project.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 **Acknowledgements**

2 We are extremely grateful to all the participants who took part in this study,  
3 the doctors for their help in recruiting them, and the whole SPCC team,  
4 which includes interviewers, computer and laboratory technicians, clerical  
5 workers, research scientists, volunteers, managers, receptionists, and  
6 nurses.

## 8 **SPCC group**

9 Gouying Huang, Weili yan, Xiaojing Ma, Weifen Luo, Wei Sheng, Yi  
10 Zhang, Yuan Jiang, Yin Ye, Dingmei Wang, Xiaotian Chen, Mengru Li,  
11 Mi Ji, Yumei Liu, Gu Qing(s), Gu Qing(o), Linmei Zhu, De'ai Hou, Peiyu  
12 Sun. (Children's Hospital of Fudan University, Shanghai, China),  
13 Hongbing Wang, Li Meng, lin Zhang (Jingan Maternal and Child Health  
14 Center), Zifen Dai, Li fen (Shanghai First Maternity and Infant health  
15 Hospital), Shufang Chen, Zhenhua Tang, Jiahao Wu (International Peace  
16 Maternal and Child Health Hospital), Shuhua Wang, Dan li, Hui Wang  
17 (Xuhui Maternal and Child Health Center), Yu Ke, Weiping Cao, Baoren  
18 Zhang, Hong Huang (Shanghai Pudong New Area Health Care Hospital for  
19 Women & Children),  
20 Nailing Wang, Min Jiang, Jie Chen, Qiumin Xia (Shanghai Punan Hospital  
21 of Pudong New District), Hui Xu, Guoying Lao (Changning Maternity and



1  
2  
3  
4 1 Infant Health Hospital), HongMei Jin, Wenjuan Xie, Pin Yi (Qingpu  
5  
6  
7 2 Hospital, Zhongshan Hospital), Weiming Gong, JianXin Xu, Yingying  
8  
9  
10 3 Qian (Shanghai Qingpu Maternal and Child Health Center), Mingjie Luo,  
11  
12 4 Jingwei Xia, Dongmei Chen, Zhenyu Tang (Shanghai Huangpu Maternal  
13  
14  
15 5 and Child Health Center), Xuejing Zhu, Qing Liu, Huiling Yang (Shanghai  
16  
17  
18 6 Huangpu Maternal and Child Health Hospital), Xiaotian Li, Zhiyong Wu,  
19  
20  
21 7 Chuanmin Ying, Shan Shi (Obstetrics & Gynecology Hospital of Fudan  
22  
23  
24 8 University (Shanghai Red House Ob & Gyn Hospital)), Yanquan Zhang,  
25  
26  
27 9 Mingyi Yang (Wujing Hospital, Minhang District, Shanghai), Xiaohua  
28  
29  
30 10 Zhang, Lei Zhang, Lin Guan (Shanghai Minhang District Maternal and  
31  
32  
33 11 Child Health Care Hospital), Jinyu Xu, Honglin Wang, Fang Shen (The  
34  
35  
36 12 Fifth People's Hospital of Shanghai, Fudan University), Wenying Li,  
37  
38  
39 13 Xiaojing Teng, Jinling Zhao (Shanghai Minhang TCM Hospital), Cuili  
40  
41  
42 14 Zhu, Lan Wang, Hongwei Chen (Shanghai Songjiang District Central  
43  
44  
45 15 Hospital), Xiaoming Yuan, Meihua Zhang, Yaqiong Jin (Sijing Hospital,  
46  
47  
48 16 Songjiang District, Shanghai), Qing Yang, Hong Zhu, Min Feng  
49  
50  
51 17 (Songjiang Maternal and Child Health Center), Ying Wang, Yan Wu, Hong  
52  
53  
54 18 Tang (Songjiang Maternal and Child Health Hospital), Sa Guo (Tongji  
55  
56  
57 19 Hospital of Tongji University), Hongling Du (Shanghai Putuo District  
58  
59  
60 20 People's Hospital), Yuhuan Liu, Zhanyue Yi, Renhua Shi (Changhai  
21  
Hospital, Second Military Medical University, Shanghai), Yu Gu, Qinfen

1  
2  
3  
4 1 Su, Yingying lv (Shanghai Zhabei District Central Hospital), Yun Sun,  
5  
6  
7 2 QiongPei Gu (Yangpu District Family Planning Service Center), Xixia  
8  
9  
10 3 Pang, Qingwu Zhang (Kong Jiang Hospital of Yangpu District, Shanghai),  
11  
12 4 Songxiao Bai, Baoqiao Qi (Shanghai East City Hospital).  
13  
14  
15  
16  
17

18 **Contributors:** Substantial contributions to the conception or design of the  
19  
20 7 work were made by GH and WY. YZ and DW prepared the original draft  
21  
22  
23 8 of the manuscript. YZ, DW, YY, JY, ML, MJ, YD and XC led study  
24  
25  
26 9 implementation at participating sites. DW and YZ were responsible for the  
27  
28  
29 10 day-to-day project management at each site. XM and WS were responsible  
30  
31  
32 11 for the biobank of the cohort. All authors provided critical review of the  
33  
34 12 manuscript for important intellectual content and approved the final  
35  
36  
37 13 version.  
38  
39  
40  
41

42 **Funding:** This work is supported by National key research and  
43  
44 16 development program (Grant No: 2016YFC1000506) and Natural Science  
45  
46  
47 17 Foundation of China (Grant No: 81273168). Three-year Planning for  
48  
49  
50 18 Strengthening the Construction of Public Health System in Shanghai  
51  
52  
53 19 (GWIV-24).  
54  
55  
56  
57

58 **Patient consent for publication:** Not required.  
59  
60

1

2 **Conflict of interest:** The authors have no conflicts of interest.

3

4 **Ethics approval:** This study was approved by Ethics Committee of  
5 Children's Hospital of Fudan University, Shanghai, China.

6

7 **Provenance and peer review** Not commissioned; externally peer  
8 reviewed.

9

10 **Data sharing statement:** The study data are not freely available due to  
11 confidentiality reasons, but the research team welcomes potential  
12 collaboration with other researchers. For further information, contact the  
13 author GH (gyhuang@shmu.edu.cn)

## REFERENCES

1. Mahle WT, Newburger JW, Matherne GP, Smith FC, Hoke TR, Koppel R, Gidding SS, Beekman RH, 3rd, Grosse SD, American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young CoCN *et al*: **Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics.** *Circulation* 2009, **120**(5):447-458.
2. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW: **Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis.** *J Am Coll Cardiol* 2011, **58**(21):2241-2247.
3. China MoPHo: **China's birth defects prevention report.** In. Edited by China MoPHo. Beijing; 2012.
4. Zhao QM, Ma XJ, Ge XL, Liu F, Yan WL, Wu L, Ye M, Liang XC, Zhang J, Gao Y *et al*: **Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study.** *Lancet* 2014, **384**(9945):747-754.
5. Bruneau BG: **The developmental genetics of congenital heart disease.** *Nature* 2008, **451**(7181):943-948.
6. Alverson CJ, Strickland MJ, Gilboa SM, Correa A: **Maternal smoking and congenital heart defects in the Baltimore-Washington Infant Study.** *Pediatrics* 2011, **127**(3):e647-653.
7. Lee LJ, Lupo PJ: **Maternal smoking during pregnancy and the risk of congenital heart defects in offspring: a systematic review and metaanalysis.** *Pediatr Cardiol* 2013, **34**(2):398-407.
8. Shi M, Wehby GL, Murray JC: **Review on genetic variants and maternal smoking in the etiology of oral clefts and other birth defects.** *Birth Defects Res C Embryo Today* 2008, **84**(1):16-29.
9. Kuciene R, Dulskiene V: **Selected environmental risk factors and congenital heart defects.** *Medicina (Kaunas)* 2008, **44**(11):827-832.
10. Carmichael SL, Shaw GM: **Maternal life event stress and congenital anomalies.** *Epidemiology* 2000, **11**(1):30-35.
11. Czeizel AE: **Periconceptional folic acid-containing multivitamin supplementation for the prevention of neural tube defects and cardiovascular malformations.** *Ann Nutr Metab* 2011, **59**(1):38-40.
12. Botto LD, Mulinare J, Erickson JD: **Occurrence of congenital heart defects in relation to maternal multivitamin use.** *Am J Epidemiol* 2000, **151**(9):878-884.
13. Ionescu-Ittu R, Marelli AJ, Mackie AS, Pilote L: **Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada.** *Brit Med J* 2009, **338**.
14. Liu SL, Joseph KS, Luo W, Leon JA, Lisonkova S, Van den Hof M, Evans J, Lim K, Little J, Sauve R *et al*: **Effect of Folic Acid Food Fortification in Canada on Congenital Heart Disease Subtypes.** *Circulation* 2016, **134**(9):647-655.
15. Czeizel AE, Dudas I: **Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation.** *N Engl J Med* 1992, **327**(26):1832-1835.
16. Liu S, Joseph KS, Luo W, Leon JA, Lisonkova S, Van den Hof M, Evans J, Lim K, Little J, Sauve R *et al*: **Effect of Folic Acid Food Fortification in Canada on Congenital Heart Disease Subtypes.** *Circulation* 2016, **134**(9):647-655.
17. Cordero AM, Crider KS, Rogers LM, Cannon MJ, Berry RJ: **Optimal serum and red blood cell folate concentrations in women of reproductive age for prevention of neural tube defects: World Health Organization guidelines.** *MMWR Morb Mortal Wkly Rep* 2015, **64**(15):421-423.
18. Kim YI: **Will mandatory folic acid fortification prevent or promote cancer?** *Am J Clin Nutr* 2004, **80**(5):1123-1128.
19. Selhub J, Rosenberg IH: **Excessive folic acid intake and relation to adverse health outcome.** *Biochimie* 2016, **126**:71-78.
20. Wiens D, DeSoto MC: **Is High Folic Acid Intake a Risk Factor for Autism?-A Review.** *Brain Sci* 2017, **7**(11).
21. Hu XJ, Ma XJ, Zhao QM, Yan WL, Ge XL, Jia B, Liu F, Wu L, Ye M, Liang XC *et al*: **Pulse Oximetry and Auscultation for Congenital Heart Disease Detection.** *Pediatrics* 2017, **140**(4).
22. Bolann BJ, Distant S, Morkrid L, Ulvik RJ: **Bloodletting therapy in hemochromatosis: Does it**

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 1      **affect trace element homeostasis?** *J Trace Elem Med Biol* 2015, **31**:225-229.
- 2      23. Lachin JM: **Sample size evaluation for a multiply matched case-control study using the score**  
3      **test from a conditional logistic (discrete Cox PH) regression model.** *Stat Med* 2008,  
4      **27(14):2509-2523.**
- 5      24. Tang YQ: **Comments on 'Sample size evaluation for a multiply matched case-control study**  
6      **using the score test from a conditional logistic (discrete Cox PH) regression model'.** *Stat Med*  
7      2009, **28(1):175-177.**
- 8      25. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM: **Folate levels and neural tube defects.**  
9      **Implications for prevention.** *JAMA* 1995, **274(21):1698-1702.**
- 10     26. Tam C, McKenna K, Goh YI, Klieger-Grossman C, O'Connor DL, Einarson A, Koren G:  
11     **Periconceptional folic acid supplementation: a new indication for therapeutic drug**  
12     **monitoring.** *Ther Drug Monit* 2009, **31(3):319-326.**
- 13  
14

For peer review only

**Table 1. Socio-demographics of participants including 6573 couples (parents) and 15 203 pregnant women that were enrolled in the Shanghai PreConception Cohort (SPCC).**

Characteristics	Couples (parents) who completed preconception questionnaires		Additional pregnant women who completed both preconception and first-trimester questionnaires		<i>P</i> *		
	Male (n=6573)	Female (n=9243)	Pregnant women (n=15203)				
Age (years), Mean±SD	6573	31.4±4.5	9243	29.9±3.9	15203	29.9±4.0	0.995
Ethnicity	6536		9188		15176		0.258
Han Nationality		6403 (98%)		8966 (97.6%)		15245 (97.8%)	
Other		133 (2%)		222 (2.4%)		342 (2.2%)	
Educational level	6530		9147		15143		<0.001
<College		514 (7.8%)		795 (8.7%)		2052 (13.6%)	
≥College		6016 (92.2%)		8352 (91.3%)		13091 (86.4%)	
Annual household income	6530		9147		NA		
< ¥10 000		1424 (21.8%)		2214 (24.2%)			
≥¥10 000		5106(78.2%)		6933 (75.8%)			
Occupation	6530		9147		14789		<0.001
Entrepreneur		157 (2.4%)		128 (1.4%)		171 (1.1%)	
Farmer		26 (0.4%)		46 (0.5%)		79 (0.5%)	
Self-employed		216 (3.3%)		274 (3%)		862 (5.6%)	
Manager		1410 (21.6%)		1765 (19.3%)		2650 (17.2%)	
Technician		2462 (37.7%)		1903 (20.8%)		3239 (20.6%)	

Company clerk		2259 (34.6%)		5031 (55%)		8451 (54.7%)	
Attending preconception pregnant examination	NA		NA		14996		-
Yes						3374 (22.5%)	
No						11622 (77.5%)	
Parity	NA		NA		15162		
1						7569 (49.9%)	
2						4604 (30.4%)	
>=3						2989 (19.7%)	
Miscarriage or stillbirth	NA		NA		15159		
Yes						4838 (31.2%)	
No						10385 (68.7%)	
Smoking	6552		9212		15159		<0.001
Yes		2073 (31.6%)		218 (2.4%)		153 (1.0%)	
No		4479 (68.4%)		8994 (97.6%)		15006 (99%)	
Alcohol drinking	6448		9075		15164		<0.001
Yes		3962 (61.5%)		2865 (31.6%)		1556 (10.3%)	
No		2486 (38.5%)		6210 (68.4%)		13608 (89.7%)	
Location of home	6573		9243		NA		
Developed districts		3034 (46.2%)		5452 (59.0%)			
Developing districts		3539 (53.8%)		3791 (41.0%)			

\* Comparisons between preconception females and pregnant women. *t* tests were used to compare numerical variable (age). Chi-square tests were used to compare categorical variables (ethnicity, educational level occupation, smoking and alcohol drinking). Of 6573 preconceptional males, values were missing in ethnicity (n=37), educational level (n=43), annual household income (n=43), occupation

1  
2  
3  
4  
5 (n=43), smoking (n=21), and alcohol drinking (n=125). Of 9243 preconceptional females, values were missing in ethnicity (n=55),  
6  
7 educational level (n=96), annual household income (n=96), occupation (n=96), smoking (n=31), and alcohol drinking (n=168). Of 15203  
8  
9 pregnant women, values were missing in ethnicity (n=27), educational level (n=60), occupation (n=414), smoking (n=31), attending  
10  
11 preconception pregnant examination (n=207), parity (n=41), miscarriage or stillbirth (n=44), smoking (n=44), and alcohol drinking  
12  
13 (n=39).  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46



**Table 2. Distributions of biomarkers in women before and at early gestation (pilot study)**

Biomarker	Preconception		Early pregnancy	
	n	level	n	level
Serum folate, Median (IQR), ng/ mL	620	9.7 (6.5, 13.8)	577	14.5 (11.2, 16.4)
RBC folate, Median (IQR), ng/ mL	570	247.0 (184.8, 340.5)	587	417.4 (308.6, 544.2)
Homocysteine, Median (IQR), $\mu\text{mol/L}$	624	6.5 (5.2, 8.6)	599	4.2 (3.5, 5.2)
Vitamin B12, Median (IQR), pg/mL	625	495.2 (394.2, 639.0)	600	388.5 (289.4, 511.4)
Vitamin D, Mean $\pm$ SD, ng/ mL	607	16.3 $\pm$ 6.0	578	15.5 $\pm$ 6.1

**Table 3. Bio-samples collected and biomarkers that can be examined in the SPCC cohort**

Bio-samples Available in participants	Available sample type and volume	Time		
		Preconception + early pregnancy (Baseline)	24-28 weeks	32-36 weeks
<b>Mother</b>		(n=25487)	(n=8668)	(n=7522)
	Serum, 200 ul*3	Yes	Yes	Yes
	Whole blood	Yes	Yes	Yes
	Genomic DNA, 150 ng	Yes	Yes	Yes
<b>Father</b>		(n= 7151)	-	-
	Serum, 200 ul*3	Yes	NA	NA
	Whole blood	Yes	NA	NA
	Genomic DNA, 150 ng	Yes	NA	NA
<b>Child</b>	NA			

**Scope of research questions:**

1. Quantitative association of preconceptional key nutrition levels (such as serum and RBC folates and related biomarkers, such as homocysteine and vitamin B12) with CHD, currently, and other folate sensitive birth defects.
2. Quantitative association of periconceptional maternal and paternal key nutrition levels (preconception levels, and dynamic levels during gestation) with important maternal and neonatal gestational complications, neuro-development of infants, childhood obesity, and clinical pediatric diseases.
3. Periconceptional maternal and paternal folate concentration with Autism spectrum disorder, allergy and asthma in children.

**Biomarkers that will be examined in different types of bio-samples:**

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
1. Biomarkers based on serum sample:
    - a) Folate and related markers: serum folate, homocysteine
    - b) Other Vitamins: vitamin A, vitamin B12, vitamin E, and vitamin D
    - c) Macro and micro metals: Mg, Fe, Zn, Se, Mn, As, Cu, Ca, etc., mg/L
    - d) Serum ferritin
    - e) Fasting glycaemic and lipid profiles: fasting glucose, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein
  2. Whole blood sample: RBC folate
  3. Genomic DNA sample: candidate genetic variants or genome-wide variants are all possible to be examined

1  
2  
3  
4  
5 Figure 1 Diagram of the protocol and follow-up of Shanghai PreConceptional Cohort (SPCC)  
6

7  
8 The baseline population of SPCC cohort was females and males at periconception stage (couples who are  
9  
10 prepare-for-pregnancy) and pregnant women at early gestation stage. The cohort includes three phases, from  
11  
12 periconception to birth (Phase I, peri-natal phase), from birth to 6 years old (Phase II, infant and pre-school age), and  
13  
14 from 7 to 18 years (Phase III, school age). The current manuscript focuses on the first phase, with congenital heart  
15  
16 disease as the primary outcome, and will cover other folate sensitive birth defects.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

1  
2  
3  
4  
5 Figure 2 Flow chart diagram  
6  
7

8 By December 2018, we consecutively recruited 19 144/19 563 (97.9%) participants at preconception settings, including  
9  
10 8045 couples and 3054 single women at pre-pregnancy sites, and an additional 15 615/16 201 (96.4%) pregnant women  
11  
12 at maternity hospitals with gestational age <14 weeks were recruited. By the end of December 2018, the last  
13  
14 participants recruited at early pregnancy were due for delivery, we have achieved birth records of 12 402 newborns in  
15  
16 Maternal Clinic Antenatal Medical Record System. The follow-up of outcomes of the rest of participants is ongoing  
17  
18 (shown in Figure 2). A total of 151 cases of CHD were identified through Shanghai Neonatal CHD Screen Platform,  
19  
20 131 cases were from the early pregnancy sample, the remaining 20 cases were from the preconception sample. The  
21  
22 prevalence of CHD in liver births is 10.5 ‰ (131/12 402) based on the present available data. In the preconception  
23  
24 sample, from March 2016 to May 2018 (the latest data extraction in Maternal Clinic Antenatal Medical Record  
25  
26 System), the number of pregnancies and delivers were 1538 and 975 respectively.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46




Figure 1 Diagram of the protocol and follow-up of Shanghai PreConceptional Cohort (SPCC)  
 The baseline population of SPCC cohort was females and males at peri-conception stage (couples who are prepare-for-pregnancy) and pregnant women at early gestation stage. The cohort includes three phases, from peri-conception to birth (Phase I, peri-natal phase), from birth to 6 years old (Phase II, infant and pre-school age), and from 7 to 18 years (Phase III, school age). The current manuscript focuses on the first phase, with congenital heart disease as the primary outcome, and will cover other folate sensitive birth defects.




Figure 2 Flow chart diagram

By December 2018, we consecutively recruited 19 144/19 563 (97.9%) participants at preconception settings, including 8045 couples and 3054 single women at pre-pregnancy sites, and an additional 15 615/16 201 (96.4%) pregnant women at maternity hospitals with gestational age <14 weeks were recruited. By the end of December 2018, the last participants recruited at early pregnancy were due for delivery, we have achieved birth records of 12 402 newborns in Maternal Clinic Antenatal Medical Record System. The follow-up of outcomes of the rest of participants is ongoing (shown in Figure 2). A total of 151 cases of CHD were identified through Shanghai Neonatal CHD Screen Platform, 131 cases were from the early pregnancy sample, the remaining 20 cases were from the preconception sample. The prevalence of CHD in liver births is 10.5 ‰ (131/12 402) based on the present available data. In the preconception sample, from March 2016 to May 2018 (the latest data extraction in Maternal Clinic Antenatal Medical Record System), the number of pregnancies and deliveries were 1538 and 975 respectively.

## Appendix 1 Types of fetus defects and birth defects

## Types of fetus defects and birth defects

---

<b>Diagnosis</b>
Anencephalus
Spina bifida
Encephalocele
Congenital Hydrocephalus
Cleft Palate
Cleft Lip
Cleft Lip with Cleft Palate
Microtia (including Anotia)
Deformity of external ear(s) (except Microtia and Anotia)
Esophageal atresia or stenosis
Anorectal atresia (including Congenital Anorectal Malformations)
Hypospadias
Ectopocystis
Pes Equinovarus
Polydactylism
Syndactylia
Limb shortening
Congenital Diaphragmatic Hernia
Promphalus
Celoschisis
Conjoined Twins
Trisomy 21 syndrome
Congenital heart disease
Others

---

Note: Down's syndrome, neural tube defects, congenital heart defects, hydrocephalus, digestive tract



1  
2  
3 malformations and urinary malformations are most common defects in China. Defects were detected by  
4 prenatal Down's syndrome screening, NT examination and Ultrasound image examination during the  
5 second trimester; and the number and type of birth defects after childbirth are diagnosed by professional  
6 clinical team. Down syndrome (DS), caused by the trisomy, translocation, or partial trisomy of  
7 chromosome 21, is the most common genetic cause of intellectual disability. DS is diagnosed by  
8 neonatologist. Neural tube defects including spina bifida and hypospadias, were diagnosed by ultrasound  
9 examination and pediatric neurosurgeon. Congenital heart disease was diagnosis by Doppler ultrasound  
10 and CHD screening (pulse oximetry plus cardiac murmurs). Hydrocephalus, digestive tract malformations,  
11 urinary malformations and other defects also were also diagnosed either by ultrasound or some other  
12 specific diagnosis methods.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Appendix 2a pre-pregnant questionnaire

姓名 Name : \_\_\_\_\_

身份证号 ID no : □□□□□□□□□□□□□□□□□□□□

医院代码 Hospital No : \_\_\_\_\_ ( 到时打印到问卷上 )

填表日期 Date : \_\_\_\_\_年\_\_\_\_\_月\_\_\_\_\_日

For peer review only

孕前膳食补充剂调查表

Pre-pregnancy nutrition supplement questionnaire

( 男女共用 )

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## A 一般情况

A1 联系电话（请您认真填写，以助于医生和您联系） Contact number: _____(手机) _____(固定电话) _____(Email)			
A2 家庭住址 Address: _____区/县_____街道/小区_____门牌号码/村			
A3 您的出生日期是 Birth date _____年_____月_____日			
A4 民族 Nationality <input type="checkbox"/> 1 汉族 <input type="checkbox"/> 2 其他（请注明）_____			
A5 您的最高学历 Education <input type="checkbox"/> 1 初高中以下 <input type="checkbox"/> 2 大专本科 <input type="checkbox"/> 3 硕士研究生以上及以上			
A6 您现在的主要职业 Occupation <input type="checkbox"/> 1 管理人员/干部 <input type="checkbox"/> 2 技术人员 <input type="checkbox"/> 3.企业主 <input type="checkbox"/> 4 工人 <input type="checkbox"/> 5 农民 <input type="checkbox"/> 6 个体户 <input type="checkbox"/> 7 其它_____			
A7 上一年您的家庭年收入是： Income of a year <input type="checkbox"/> 1. <2 万元 <input type="checkbox"/> 2. (2~3.9)万 <input type="checkbox"/> 3.(5.9)万 <input type="checkbox"/> 4.(6~9.9)万 <input type="checkbox"/> 5.(10~14.9)万 <input type="checkbox"/> 6.15 万及以上 <input type="checkbox"/> 9.不详			
A8 填表日期 Date _____年_____月_____日			

## B 营养补充剂使用情况

营养补充剂种类 Nutritional supplement types	叶酸 Folic acid	复合维生素 multi-vitamins	单一维生素 Single vitamin
您在近三个月是否服用 Have you taken it in the last three months?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂？（如果没有对应选项请在其他处写明） Brand name	<input type="checkbox"/> 1、创盈金斯利安多维片 <input type="checkbox"/> 2、福施福胶囊营养素 <input type="checkbox"/> 3、汤臣倍健 <input type="checkbox"/> 4、安利纽崔莱铁 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、爱乐维 <input type="checkbox"/> 2、汤臣倍健孕妇专用 <input type="checkbox"/> 3、惠氏玛特纳 <input type="checkbox"/> 4、21 金维他 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> V <sub>C</sub> <input type="checkbox"/> V <sub>E</sub> <input type="checkbox"/> V <sub>B1</sub> <input type="checkbox"/> V <sub>B2</sub> <input type="checkbox"/> 其他_____
您这三个月的服用频率？（如果食用频率小于每天/周一次，请填写每周/月食用几次，并勾出周/月） How often did	_____次/□天 □周 □月	_____次/□天□周□月	_____次/□天 □周 □月

<b>营养补充剂种类</b> <b>Nutritional supplement types</b>	<b>铁</b> <b>Fe</b>	<b>钙</b> <b>Ca</b>	<b>锌</b> <b>Zn</b>
<b>您在近三个月是否服用</b> <b>Have you taken it in the last</b>	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否

<b>you take in</b>			
--------------------	--	--	--

three months?			
<b>您服用的什么品牌的营养补充剂？(如果没有, 选项请在其他处写明)</b> <b>Brand name</b>	<input type="checkbox"/> 1、汤臣倍健叶酸亚铁片 <input type="checkbox"/> 2、安利纽崔莱铁片 <input type="checkbox"/> 3、金康倍叶酸铁片 <input type="checkbox"/> 4、其他_____	<input type="checkbox"/> 1、惠氏金钙尔奇 <input type="checkbox"/> 2、君宝康孕妇钙片 <input type="checkbox"/> 3、十月妈咪维生素 AD 钙锌咀嚼片 <input type="checkbox"/> 4、安利钙镁片 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、美康利健 MK 硒金牡蛎锌片 <input type="checkbox"/> 2、汤臣倍健 锌咀嚼片 <input type="checkbox"/> 3、宫诺肽片 <input type="checkbox"/> 4、其他_____
<b>您这三个月的服用频率？(如果食用频率小于每天/周一次, 请填写每周/月食用几次, 并勾出周/月)</b> <b>How often did you take in</b>	_____次/□天 □周 □月	_____次/□天□周□月	_____次/□天 □周 □月

## B 营养补充剂使用情况

<b>C 吸烟情况</b>	
C1 您有吸烟史吗? Have you smoked cigarettes ever before?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 ( <b>跳至 F6</b> )
C2 在您最近的 3 个月内, 您是否吸烟? Did you smoke cigarettes in 3 month	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C3 如果是, 您平均每天吸多少支烟? On average, how many cigarettes did you smoke each day in the month after your last menstrual period?	_____ 支
C4 如果您曾经戒过烟, 您戒了多少次? How many times did you stop smoking?	_____
C5 在您生活的大多数时间里, 您是否暴露于他人烟草烟雾中? On most days during your pregnancy, were you exposed to someone else's cigarette smoke?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 ( <b>跳至 G1</b> )
C6 您在哪里暴露与烟草烟雾中 Where were you exposed to the smoke?	<input type="checkbox"/> 1 仅在家中 <input type="checkbox"/> 2 仅在工作单位 <input type="checkbox"/> 3 在家和在工作单位均暴露
<b>D 酒精</b>	
D1 您最近三个月的饮酒情况? During the 3 months before or during your pregnancy, did you ever drink any alcoholic beverages?	<input type="checkbox"/> 0.从未饮酒; <input type="checkbox"/> 1.尝试饮酒 (曾饮至少半瓶或一听啤酒, 一小盅白酒等); <input type="checkbox"/> 2.现在饮酒 (过去 30 天, 至少有一天喝过一杯酒); <input type="checkbox"/> 3.重度饮酒 (过去 30 天, 至少有一天在 2 小时内喝过五杯酒); <input type="checkbox"/> 4.醉酒 (过去 12 个月内, 因喝酒太多而感到头晕/头疼/嗜睡等醉酒症状)。

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

核查人员签名：\_\_\_\_\_

For peer review only

## Appendix 2b pregnant questionnaire

Name of pregnancy : \_\_\_\_\_

ID no : \_\_\_\_\_

## 孕期危险因素暴露调查表

## Pregnancy risk factor exposure questionnaire

For peer review only

**A 一般情况 General information**

A1 您的出生日期是 Birth date	_____年_____月_____日
A2 民族 Nationality	<input type="checkbox"/> 1 汉族 Han <input type="checkbox"/> 2 其他 other_____
A3 您的最高学历 Education	<input type="checkbox"/> 1 初高中以下 Mid <input type="checkbox"/> 2 大专本科 High <input type="checkbox"/> 3 硕士研究生以上及以上 College
A4 您现在的主要职业 Occupation	<input type="checkbox"/> 1 管理人员/干部 <input type="checkbox"/> 2 技术人员 <input type="checkbox"/> 3. 企业主 <input type="checkbox"/> 4 工人 <input type="checkbox"/> 5 农民 <input type="checkbox"/> 6 个体户 <input type="checkbox"/> 7 其它_____
A6 家庭住址: Address	_____区/县_____街道/小区_____门牌号码/村
A7 联系电话 (请您认真填写, 以助于医生和您联系): Contact number	_____(手机) _____(固定电话) _____(Email) _____(微信号)

**B 本次妊娠情况**

B1 您孕前体重通常为? Current weight	_____ (公斤 Kg)
B2 您身高是? Height	_____ (厘米 cm)
B3 您的腰围是? Waist	_____ (厘米 cm)
B4 您此次怀孕的末次月经时间? What was the first day of the menstrual period that came right before this pregnancy (LMP)?	_____年_____月_____日
B5 孕期是否发生过重大负性生活事件而使您的精神受到刺激? Have you ever experienced the negative events which irritate you and generate some negative emotion?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
B6 生这个孩子是您第几次怀孕? How many times have you been pregnant?	_____次
B7 是否有不良生育史? Did you have the adverse reproductive history?	<input type="checkbox"/> 1 有 (继续回答 B6.1) <input type="checkbox"/> 0 无 (跳至 B7)
B6.1 流产史 Abortion	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B6.2 早产史 Preterm	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B6.3 死产史 Stillbirth	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B8 您是否有糖尿病和高血压疾病? Do you have hypertension or diabetes	<input type="checkbox"/> 1 是 (继续回答 B8) <input type="checkbox"/> 0 否 (跳至 C1) <input type="checkbox"/> 999 不知道 (跳至 C1)
B9 您的直系亲属中是否患有糖尿病、高血压疾病? Is there the family history of hypertension or diabetes in children's immediate family members	<input type="checkbox"/> 1 是 (继续回答 B8) <input type="checkbox"/> 0 否 (跳至 C1) <input type="checkbox"/> 999 不知道 (跳至 C1)
B10 若有, 请选择出该亲属与您的关系 (可多选) If so, please choose the relationship with the child	<input type="checkbox"/> 1. 父亲 <input type="checkbox"/> 2. 母亲 <input type="checkbox"/> 3. 爷爷 <input type="checkbox"/> 4. 奶奶 <input type="checkbox"/> 5. 兄弟 <input type="checkbox"/> 6. 姐妹



## C 叶酸使用

C1 在您末次月经前三个月内，您是否服用过叶酸？ Did you take folic acid in the month before your last period?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否	
C2 在您末次月经之后至今，您是否服用过叶酸？ Did you take any folic acid after your last period and during pregnancy ?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否	
	叶酸 1	叶酸 2	叶酸 3
C3 药物名称(商品名) Brand name			
C4 使用时间 When did you take it?	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always
C5 是否在怀孕期间一直使用？ Did you take it during the rest of your pregnancy?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C6 是否停止使用过？ Did you stop taking it?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C7 使用频率？ How often did you take it?	____次/□天 □周 □月	____次/□天 □周 □月	____次/□天 □周 □月
C8 每次的使用量 What is the usage per time?	一次____片	一次____片	一次____片

## D 维生素使用

D1 在您末次月经的前三个月内，您是否服用过维生素？ Did you take any vitamins in the three months before your last period ?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否	
D2 在您末次月经之后至今，您是否服用过维生素？ Did you take any vitamins after your last period and during pregnancy?	<input type="checkbox"/> 1 是	<input type="checkbox"/> 0 否 (跳至 E1)	
	维生素 1	维生素 2	维生素 3
D3 维生素名称 Vitamin name			
D4 维生素商品名称 Brand name			
D5 是否是医生给药？ Did your doctor give it to you?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
D6 是否包括叶酸？ Does it contain folic acid?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道

D7 使用时间 When did you take it?	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always
D8 是否停止使用过? Did you stop taking it?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
D9 使用频率? How often did you take it?	____次/□天 □周 □月	____次/□天 □周 □月	____次/□天 □周 □月
D10 每次的使用量 What is the usage per time?	一次____片	一次____片	一次____片

### E 其他营养补充剂使用情况 Other nutritional supplement use

营养补充剂种类 Nutritional supplement types	铁 Fe	钙 Ca	锌 Zn
您在近三个月是否服用 Did you take it around the time you became pregnant?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂? (如果没有, 选项请在其他处写明) Brand name	<input type="checkbox"/> 1、汤臣倍健叶酸亚铁片 <input type="checkbox"/> 2、安利纽崔莱铁片 <input type="checkbox"/> 3、金康倍叶酸铁片 <input type="checkbox"/> 4、其他_____	<input type="checkbox"/> 1、惠氏金钙尔奇 <input type="checkbox"/> 2、君宝康孕妇钙片 <input type="checkbox"/> 3、十月妈咪维生素 AD 钙锌咀嚼片 <input type="checkbox"/> 4、安利钙镁片 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、美康利健 MK 硒金牡蛎锌片 <input type="checkbox"/> 2、汤臣倍健 锌咀嚼片 <input type="checkbox"/> 3、宫诺肽片 <input type="checkbox"/> 4、其他_____
您这三个月的服用频率? (如果食用频率小于每天/周一一次, 请填写每周/月食用几次, 并勾出周/月) How often did you take it?	____次/□天 □周 □月	____次/□天□周□月	____次/□天 □周 □月

### F 草本药物使用

F1 在您末次月经前三个月内, 您是否使用过任何一种草本药物/传统医学药物? Did you take any herbal supplements/traditional Chinese medicine in the three months before your last period

1 是  0 否

F2 在您末次月经之后，您是否使用过任何一种草本药物/传统医学药物 Did you take any herbal supplements/traditional Chinese medicine after your last period and during pregnancy? ? □ 1 是      □ 0 否 (跳至 F1)			
	草本药物 1 Herbal 1	草本药物 2 Herbal 2	草本药物 3 Herbal 3
F3 草本药物类型 Name of herb	□ 1 中成药 □ 2 中医草药	□ 1 中成药 □ 2 中医草药	□ 1 中成药 □ 2 中医草药
F4 药物名称(如果选择中医草药，请填写中药功效) The use of traditional Chinese medicine			
F5 用药持续多少天 How long did you take in?	_____天	_____天	_____天

### G 吸烟情况

G1 您在怀孕前或者怀孕期间吸烟吗? Did you smoke cigarettes before or during your pregnancy with the baby?	□ 1 是	□ 0 否(跳至 F9)
G2 在您末次月经的当月，您是否吸烟? Did you smoke during the month before your last menstrual period ?	□ 1 是	□ 0 否
G3 在您末次月经的一个月后（末次月经结束直至一个月后），您是否吸烟？ (跳至 5) Did you smoke during the month after your last menstrual period, that is between LMP and LMP+1 month	□ 1 是	□ 0 否
G4 如果是，您平均每天吸多少支烟? On average, how many cigarettes did you smoke each day in the month after your last menstrual period ? 支		
G5 在您怀孕期间，您是否吸烟? Did you smoke during your pregnancy?	□ 1 是	□ 0 否(跳至 F7)
G6 在您怀孕期间，您平均每天吸多少支烟? On average how many cigarettes did you smoke each	_____ 支	
G7 在您末次月经期间至今，您是否戒过吸烟? Did you stop smoking at any time between your last menstrual period and the end of your pregnancy?	□ 1 是	□ 0 否 (跳至 F9)
G8 您戒烟有多少次？ How many times did you stop?		_____ 次
G9 在您怀孕的大多数时间里，您是否暴露于他人烟草烟雾中? On most days during your pregnancy, were you exposed to someone else's cigarette smoke?	□ 1 是	□ 0 否 (跳至 G1)

G10 您在哪里暴露与烟草烟雾中?

Where were you exposed to the smoke?

1 仅在家中      2 仅在工作单位      3 在家和在工作单位均暴露

## H 酒精

H1 在您怀孕前三个月至今，您是否饮用过任何含有酒精的饮料?

1 是      0 否

During the 3 months before or during your pregnancy, did you ever drink any alcoholic beverages?

H2 在这三个月内，您通常每次饮几杯酒?

\_\_\_\_\_ 杯

On those days that you drank, how many drinks did you have?

## I 环境暴露情况

I1 怀孕前三个月到现在，您是否染烫发?

1 是      0 否

Did you dye perm in the first three months of pregnancy?

I2 怀孕前三个月到现在，后您工作的地点或家里是否装修过?

1 是      0 否

Did you exposed to formaldehyde in the first three months of pregnancy?

I3 怀孕前后您是否接触过下列物质? Have you been exposed to the following substances before and after pregnancy? (Toxic chemicals)

1 除草剂    2 杀虫剂    3 灭鼠剂    4 有机溶剂    5 消毒剂  
6 金属制剂    7 有害气体    8 有害固体

## J 药物使用情况

以下问题是有关于您在末次月经之前三个月内至今期间的用药情况

	治疗高血压 药物 Medication for hypertension	胰岛素 Insulin for diabetes	口服降血糖 药物 Oral hypoglycemic for diabetes	抗癫痫药物 Medications for epilepsy	每天都要服用的 药物 Medications at least once a day	
1 您是否使用过? Did you take?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	
2 您使用的药物名称? What did you take?	_____	_____	_____	_____	_____	
<b>如果下一个问题令您感到不安且不愿意回答，请在“拒答”上打√，我们将对您所有回答进行严格保密!</b>						
	安定\有助于您放松药物 Valium\drugs to help you	使您感觉良好\精力旺盛 Make you feel	美沙酮\氧可酮\其他止痛药 Methadone oxymoron\other	可卡因 Cocaine or crack cocaine	海洛因 Heroin	大麻 Marijuana

	relax	good\have more energy	pain killers			
1 您是否使用过? Did you take?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚
2 您使用的药物名称? What did you take?	_____	_____	_____	_____	_____	_____

### I 您在怀孕期间是否患过以下疾病？

I.3 发热性疾病及呼吸道感染 Febrile illness and respiratory infections	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
I.3.1 您发烧时的最高温度是多少？ What was the highest temperature of your fever during your illness?	_____ °C
I.3.2 您发烧有几天？ How long did you have a fever?	_____ 天
I.6 其他 _____	

**调查结束，感谢您的配合！**

调查员姓名 \_\_\_\_\_

调查日期 \_\_\_\_/\_\_\_\_/\_\_\_\_  
                  年    月    日

### Appendix 3 Variable list

<b>Pre-pregnant variable list</b>		
No	Variables	Data type
	<b>General information</b>	
1	Wife id	Text
2	Husband nation	Text
3	Husband age	N
4	Husband education	Text
5	Husband id	Text
6	Husband occupation	Text
7	Wife nation	Text
8	Wife age	N
9	Wife education	Text
10	Wife occupation	Text
11	Tel No	Text
12	Mobile phone No	Text
	<b>Medical history</b>	
13	Female anemia	Category
14	Female EH	Category
15	Female heart disease	Category
16	Female DM	Category
17	Female epilepsy	Category
18	Female thyroid disease	Category
19	Female CGN	Category
20	Female mental disease	Category
21	Female tumour	Category
22	Female TB	Category
23	Female HBV	Category
24	Female VD	Category
25	Male anemia	Category
26	Male EH	Category
27	Male heart disease	Category
28	Male DM	Category
29	Male epilepsy	Category
30	Male thyroid disease	Category
31	Male CGN	Category
32	Male mental disease	Category
33	Male tumour	Category
34	Male TB	Category
35	Male HBV	Category
36	Male VD	Category

	<b>Vaccine</b>	
37	Female rubella vaccine	Category
38	Female hepB vaccine	Category
39	Male hepB vaccine	Category
	<b>Drug use</b>	
40	Female current medicine	Category
41	Female medicine name	Category
42	Male current medicine	Category
43	Male medicine name	Category
	<b>Childbearing history</b>	
44	Birth history	Category
45	Pregnancy times	Category
46	Live birth	Category
47	Dead fetus	Category
48	Dead birth	Category
49	Term delivery	Category
50	Premature delivery	Category
51	Natural abortion	Category
52	Abactio	Category
53	Children number	Category
54	Birth defect	Category
55	Defect type	Category
56	Menarche age	Category
57	Period menstruation	Category
58	Menstrual cycle	Category
59	Menstrual quantity	Category
60	LMP	Date
	<b>Family history of disease</b>	
61	Female family history thalassemia	Category
62	Female family history albinism	Category
63	Female family history favism	Category
64	Female family history hemophilia	Category
65	Female family history CHD	Category
66	Female family history DS	Category
67	Female family history openNTDs	Category
68	Female family history DM	Category
69	Female family history dysnoesia	Category
70	Female family history daysaudia	Category
71	Female family history vidual disorder	Category
72	Female family history neuropsychiatric	Category
73	Female family history other birth defects	Category
74	Female family history fetal death	Category
75	Female family history intermarry	Category

76	Female family history relations	Category
77	Male family history thalassemia	Category
78	Male family history albinism	Category
79	Male family history favism	Category
80	Male family history hemophilia	Category
81	Male family history CHD	Category
82	Male family history DS	Category
83	Male family history openNTDs	Category
84	Male family history DM	Category
85	Male family history dysnoesia	Category
86	Male family history dysaudia	Category
87	Male family history vidual disorder	Category
88	Male family history neuropsychiatric	Category
89	Male family history other birth defects	Category
90	Male family history fetal death	Category
91	Male family history intermarry	Category
92	Male family history relations	Category
	<b>Anthroposomatology</b>	
93	Female height	Numeric
94	Female weight	Numeric
95	Female BMI	Numeric
96	Female heart rate	Numeric
97	Female SBP	Numeric
98	Female SDP	Numeric
99	Male height	Numeric
100	Male weight	Numeric
101	Male BMI	Numeric
102	Male heart rate	Numeric
103	Male SBP	Numeric
104	Male SDP	Numeric
	<b>Lab data</b>	
105	Leucorrhoea check	Numeric
106	Clue cell	Numeric
107	Monilia infection	Numeric
108	Trichomomas	Numeric
109	Cleanness	Numeric
110	Whiff test	Numeric
111	PH	Numeric
112	Wom blood analysis	Numeric
113	Female hb	Numeric
114	Female wbc	Numeric
115	Female rbc	Numeric
116	Wom urine test	Numeric



117	Female ABO	Numeric
118	Female Rh	Numeric
119	Female GLU	Numeric
120	Female GLU levels	Numeric
121	Female NG	Numeric
122	Female chlamydia	Numeric
123	Female syphilis	Numeric
124	Female HIV	Numeric
125	Female ALT	Numeric
126	Female ALT levels	Numeric
127	Female HBs-Ag	Numeric
128	Female HBs-Ab	Numeric
129	Female HBe-Ag	Numeric
130	Female HBe-Ab	Numeric
131	Female HBc-Ab	Numeric
132	Female HCV-Ab	Numeric
133	Female CMV IgM	Numeric
134	Female CMV IgG	Numeric
135	Female RV IgM	Numeric
136	Female RV IgG	Numeric
137	Female TOX IgM	Numeric
138	Female TOX IgG	Numeric
139	Male blood analysis	Numeric
140	Male hb	Numeric
141	Male wbc	Numeric
142	Male rbc	Numeric
<b>During-pregnancy variable list</b>		
	<b>Basic information</b>	
1	Hospital card number	Text
2	Inpatient number	Text
3	Name	Text
4	Age	Numeric
5	Pregnant times	Numeric
6	Delivery times	Numeric
7	Last menstrual period	Date
8	Gestational week at the first visit	Numeric
9	The first visit date	Date
10	Height	Numeric
11	Weight	Numeric
12	Systolic blood pressure at the first visit	Numeric
13	Diastolic blood pressure at the first visit	Numeric

14	Occupation	Text
15	Education	Text
	<b>Antenatal care record</b>	
16	Weight at each antenatal care	Numeric
17	Systolic blood pressure at each antenatal care	Numeric
18	Diastolic blood pressure at each antenatal care	Numeric
19	Gestational week at each antenatal care	Numeric
20	Antenatal care date	Date
	<b>Lab data</b>	
21	Cytomegalovirus	Numeric
22	Cytomegalovirus examination date	Date
23	Rubella virus	Numeric
24	Rubella virus examination date	Date
25	Toxoplasmosis	Numeric
26	Toxoplasmosis examination date	Date
27	Syphilis screening	Numeric
28	Syphilis screening examination date	Date
29	Fasting blood-glucose	Numeric
30	Fasting blood-glucose examination date	Date
31	HCT(hematokrit)	Numeric
32	HCT(hematokrit) examination date	Date
33	Serum folate	Numeric
34	Serum folate examination date	Date
35	HCY(homocysteine)	Numeric
36	HCY(homocysteine) examination date	Date
37	OGTT 0 hours	Numeric
38	OGTT 1 hours	Numeric
39	OGTT 2 hours	Numeric
40	OGTT examination date	Date
41	Triglyceride	Numeric
42	Triglyceride examination date	Date
43	Total cholesterol	Numeric
44	Total cholesterol examination date	Date
45	Hemoglobin	Numeric
46	Hemoglobin examination date	Date
	<b>Delivery date</b>	
47	Gestational week at delivery	Numeric
48	Delivery mode	Text
49	Birth weight	Numeric
50	Birth weight(second baby)	Numeric
51	Systolic blood pressure at delivery	Numeric
52	Diastolic blood pressure at delivery	Numeric
53	Apgar scoring	Numeric

54	Delivery date	Date
55	Birth defect records	Text
56	Weight blood pressure at delivery	Numeric
<b>Offspring variable list</b>		
	<b>0 - 6 years (6 weeks, 6 months, 12 months, 36 months, 60 months)</b>	
1	Name	Text
2	ID number	Text
3	Weight	Numeric
4	Height/ Length	Numeric
5	Vision detection	Numeric
6	DDST: Denver developmental screening test	Numeric
	<b>6 - 18 years (each year)</b>	
7	Weight	Numeric
8	Height	Numeric
9	Diastolic blood pressure	Numeric
10	Systolic blood pressure	Numeric
11	Vision detection	Numeric
12	Vital capacity	Numeric
13	Physical fitness measurement (running, jumping, solid balls, etc)	Text
The clinical diagnosis during 0 – 18 years will be extracted from the routine medical system each year.		

## **Future Plan of Shanghai PreConception Cohort, Shanghai, China (SPCC)**

The Shanghai PreConception Cohort (SPCC) is a long-term cohort and meets the “Cohort profile” requirement. We have a complete plan to follow-up offspring to the age of 18 years old. The cohort will be financially supported by different grants. The current manuscript focuses on the first phase, the establishment of the baseline and our first main outcome, the congenital heart disease (CHD).

The second phase of this cohort study is from birth to 6 years old. Follow-up work will rely on Shanghai Community health care centers-child care. The third phase is from 6 to the age of 18 (school age). We will cooperate with Shanghai Student Health and Fitness Surveillance Center for the follow-up of the school age children.

Multiple outcomes for pediatrics, including growth, physical and neuro-developments, obesity, common and rare diseases will be investigated. Nested case-control design will be used for rare outcomes.

## The data collection plan for infants and children

	At birth	6 weeks	6 months	12 months	36 months	60 months	6 – 18 years*
General information (gender, ID number, Home Address, etc)	√	√					
Delivery outcome (Congenital malformation, preterm birth, miscarriage, stillbirth)	√						
Body measurement (weight, height, waistline, hipline)	√	√	√	√	√	√	√
Diet investigation (questionnaire)	√	√	√	√	√	√	√
Neurobehavioral developmental assessment (DDST <sup>\$</sup> )		√	√	√	√	√	
Anthropometrics data (Shanghai Community health care centers-child care and Shanghai Student Health and Fitness Surveillance Center) weight, height, waist circumference	√	√	√	√	√	√	√
Physical fitness measurement (running, jumping, solid balls, etc)							√
Blood pressure measurement, annually							√
Hemachrome (anemia)							√
Renal functions, at grade 9 and 12							√
Cardiovascular-related chronic diseases (Hypertension, Obesity, Diabetes/Pre-diabetes and Dyslipidemia)							√
Venous blood <sup>#</sup>							√

Note: \* Shanghai Student Health and Fitness Surveillance Center routinely conducts all-round physical examinations for students in the school as a health care policy for Shanghai students. It is usually in September-November of each year.

\$ DDST: Denver developmental screening test.

# Venous blood will be collected at 12, 15 and 18 years of age.

# BMJ Open

## Cohort profile: The Shanghai PreConception Cohort (SPCC) for the association of periconceptual parental key nutritional factors with health outcomes of children with congenital heart disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031076.R4
Article Type:	Cohort profile
Date Submitted by the Author:	13-Oct-2019
Complete List of Authors:	Wang, Dingmei; Children's Hospital of Fudan University Zhang, Yi; Children's Hospital of Fudan University Jiang, Yuang; Children's Hospital of Fudan University Ye, Ying; Clinical Epidemiology Ji, Mi; Children's Hospital of Fudan University Dou, Yalan; Children's Hospital of Fudan University, Dermatology Chen, Xiaotian; Children's Hospital of Fudan University Li, Mengru; Children's Hospital of Fudan University Ma, Xiaojing ; Children's Hospital of Fudan University Sheng, Wei; Children's Hospital of Fudan University Huang, Guoying; Children's Hospital of Fudan University, Pediatric Heart Center Yan, Weili; Children's Hospital of Fudan University,
<b>Primary Subject Heading</b>:	Research methods
Secondary Subject Heading:	Public health, Obstetrics and gynaecology, Nutrition and metabolism
Keywords:	red blood cell folate, vitamin, congenital heart diseases, periconceptual health care

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **1 Cohort profile: The Shanghai PreConception Cohort (SPCC) for the**  
5  
6  
7 **2 association of periconceptual parental key nutritional factors with**  
8  
9  
10 **3 health outcomes of children with congenital heart disease**

11  
12 4 Dingmei Wang\*<sup>1,2</sup>, Yi Zhang\*<sup>1,2</sup>, Yuan Jiang<sup>1,2</sup>, Ying Ye<sup>1</sup>, Mi Ji<sup>1</sup>, Yalan  
13  
14  
15 5 Dou<sup>1</sup>, Xiaotian Chen<sup>1,2</sup>, Mengru Li<sup>2</sup>, Xiaojing Ma<sup>2</sup>, Wei Sheng<sup>2</sup>, Guoying  
16  
17  
18 6 Huang<sup>2</sup>#, Weili Yan<sup>1,2</sup>#; SPCC group

19  
20 7 1 Department of Clinical Epidemiology & Clinical Trial Unit (CTU),  
21  
22  
23 8 Children's Hospital of Fudan University, Shanghai, China.

24  
25 9 2 Shanghai Key Lab of Birth Defect, Children's Hospital of Fudan University,  
26  
27  
28 10 Shanghai, China.

29  
30  
31 11  
32  
33 12 \* Contributed equally to this work.

34  
35  
36 13 # Co-corresponding author.

37  
38  
39 14 A full list of SPCC group can be found after Acknowledgements.

40  
41  
42  
43 15 Weili Yan, PhD

44  
45  
46 16 86-21-64931215

47  
48  
49 17 Email: yanwl@fudan.edu.cn

50  
51  
52 18 Guoying Huang, MD PhD

53  
54  
55 19 86-21-64931913

56  
57  
58 20 Email: gyhuang@shmu.edu.cn  
59  
60

## 1 ABSTRACT (292)

2 **Purpose:** The Shanghai PreConception Cohort (SPCC) was initially  
3 established to investigate the associations of parental periconceptual  
4 nutritional factors with congenital heart disease (CHD) but has further  
5 analyzed child growth and development and pediatric diseases.

6 **Participants** Preparing-for-pregnancy couples who presented at Shanghai  
7 preconception examination clinics and early pregnant women before 14  
8 gestational weeks were enrolled to comprise the periconceptual baseline  
9 study population. General characteristics, routine clinical data, and  
10 consumption of diet supplements, such as folic acid and multivitamins, were  
11 collected. Blood samples were obtained at preconception and early, middle,  
12 and late gestation using standard procedures. Multiple nutritional factors,  
13 including folate, homocysteine, vitamin A, vitamin D, vitamin E, and metals,  
14 in the blood samples of participants, selected using a case-control design,  
15 were examined. Genomic DNA was extracted.

16 **Findings to date** The baseline population included 8045 preconception  
17 couples, 3054 single women, and 15,615 early-pregnant women. Data from  
18 12,402 births were collected, and follow-up of the cohort for other outcomes  
19 is ongoing. Currently, 151 cases of CHD were identified after birth. The pilot  
20 analysis in a small subgroup showed that approximately 20.0% of  
21 preconception women and 44.9% of early-pregnant women had red blood



1  
2  
3  
4 1 cell folate levels that met the international recommendation for preventing  
5  
6  
7 2 neural tube defects.  
8  
9

### 3 **Future plans**

4 Once a sufficient number of CHD cases are achieved, we will investigate the  
5 quantitative association of preconception red blood cell folate levels with  
6 CHD using a nested case-control design. The SPCC will be followed for 18  
7 years to investigate extensive outcomes of growth, development, obesity,  
8 and common and rare diseases during childhood and adolescence according  
9 to our plan. Blood nutritional factors will be examined in participants  
10 selected for specific aims. The SPCC will also allow for prospective cohort  
11 studies on extensive research questions.  
12

12 **Trial registration number:** NCT 02737644

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 **Strengths and limitations of this study**

- 2 ● The SPCC is the first prospective birth cohort with CHD as primary  
3 outcome with recruitment starting from the preconception stage.  
4 Temporal sequence of exposures and outcomes can be achieved for  
5 causal inference of birth defects and other diseases that develop during  
6 the early stage of gestation.
- 7 ● Preconception blood samples were appropriately collected and stored,  
8 which allow for the examination of individual blood levels for nutritional  
9 factors and other exposures.
- 10 ● Preconception clinical data and blood samples from both the father and  
11 mother were collected to determine the effect of both maternal and  
12 paternal genetic and nutritional factors on fetal and pediatric diseases.
- 13 ● Although the response rate was high (>95%), preconception participants  
14 were recruited from the population who voluntarily presented at  
15 preconception physical examination sites in Shanghai. They may have  
16 stronger willingness for a healthy pregnancy, which may induce  
17 selection bias.
- 18 ● Biological samples (cord blood, placenta) of the newborns were not  
19 collected.

## 1 INTRODUCTION

2 Congenital heart disease (CHD) is a common congenital malformation that  
3 seriously affects children's quality of life.[1] CHD is a leading cause of  
4 infant death in high-income countries, affecting 8 of 1000 live births.[2]  
5 According to the report from National Health and Family Planning  
6 Commission of the People's Republic of China, CHD accounts for about a  
7 quarter of the birth defects of newborns in China, ranking first among birth  
8 defects.[3] In a prospective, nationwide large-scale study in >120,000  
9 newborns in China in 2013, the prevalence of CHD in live births was 8.94%.  
10 The incidence of severe CHD was 2.9%.[4]

11 The cause of CHD is multifactorial. With the development of genetic  
12 engineering technology, genetic factors have been better understood in the  
13 past decade.[5] Multiple environmental risk factors have been reported in  
14 epidemiological studies, maternal social variables such as occupation,  
15 educational background, health status, unhealthy lifestyle, maternal medical  
16 history and emotional status, family history of the disease, and  
17 consanguineous marriages.[6-10] Additionally, maternal key nutrients are  
18 related to the risk of offspring's CHD as a modifiable environmental factor  
19 during periconception.[11, 12] The periconceptional intake of folic acid  
20 supplement has been shown to reduce the risk of CHD,[13, 14] and women  
21 worldwide have been recommended to use folic acid supplements before

1  
2  
3  
4 1 conception and at the beginning of pregnancy. Awareness of the relationship  
5  
6  
7 2 between folic acid deficiency and CHD is actually a byproduct finding from  
8  
9  
10 3 the well-known Hungarian randomized control trials (RCT) study of folic  
11  
12 4 acid supplementation to prevent neural tube defects. The study found that  
13  
14  
15 5 prenatal supplementation with a vitamin complex containing 0.8 mg of folic  
16  
17  
18 6 acid daily reduced the incidence of congenital neural tube defects.  
19  
20 7 Additionally, the incidence of various heart defects has also been reduced by  
21  
22  
23 8 nearly half.[15] Longitudinal data from >1,000,000 births in Canada in 22  
24  
25  
26 9 years, from 1990 to 2011, also showed that food fortification with folic acid  
27  
28  
29 10 reduced the risk of CHD by 20–30% [14] The current guideline for folic acid  
30  
31  
32 11 supplementation recommends that all women of childbearing potential be  
33  
34  
35 12 supplemented with at least 0.4 mg folic acid daily prior to conception and  
36  
37  
38 13 during pregnancy, which is designed to prevent neural tube defects.[16]  
39  
40  
41 14 However, excessive folic acid intake may increase the risk of cancer,[17]  
42  
43  
44 15 vitamin B12 deficiency,[18] and autism spectrum disorder.[19] The optimal  
45  
46  
47 16 dose of folic acid for preventing CHD warrants further investigation.  
48  
49  
50 17 Additionally, most previous studies only focused on the folic acid  
51  
52  
53 18 supplement or serum folate level during or after pregnancy, which may not  
54  
55  
56 19 be the optimal period and method to reflect the exposure level to the risk of  
57  
58  
59 20 CHD.

21 To investigate the association between parental periconceptional key

1 nutritional factors, such as folate level, with the development of CHD and  
2 explore the cutoff biomarker levels, we conducted the Shanghai  
3 PreConception Cohort (SPCC) and a nested case-control analysis.

4 The SPCC was initiated primarily to evaluate CHD. However, based on  
5 the strengths of its baseline data collection, it has received attention and  
6 support, with improved additional extensive outcomes for children that will  
7 be followed for a longer term.

## 8 **COHORT DESCRIPTION**

### 9 **Who is in the cohort?**

10 The SPCC recruited parent-planning women and men who were permanent  
11 residents and voluntarily presented at preconception clinical clinics at 28  
12 maternity institutions in 10 districts of Shanghai (Minhang District, Huangpu  
13 District, Xuhui District, Changning District, Jing'an District, Putuo District,  
14 Yangpu District, Pudong District, Songjiang District, and Qingpu District)  
15 from March 2016 to December 2018. The preconception examination policy  
16 in the city of Shanghai provides a unique opportunity and clinical resources  
17 to support recruitment in the SPCC. Since 2010, married couples in Shanghai  
18 have been encouraged to attend a free preconception health examination.  
19 Moreover, these maternity institutions receive strong local administrative  
20 support and integrated maternal healthcare networking, providing service to  
21 150,000–200,000 annual deliveries in Shanghai. Couples who were present

1  
2  
3  
4 1 at preconception clinics, living in Shanghai, preparing for pregnancy within  
5  
6  
7 2 1 year, and planning to receive antenatal care and deliver in Shanghai, were  
8  
9  
10 3 eligible for the study. Written informed consent was obtained from all  
11  
12 4 participants before data collection. Additionally, we recruited early-pregnant  
13  
14  
15 5 women at their first antenatal examination who were at <14 gestational  
16  
17  
18 6 weeks. These two groups of participants comprised the periconceptual  
19  
20  
21 7 baseline study population.

22  
23 8 The first primary outcome of the SPCC is CHD. The hypothesis is that  
24  
25  
26 9 maternal preconception serum or red blood cell (RBC) folate level is  
27  
28  
29 10 quantitatively associated with CHD development in the offspring. The study  
30  
31  
32 11 design and protocol have been registered in the ClinicalTrials Registry (NCT  
33  
34  
35 12 02737644).

36  
37 13 As shown in Figure 1, the baseline population will be followed until  
38  
39  
40 14 delivery, and their infants will be followed until 18 years of age (Figure 1).

#### 41 42 15 **Follow-up procedure**

43  
44  
45 16 Upon enrollment, the participants completed the questionnaire of key  
46  
47  
48 17 nutrient supplementation and blood sample collection. When participants  
49  
50  
51 18 became pregnant, the same investigations (questionnaire/blood sample  
52  
53  
54 19 collection) were conducted during early pregnancy (first antenatal visit at  
55  
56  
57 20 16–20 gestational weeks). Pregnancies were followed along with routine  
58  
59  
60 21 maternal healthcare procedures. Blood samples were also collected at the

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 second (24–28 gestational weeks) and third trimester (32–34 gestational  
2 weeks). The follow-up data of CHD outcome and birth were obtained  
3 through the Shanghai Neonatal CHD Screening Platform (Figure 1).

4 As shown in Figure 1, outcomes at birth, from infancy to childhood  
5 (preschool phase) and between 7 and 18 years (school ages), will be collected  
6 or extracted from multiple public platforms and data sources. First,  
7 preconception clinical visit data from the Preconception Care Electronic  
8 Data System, supported by the national and local government, were collected,  
9 including height, weight, age, infections, sexually transmitted disease, and  
10 family history. Second, the routine pregnancy data were obtained from the  
11 Maternal Clinic Antenatal Medical Record System, managed by the  
12 Shanghai Center for Women and Children's Health, including height,  
13 gestational weight, last menstrual period, childbearing history, delivery  
14 outcomes, infections, hematocrit, coagulation function, and liver and kidney  
15 function. Lastly, the maternal and neonatal data at delivery were obtained  
16 from the Shanghai Neonatal CHD Screening Platform, including birth  
17 weight, CHD diagnosis, birth defects, and Apgar score. Additionally, we will  
18 work with the Shanghai Student Health and Fitness Surveillance Center to  
19 obtain outcome data. The personal national identification card numbers of  
20 participants are applied as index variables through multiple data sources. The  
21 detailed variable list and codebook of data collection are presented in

## 1 Appendix 1.

2 During the first phase of the cohort, from preconception to delivery,  
3 comprehensive strategies were used to retain participants in the study. For  
4 mothers, we provided a variety of engagement activities including green  
5 channel (fast track) to their antenatal care to provide convenience and save  
6 their time in hospitals. We also provided a contact number on the participant  
7 card to answer their calls or queries about the study procedures. Site  
8 investigators at early pregnancy clinics in collaborative hospitals were  
9 provided a smartphone application to help timely identification of recruited  
10 cohort participants and to manage data and blood sample collection  
11 procedures. We also provided green channel echocardiography for  
12 diagnosing CHD in all site hospitals to enhance the compliance of  
13 participants. Moreover, an automated text message system is adopted to  
14 remind participants of schedules and follow-up appointments.

### 15 **Study measures**

#### 16 Personal characteristics questionnaires

17 As shown in Figure 1, Questionnaire 1 was administered during recruitment  
18 at preconception examination sites, and Questionnaire 2 was administered at  
19 early pregnancy sites to collect information on the consumption of folic acid  
20 and vitamin supplements and on the brand and content of nutritional  
21 supplement. Information on the demographics, maternal education,



1 sociodemographic status, occupation, smoking status, alcohol consumption,  
2 body mass index (BMI), medication, and health status was also included. In  
3 addition to the content of Questionnaire 1, Questionnaire 2 added drug  
4 information, reproductive history, and health status. Questionnaire 1 for  
5 baseline and Questionnaire 2 for the first antenatal visit at early pregnancy  
6 are presented in Appendix 2a and Appendix 2b.

### 7 Blood sample collection

8 In this study, the remaining blood samples for routine clinical blood  
9 examination were collected. The blood sample for routine clinical  
10 examination was usually 5 mL and extracted in the morning. Routine clinical  
11 blood examination was performed at room temperature (20 °C –25 °C). The  
12 remaining samples (fasting serum and Ethylene Diamine Tetraacetic Acid (EDTA)  
13 anticoagulation) of peripheral venous blood from routine laboratory clinical  
14 blood examination were retained. These blood samples were temporarily  
15 stored in a 4 °C refrigerator for dispensing within 6 h and transferred to a -20 °C  
16 refrigerator. After completion of blood sample distribution, the serum and  
17 whole blood were stored at the site laboratory and then transported by three  
18 trained investigators to the central laboratory for storage in -80 °C freezers for  
19 2 weeks. Sampling tubes were made of a light-proof material, and the process  
20 of collecting blood samples was completely protected from light.

### 21 Examination of key nutritional factors in blood samples

1  
2  
3  
4 1 The examinations will be conducted in participants selected by nested case-  
5  
6  
7 2 control designs based on specific aims.

8  
9  
10 3 (1) *RBC folate, serum folate, serum homocysteine, vitamin D, vitamin B12,*  
11  
12 4 *and serum ferritin*

13  
14  
15 5 EDTA anticoagulated blood samples were collected to measure RBC folate,  
16  
17 6 serum folate, serum homocysteine, vitamin D, vitamin B12, and serum  
18  
19 7 ferritin. All six biomarkers were analyzed using electrochemiluminescence  
20  
21 8 assays (ARCHITECT i2000SR Analyzer, Abbott Laboratories, USA). A  
22  
23 9 standard solution with known level (produced by Abbott Laboratories) was  
24  
25 10 used daily to control the quality before the measurement. If the quality  
26  
27 11 control level was out of range, the measurement would be suspended and  
28  
29 12 adjusted. External quality control was conducted with the control laboratory  
30  
31 13 data program from Abbott Laboratories (Abbott Laboratories, Shanghai,  
32  
33 14 China). RBC folate levels were adjusted for hematocrit. If the RBC folate  
34  
35 15 level is <126.0 ng/mL or >651.1 ng/mL, adjustment was needed based on  
36  
37 16 the serum folate level. The hematocrit data were extracted from the hospital  
38  
39 17 laboratory information system. These examinations were performed in the  
40  
41 18 central laboratory of the Children's Hospital of Fudan University.

42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52 19 (2) *Vitamin A and E*

53  
54  
55 20 The serum vitamin A and E levels were quantitatively determined by liquid  
56  
57 21 chromatography tandem-mass spectrometry in the central laboratory of the  
58  
59  
60

1  
2  
3  
4 1 Children's Hospital of Fudan University. The testing instrument was triple  
5  
6  
7 2 quadrupole mass spectrometer LC/MS/MS system (API 3200MDTM, AB  
8  
9  
10 3 Sciex Pte. Ltd.). A standard solution of vitamin A-d6 and E-d6 was applied  
11  
12 4 as an internal standard.

15 5 *(3) Glycemic and lipid profiles*

17 6 Fasting serum cholesterol, high-density lipoprotein, low-density lipoprotein,  
18  
19  
20 7 triglyceride, and glucose levels were measured using the Beckman Coulter  
21  
22  
23 8 AU chemistry analyzers (Beckman Coulter Inc., USA) in the central  
24  
25  
26 9 laboratory of the Children's Hospital of Fudan University.

28 10 *(4) Metals*

30  
31 11 Serum levels of Mg, Fe, Zn, Se, Mn, As, Cu, and Ca were analyzed by  
32  
33  
34 12 inductively coupled plasma mass spectrometry (Inductively Coupled Plasma  
35  
36  
37 13 Optical iCAP6300, Thermo Scientific, USA) in standard mode.[20] The  
38  
39  
40 14 metal examination was conducted in the Instrumental Analysis Center of  
41  
42 15 Shanghai Jiao Tong University, which is a national key laboratory.

44 16 *(5) Genomic DNA extraction*

46  
47 17 Genomic DNA of all participants was extracted using a magnetic bead-based  
48  
49  
50 18 kit (TGuide M16 Automatic Nucleic Acid Extractor (OSE-M16), Tiangen  
51  
52  
53 19 Biotech (Beijing) Co., Ltd., China) from 2 mL of EDTA anticoagulated  
54  
55  
56 20 whole blood sample after routine blood examination. Genomic DNA  
57  
58 21 samples were stored for future studies. An average of 150 ng DNA was  
59  
60

1 available. Similar to that of blood chemicals, future genetic variant  
2 genotyping will be performed in selected participants according to the nested  
3 case-control design for specific aims. Currently, there are no candidate genes  
4 or variants that are listed.

#### 5 Outcomes: CHD in neonates

6 The diagnosis of CHD was the primary outcome of the study at this stage  
7 and obtained from the Shanghai Neonatal CHD Screening Platform, which  
8 was initiated as a routine screening tool for newborns in Shanghai since June  
9 1, 2016. The standard protocol of CHD screening in the platform was  
10 previously described in detail.[21] All newborns underwent the screening  
11 using a double-index method (i.e., cardiac murmur auscultation and pulse  
12 oximetry) at 6–72 h after delivery, and screening-positive newborns would  
13 undergo subsequent echocardiography for further confirmative diagnosis.

14 SPCC will also collect data on other birth defects as secondary outcomes,  
15 including Down's syndrome, neural tube defects, hydrocephalus, digestive  
16 tract malformations, urinary malformations, and behavioral cognitive  
17 developmental disorder. After delivery, the infants underwent routine  
18 childcare procedures organized by the Shanghai Child Health Care System,  
19 which are administered by the Shanghai Center for Women and Children's  
20 Health. All records of birth defects, which were diagnosed after birth, as well  
21 as routine neurodevelopmental examinations and longitudinal

1 anthropometric data, were abstracted from the system by a professional  
2 clinical team from the Children's Hospital of Fudan University (for details  
3 of the types of birth defects, please see Appendix 3)

#### 4 **Statistical methods**

5 To investigate the association of maternal preconception nutrition factor  
6 levels with offspring CHD risk, a nested case-control study will be conducted.  
7 The control will be matched by age and site.

8 The sample size for the nested case-control analysis was planned as 180  
9 CHD cases and 720 matched controls to detect maternal folate deficiency  
10 with a prevalence of 50% in controls (with an odds ratio [OR] of 1.6) to  
11 achieve a power of 80% at an alpha of 0.05. Based on CHD incidence >8.94  
12 per 1,000 live births,[4] 20,000 pregnancies will be needed. For a continuous  
13 nutrient variable with standard deviation of 2.0, 50 matched pairs (1:4) are  
14 required to achieve 90% power to detect an OR of 1.3 calculated using  
15 conditional logistic regression with a 0.05 significance level.[22, 23] Once a  
16 sufficient number of CHD cases are achieved, the quantitative association of  
17 preconception RBC folate levels with CHD development using nested case-  
18 control design will be investigated.

19 Conditional multivariate logistic regression will be used in the association  
20 analysis with offspring CHD status being the dependent variable and  
21 nutrition factor levels as exposure variables, after adjustment for all potential

1 paternal and maternal covariates. ORs and 95% confidence intervals will be  
2 reported. To explore a potential cutoff point of the nutrition factor levels that  
3 significantly increases the risk of CHD, a dummy variable will be set by  
4 categorizing the maternal preconception nutrition factor levels based on the  
5 distribution of the control group. The dose-response relationship will be also  
6 be analyzed. Sensitivity analysis will include non-conditional logistic  
7 regression analysis or generalized estimating equations model or generalized  
8 linear models, when necessary.

## 9 **FINDINGS TO DATE**

10 The SPCC started recruitment in March 2016. As shown in Figure 2, by  
11 December 2018, we consecutively recruited 19,144/19,563 (97.9%)  
12 participants at preconception settings, including 8045 couples and 3054  
13 single women, and an additional 15,615/16,201 (96.4%) pregnant women at  
14 maternity hospitals with gestational age <14 weeks. Table 1 describes the  
15 basic demographic characteristics of the preparing-for-pregnancy  
16 participants and pregnant women. The average age of the preconception  
17 population was 29.9 (SD, 3.9) years for women and 31.4 (SD, 4.5) years for  
18 men, 31.4% of men and 2.2% of women were smokers, and 61.4% of men,  
19 and 30.9 of women had an alcohol drinking habit. In pregnant women, the  
20 average age was 29.9 (SD, 4.0) years, with half having their first pregnancy.  
21 Preconception women were similar in age but different in education levels

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 and occupation. The prevalence of smoking and alcohol drinking was much  
2 lower. The descriptive data of Table 1 are partly included in another  
3 manuscript.  
4

For peer review only

**Table 1. Sociodemographic characteristics of participants, including 8,045 couples (parents) and 15,615 pregnant women, who were enrolled in the Shanghai PreConception Cohort**

Characteristics	Couples (parents) who completed preconception questionnaires		Additional pregnant women who completed both preconception and first-trimester questionnaires		<i>P</i> -value*		
	Men (n=8045)	Women (n=11099)	Pregnant women (n=15615)				
Age (years), mean±SD	8045	31.4±4.5	11099	29.9±3.9	15615	29.9±4.0	0.995
Ethnicity, n (%)	8001		11032		15587		0.407
Han nationality		7843 (98.0)		10773 (97.6)		15245 (97.8)	
Others		158 (2.0)		259 (2.4)		342 (2.2)	
Educational level, n (%)	7996		10988		15553		<0.001
High school or less		613 (7.7)		947 (8.6)		2117 (13.6)	
College or above		7383 (92.3)		10041 (91.4)		13436 (86.4)	
Annual household income, n (%)	7134		8747		NA		–
<¥ 100,000		1555 (21.8)		2114 (24.2)			
≥¥ 100,000		5579 (78.2)		6636 (75.8)			
Occupation, n (%)	7937		10909		15453		<0.001
Entrepreneur		190 (2.4)		156 (1.4)		171 (1.1)	
Farmer		35 (0.4)		49 (0.5)		79 (0.5)	
Self-employed		261 (3.3)		329 (3.0)		862 (5.6)	
Manager		1712 (21.6)		2101 (19.3)		2650 (17.2)	
Technician		2998 (37.7)		2269 (20.8)		2403 (15.6)	
Company clerk		678 (8.5)		857 (7.9)		3422 (22.1)	
Others		2063(26.0)		5148 (47.2)		5866 (37.9)	



Attending preconception pregnancy examination, n (%)	NA	NA	15594	-
Yes			3374 (22.5)	
No			11654 (77.5)	
Number of pregnancies, n (%)	NA	NA	15028	-
1			7804 (49.9)	
2			4598 (30.4)	
≥3			3192 (19.7)	
Miscarriage or stillbirth, n (%)	NA	NA	15532	-
Yes			4838 (31.1)	
No			10694 (68.9)	
Smoking, n (%)	8018	11064	15571	<0.001
Yes	2517 (31.4)	248 (2.2)	161 (1.0)	
No	5501 (68.6)	10816 (97.8)	15410 (99.0)	
Alcohol drinking, n (%)	7883	10906	15566	<0.001
Yes	4840 (61.4)	3374 (30.9)	1599 (0.3)	
No	3043 (38.6)	7532 (69.1)	13976 (89.7)	
Location of home, n (%)	8045	11099	NA	-
Developed districts	4473 (55.6)	4728 (42.6)		
Developing districts	3572 (44.4)	6371 (57.4)		

\*Comparisons between preconception women and pregnant women. t-tests were used to compare numerical variable (age). Chi-square tests were used to compare categorical variables (ethnicity, educational level, occupation, smoking, and alcohol drinking). Of 8045 preconception men, values were missing in ethnicity (n=44), educational level (n=49), annual household income (n=911), occupation (n=108), smoking (n=27), and alcohol drinking (n=162). Of 11099 preconception women, values were missing in ethnicity (n=67), educational level (n=111), annual household income (n=2352), occupation (n=190), smoking (n=35), and alcohol drinking (n=193). Of 15615 pregnant women, values were missing in ethnicity (n=28), educational level (n=62), occupation (n=162), attending preconception pregnant examination (n=21), parity (n=587), miscarriage or stillbirth (n=83), smoking (n=44), and alcohol drinking (n=49).

1  
2  
3  
4 By the end of December 2018, the last participants recruited at early  
5 pregnancy were due for delivery; however, we have obtained birth records  
6 of only 12,402 newborns. The follow-up of outcomes of the remaining  
7 participants is ongoing (shown in Figure 2). A total of 151 cases of CHD  
8 were identified through the CHD screening platform: 131 cases from the  
9 early pregnancy sample and the remaining 20 cases from the preconception  
10 sample. The prevalence of CHD in live births is 10.5‰ (131/12,402) based  
11 on the present available data.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 We conducted a small pilot study in April 2017 to determine blood levels  
27 of nutritional factors, including serum folate, RBC folate, vitamin A, vitamin  
28 E, and vitamin D. The blood samples from 627 women were selected  
29 consecutively from the preconception sample according to those who were  
30 identified as pregnant. Additionally, 597 women who were consecutively  
31 recruited from the antenatal care clinics were selected. As shown in Table 2,  
32 the median RBC folate levels were 247.0 ng/mL (Interquartile range (IQR),  
33 184.8–340.5 ng/mL) in preconception women and 417.4 ng/mL (IQR,  
34 308.6–544.2 ng/mL) in early-pregnant women. Moreover, 20.0% of  
35 preconceptional participants and 44.9% of pregnant participants had a folate  
36 level >400 ng/mL, which was suggested as optimal level for preventing  
37 neural tube development defects.[24, 25] These results suggest that effort is  
38 urgently needed to improve folic acid supplementation in the preparing-for-  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

pregnancy population, especially before pregnancy.

**Table 2. Distributions of biomarkers in women before and at early gestation (pilot study)**

Biomarker	Preconception		Early pregnancy	
	n	Level	n	Level
Serum folate, median (IQR), ng/ mL	620	9.7 (6.5, 13.8)	577	14.5 (11.2, 16.4)
RBC folate, median (IQR), ng/ mL	570	247.0 (184.8, 340.5)	587	417.4 (308.6, 544.2)
Homocysteine, median (IQR), $\mu$ mol/L	624	6.5 (5.2, 8.6)	599	4.2 (3.5, 5.2)
Vitamin B12, median (IQR), pg/mL	625	495.2 (394.2, 639.0)	600	388.5 (289.4, 511.4)
Vitamin D, mean $\pm$ SD, ng/mL	607	16.3 $\pm$ 6.0	578	15.5 $\pm$ 6.1

Based on the SPCC, the possible scope of research questions and available types and number of biosamples and biomarkers that can be examined are shown in Table 3.

**Table 3. Biosamples collected and biomarkers that can be examined in the SPCC**

Biosamples available in participants	Available sample type and volume	Time		
		Preconception+early pregnancy (Baseline) (n=25,487)	24–28 weeks (n=8668)	32–36 weeks (n=7522)
<b>Mother</b>				
	Serum, 200 µL*3	Yes	Yes	Yes
	Whole blood	Yes	Yes	Yes
	Genomic DNA, 150 ng	Yes	Yes	Yes
<b>Father</b>		(n=7151)	-	-
	Serum, 200 µL*3	Yes	NA	NA
	Whole blood	Yes	NA	NA
	Genomic DNA, 150 ng	Yes	NA	NA
<b>Child</b>	NA			

**Scope of research questions**

1. Quantitative association of preconception key nutrition factor levels (e.g., serum and RBC folates and related biomarkers, such as homocysteine and vitamin B12) with CHD, currently, and other folate-sensitive birth defects.
2. Quantitative association of periconceptual maternal and paternal key nutrition factor levels (preconception and dynamic levels during gestation) with important maternal and neonatal gestational complications, neurodevelopment of infants, childhood obesity, and clinical pediatric diseases.
3. Periconceptual maternal and paternal folate level with autism spectrum disorder, allergy, and asthma in children.

**Biomarkers that will be examined in different types of biosamples:**

1. Biomarkers based on serum sample:
  - a) Folate and related markers: serum folate, homocysteine
  - b) Other vitamins: vitamin A, vitamin B12, vitamin E, and vitamin D
  - c) Macro- and micrometals: Mg, Fe, Zn, Se, Mn, As, Cu, Ca, etc. – mg/L
  - d) Serum ferritin
  - e) Fasting glycemic and lipid profiles: fasting glucose, total cholesterol, triglyceride, high-density lipoprotein, and low-density lipoprotein
2. Whole blood sample: RBC folate
3. Genomic DNA sample: candidate genetic variants or genome-wide variants are possibly examined

## **FUTURE PLANS**

We have a complete plan to follow offspring until the age of 18 years. The cohort will be financially supported by different grants. The current manuscript focuses on the first phase, the establishment of the baseline and our first main outcome, CHD. The data collection plan for infants and children (from birth to 6 years [pre-school stage] and from 6 to 18 years [school age]) is included. During the stage of 0–6 years, the neurodevelopmental data will be collected from routine childcare clinical visits at birth, 6 weeks, 6 months, 12 months, 36 months, and 60 months through the cooperating medical institutions. Physical measurement data and dietary intake information can also be collected at this stage. During the stage of 6–18 years, we plan to follow their growth (height, weight, blood pressure), mainly relying on the annual physical examination results of the Shanghai Student Health and Fitness Surveillance Center System. Multiple outcomes for children, including growth and development, cardiovascular diseases, neurodevelopment, metabolic diseases, obesity, and hypertension, will be investigated. Please see Appendix 4 for details.

## **STRENGTHS AND LIMITATIONS**

Compared with existing birth cohorts, there are three important strengths in our cohort. First, the SPCC is the first prospective birth cohort with CHD as primary outcome and recruitment starting from preconception. Blood

1  
2  
3  
4 samples were collected and stored, which allows direct measurement of  
5  
6  
7 individual exposure levels before the development of CHD and causal  
8  
9  
10 inference. Temporal sequence of exposures and outcomes can be achieved  
11  
12 for causal inference of birth defects and other diseases that develop during  
13  
14 the early stage of gestation. To date, no published studies have measured  
15  
16 maternal blood folate levels before conception and associated it to disease  
17  
18 outcomes. Second, this cohort also allows the investigation of associations  
19  
20 between periconceptional maternal and paternal nutrition exposures and  
21  
22 other birth defects, early-onset diseases, and neurodevelopmental outcomes.  
23  
24 Preconception blood samples were appropriately collected and stored, which  
25  
26 allows the examination of individual blood levels of nutritional factors and  
27  
28 other exposures. Lastly, both paternal and maternal clinical data and blood  
29  
30 samples before conception were collected, which will allow for the testing  
31  
32 of the effects of both maternal and paternal genetic and nutritional factors on  
33  
34 fetal and pediatric diseases.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 Two limitations of this cohort study should be considered. First, there are  
46  
47 approximately 200,000 pregnant women giving birth annually in Shanghai,  
48  
49 and approximately 20,000 of them will participate in the free preconception  
50  
51 care in Shanghai, where participants were recruited consecutively. Although  
52  
53 the response rate was high (>95%), preconception participants were  
54  
55 recruited from a population who voluntarily presented in Shanghai  
56  
57  
58  
59  
60

1  
2  
3  
4 preconception physical examination sites, who may have a stronger  
5  
6  
7 willingness for a healthy pregnancy. This may induce selection bias. Second,  
8  
9  
10 in this study, biological samples (cord blood, placenta) of the newborns are  
11  
12  
13 not collected. We plan to provide new informed consent to the family who  
14  
15  
16 are willing to participate in future studies to collect biological samples not  
17  
18  
19 previously mentioned. Furthermore, electrochemiluminescence assay was  
20  
21  
22 used to examine serum and RBC folate levels, which is different from the  
23  
24  
25 widely used microbiological assay. This will not result in bias in the  
26  
27  
28 association analysis, but comparison with international populations needs  
29  
30  
31 caution.

## 32 **COLLABORATION**

33  
34 Investigators with an interest in hypotheses related to SPCC (who meet the  
35  
36  
37 requirements of current approvals) are welcome to contact Dr. Guoying  
38  
39  
40 Huang or Weili Yan. A “Research Collaboration application” should be sent  
41  
42  
43 to the corresponding author by email. The application should include a brief  
44  
45  
46 description of the project.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgements

We are extremely grateful to all participants in this study, physicians for their help in the recruitment, and the whole SPCC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. We would like to thank Editage ([www.editage.com](http://www.editage.com)) for English language editing.

## SPCC group

Gouying Huang, Weili yan, Xiaojing Ma, Weifen Luo, Wei Sheng, Yi Zhang, Yuan Jiang, Yin Ye, Dingmei Wang, Xiaotian Chen, Mengru Li, Mi Ji, Yumei Liu, Gu Qing(s), Gu Qing(o), Linmei Zhu, De'ai Hou, Peiyu Sun. (Children's Hospital of Fudan University, Shanghai, China), Hongbing Wang, Li Meng, lin Zhang (Jingan Maternal and Child Health Center), Zifen Dai, Li fen (Shanghai First Maternity and Infant health Hospital), Shufang Chen, Zhenhua Tang, Jiahao Wu (International Peace Maternal and Child Health Hospital), Shuhua Wang, Dan li, Hui Wang (Xuhui Maternal and Child Health Center), Yu Ke, Weiping Cao, Baoren Zhang, Hong Huang (Shanghai Pudong New Area Health Care Hospital for Women & Children), Nailing Wang, Min Jiang, Jie Chen, Qiumin Xia (Shanghai Punan Hospital of Pudong New District), Hui Xu, Guoying Lao (Changning Maternity and Infant Health Hospital), HongMei Jin, Wenjuan Xie, Pin Yi (Qingpu



1  
2  
3  
4 Hospital, Zhongshan Hospital), Weiming Gong, JianXin Xu, Yingying Qian  
5  
6 (Shanghai Qingpu Maternal and Child Health Center), Mingjie Luo, Jingwei  
7  
8 Xia, Dongmei Chen, Zhenyu Tang (Shanghai Huangpu Maternal and Child  
9  
10 Health Center), Xuejing Zhu, Qing Liu, Huiling Yang (Shanghai Huangpu  
11  
12 Maternal and Child Health Hospital), Xiaotian Li, Zhiyong Wu, Chuanmin  
13  
14 Ying, Shan Shi (Obstetrics & Gynecology Hospital of Fudan University  
15  
16 (Shanghai Red House Ob & Gyn Hospital)), Yanquan Zhang, Mingyi Yang  
17  
18 (Wujing Hospital, Minhang District, Shanghai), Xiaohua Zhang, Lei Zhang,  
19  
20 Lin Guan (Shanghai Minhang District Maternal and Child Health Care  
21  
22 Hospital), Jinyu Xu, Honglin Wang, Fang Shen (The Fifth People's Hospital  
23  
24 of Shanghai, Fudan University), Wenying Li, Xiaojing Teng, Jinling Zhao  
25  
26 (Shanghai Minhang TCM Hospital), Cuili Zhu, Lan Wang, Hongwei Chen  
27  
28 (Shanghai Songjiang District Central Hospital), Xiaoming Yuan, Meihua  
29  
30 Zhang, Yaqiong Jin (Sijing Hospital, Songjiang District, Shanghai), Qing  
31  
32 Yang, Hong Zhu, Min Feng (Songjiang Maternal and Child Health Center),  
33  
34 Ying Wang, Yan Wu, Hong Tang (Songjiang Maternal and Child Health  
35  
36 Hospital), Sa Guo (Tongji Hospital of Tongji University), Hongling Du  
37  
38 (Shanghai Putuo District People's Hospital), Yuhuan Liu, Zhanyue Yi,  
39  
40 Renhua Shi (Changhai Hospital, Second Military Medical University,  
41  
42 Shanghai), Yu Gu, Qinfen Su, Yingying lv (Shanghai Zhabei District Central  
43  
44 Hospital), Yun Sun, QiongPei Gu (Yangpu District Family Planning Service  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Center), Xixia Pang, Qingwu Zhang (Kong Jiang Hospital of Yangpu District, Shanghai), Songxiao Bai, Baoqiao Qi (Shanghai East City Hospital).

**Contributors:** Substantial contributions to the conception or design of the study were made by GH and WY. YZ and DW prepared the original draft of the manuscript. YZ, DW, YY, JY, ML, MJ, YD, and XC led the study implementation at participating sites. DW and YZ were responsible for the day-to-day project management at each site. XM and WS were responsible for the biobank of the cohort. All authors provided critical review of the manuscript for important intellectual content and approved the final version.

**Funding:** This work is supported by the National Key Research and Development Program (grant no. 2016YFC1000506) and Natural Science Foundation of China (grant no. 81273168) and Three-year Planning for Strengthening the Construction of Public Health System in Shanghai (GWIV-24).

**Patient and public involvement:** No patients were directly involved in the design and conception of this study.

**Conflict of interest:** The authors have no conflicts of interest.

1  
2  
3  
4  
5  
6  
7 **Ethics approval:** This study was approved by the Ethics Committee of the  
8  
9 Children's Hospital of Fudan University, Shanghai, China.  
10  
11  
12  
13  
14

15 **Provenance and peer review** Not commissioned; externally peer reviewed.  
16  
17  
18  
19

20 **Data sharing statement:** The study data are not freely available due to  
21  
22 confidentiality reasons, but the research team welcomes potential  
23  
24 collaboration with other researchers. For further information, contact the  
25  
26 author GH (gyhuang@shmu.edu.cn)  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

- 1 Mahle WT, Newburger JW, Matherne GP, et al. Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics. *Circulation* 2009;120:447–58.
- 2 van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. *J Am Coll Cardiol* 2011;58:2241–7.
- 3 China MoPHo. China's Birth Defects Prevention Report. In. Edited by China MoPHo. Beijing 2012.
- 4 Zhao QM, Ma XJ, Ge XL, et al. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study. *Lancet* 2014;384:747–54.
- 5 Bruneau BG. The developmental genetics of congenital heart disease. *Nature* 2008;451:943–8.
- 6 Alverson CJ, Strickland MJ, Gilboa SM, et al. Maternal smoking and congenital heart defects in the Baltimore-Washington Infant Study. *Pediatrics* 2011;127:e647–53.
- 7 Lee LJ, Lupo PJ. Maternal smoking during pregnancy and the risk of congenital heart defects in offspring: a systematic review and metaanalysis. *Pediatr Cardiol* 2013;34:398–407.
- 8 Shi M, Wehby GL, Murray JC. Review on genetic variants and maternal smoking in the etiology of oral clefts and other birth defects. *Birth Defects Res C Embryo Today* 2008;84:16–29.
- 9 Kuciene R, Dulskiene V. Selected environmental risk factors and congenital heart defects. *Medicina (Kaunas)* 2008;44:827–32.
- 10 Carmichael SL, Shaw GM. Maternal life event stress and congenital anomalies. *Epidemiology* 2000;11:30–5.
- 11 Czeizel AE. Periconceptional folic acid-containing multivitamin supplementation for the prevention of neural tube defects and cardiovascular malformations. *Ann Nutr Metab* 2011;59:38–40.
- 12 Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal multivitamin use. *Am J Epidemiol* 2000;151:878–84.
- 13 Ionescu-Ittu R, Marelli AJ, Mackie AS, et al. Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada. *BMJ* 2009;338:b1673.
- 14 Liu SL, Joseph KS, Luo W, et al. Effect of folic acid food fortification in Canada on congenital heart disease subtypes. *Circulation* 2016;133:647–55.
- 15 Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube

- 1  
2  
3  
4 defects by periconceptional vitamin supplementation. *N Engl J Med*  
5 1992;327:1832–5.  
6  
7 16 Cordero AM, Crider KS, Rogers LM, et al. Optimal serum and red  
8 blood cell folate concentrations in women of reproductive age for  
9 prevention of neural tube defects: World Health Organization  
10 guidelines. *MMWR Morb Mortal Wkly Rep* 2015;64:421–3.  
11  
12 17 Kim YI. Will mandatory folic acid fortification prevent or promote  
13 cancer? *Am J Clin Nutr* 2004;80:1123–8.  
14  
15 18 Selhub J, Rosenberg IH. Excessive folic acid intake and relation to  
16 adverse health outcome. *Biochimie* 2016;126:71–8.  
17  
18 19 Wiens D, DeSoto MC. Is high folic acid intake a risk factor for autism?  
19 A review. *Brain Sci* 2017;7, 149.  
20  
21 20 Bolann BJ, Distant S, Morkrid L, et al. Bloodletting therapy in  
22 hemochromatosis: Does it affect trace element homeostasis? *J Trace*  
23 *Elem Med Biol* 2015;31:225–9.  
24  
25 21 Hu XJ, Ma XJ, Zhao QM, et al. Pulse oximetry and auscultation for  
26 congenital heart disease detection. *Pediatrics* 2017; 140: e20171154.  
27  
28 22 Lachin JM. Sample size evaluation for a multiply matched case-  
29 control study using the score test from a conditional logistic (discrete  
30 Cox PH) regression model. *Stat Med* 2008;27:2509–23.  
31  
32 23 Tang YQ. Comments on “Sample size evaluation for a multiply  
33 matched case-control study using the score test from a conditional  
34 logistic (discrete Cox PH) regression model”. *Stat Med* 2009;28:175–  
35 7.  
36  
37 24 Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube  
38 defects. Implications for prevention. *JAMA* 1995;274:1698–702.  
39  
40 25 Tam C, McKenna K, Goh YI, et al. Periconceptional folic acid  
41 supplementation: a new indication for therapeutic drug monitoring.  
42 *Ther Drug Monit* 2009;31:319–26.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Figure 1. Protocol and follow-up of the Shanghai PreConceptional Cohort  
5  
6  
7 (SPCC)  
8  
9

10 The baseline population of SPCC consisted of women and men at the  
11 periconception stage (couples who are preparing for pregnancy) and  
12 pregnant women at the early gestation stage. The cohort includes three  
13 phases, from periconception to birth (Phase I, perinatal phase), from birth to  
14 6 years (Phase II, infant and preschool age), and from 7 to 18 years (Phase  
15 III, school age). The current manuscript focuses on the first phase, with  
16 congenital heart disease as the primary outcome, and will cover other folate-  
17 sensitive birth defects.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure 2. Flowchart

By December 2018, we consecutively recruited 19,144/19,563 (97.9%) participants at preconception settings, including 8045 couples and 3054 single women at pre-pregnancy sites, and additional 15,615/16,201 (96.4%) pregnant women at maternity hospitals with gestational age <14 weeks were recruited. By the end of December 2018, the last participants recruited at early pregnancy were due for delivery. We have achieved birth records of 12,402 newborns in the Maternal Clinic Antenatal Medical Record System. The follow-up of outcomes of the remaining participants is ongoing. A total of 151 cases of CHD were identified through the Shanghai Neonatal CHD Screening Platform: 131 cases from the early pregnancy sample and the remaining 20 cases from the preconception sample. The prevalence of CHD in live births is 10.5‰ (131/12,402) based on the present available data. In the preconception sample, from March 2016 to May 2018 (the latest data extraction in the Maternal Clinic Antenatal Medical Record System), the number of pregnancies and deliveries were 1538 and 975, respectively.





Figure 1. Protocol and follow-up of the Shanghai PreConceptional Cohort (SPCC)

The baseline population of SPCC consisted of women and men at the periconception stage (couples who are preparing for pregnancy) and pregnant women at the early gestation stage. The cohort includes three phases, from periconception to birth (Phase I, perinatal phase), from birth to 6 years (Phase II, infant and preschool age), and from 7 to 18 years (Phase III, school age). The current manuscript focuses on the first phase, with congenital heart disease as the primary outcome, and will cover other folate-sensitive birth defects.





45 Figure 2. Flowchart By December 2018, we consecutively recruited 19,144/19,563 (97.9%) participants at  
46 preconception settings, including 8045 couples and 3054 single women at pre-pregnancy sites, and  
47 additional 15,615/16,201 (96.4%) pregnant women at maternity hospitals with gestational age <14 weeks  
48 were recruited. By the end of December 2018, the last participants recruited at early pregnancy were due  
49 for delivery. We have achieved birth records of 12,402 newborns in the Maternal Clinic Antenatal Medical  
50 Record System. The follow-up of outcomes of the remaining participants is ongoing. A total of 151 cases of  
51 CHD were identified through the Shanghai Neonatal CHD Screening Platform: 131 cases from the early  
52 pregnancy sample and the remaining 20 cases from the preconception sample. The prevalence of CHD in  
53 live births is 10.5‰ (131/12,402) based on the present available data. In the preconception sample, from  
54 March 2016 to May 2018 (the latest data extraction in the Maternal Clinic Antenatal Medical Record System),  
55 the number of pregnancies and deliveries were 1538 and 975, respectively.

## Appendix 1 Types of fetus defects and birth defects

## Types of fetus defects and birth defects

---

**Diagnosis**

---

Anencephalus

Spina bifida

Encephalocele

Congenital Hydrocephalus

Cleft Palate

Cleft Lip

Cleft Lip with Cleft Palate

Microtia (including Anotia)

Deformity of external ear(s) (except Microtia and Anotia)

Esophageal atresia or stenosis

Anorectal atresia (including Congenital Anorectal Malformations)

Hypospadias

Ectopocystis

Pes Equinovarus

Polydactylism

Syndactylia

Limb shortening

Congenital Diaphragmatic Hernia

Pcomphalus

Celoschisis

Conjoined Twins

Trisomy 21 syndrome

Congenital heart disease

Others

---

Note: Down's syndrome, neural tube defects, congenital heart defects, hydrocephalus, digestive tract

1  
2  
3 malformations and urinary malformations are most common defects in China. Defects were detected by  
4 prenatal Down's syndrome screening, NT examination and Ultrasound image examination during the  
5 second trimester; and the number and type of birth defects after childbirth are diagnosed by professional  
6 clinical team. Down syndrome (DS), caused by the trisomy, translocation, or partial trisomy of  
7 chromosome 21, is the most common genetic cause of intellectual disability. DS is diagnosed by  
8 neonatologist. Neural tube defects including spina bifida and hypospadias, were diagnosed by ultrasound  
9 examination and pediatric neurosurgeon. Congenital heart disease was diagnosis by Doppler ultrasound  
10 and CHD screening (pulse oximetry plus cardiac murmurs). Hydrocephalus, digestive tract malformations,  
11 urinary malformations and other defects also were also diagnosed either by ultrasound or some other  
12 specific diagnosis methods.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Appendix 2a pre-pregnant questionnaire

姓名 Name : \_\_\_\_\_

身份证号 ID no : □□□□□□□□□□□□□□□□□□□□□□

医院代码 Hospital No : \_\_\_\_\_ ( 到时打印到问卷上 )

填表日期 Date : \_\_\_\_\_年\_\_\_\_月\_\_\_\_日

**孕前膳食补充剂调查表****Pre-pregnancy nutrition supplement  
questionnaire****( 男女共用 )**

## A 一般情况

A1 联系电话（请您认真填写，有助于医生和您联系） Contact number: _____(手机) _____(固定电话) _____(Email)			
A2 家庭住址 Address: _____区/县_____街道/小区_____门牌号码/村			
A3 您的出生日期是 Birth date _____年_____月_____日			
A4 民族 Nationality <input type="checkbox"/> 1 汉族 <input type="checkbox"/> 2 其他（请注明）_____			
A5 您的最高学历 Education <input type="checkbox"/> 1 初高中以下 <input type="checkbox"/> 2 大专本科 <input type="checkbox"/> 3 硕士研究生以上及以上			
A6 您现在的主要职业 Occupation <input type="checkbox"/> 1 管理人员/干部 <input type="checkbox"/> 2 技术人员 <input type="checkbox"/> 3.企业主 <input type="checkbox"/> 4 工人 <input type="checkbox"/> 5 农民 <input type="checkbox"/> 6 个体户 <input type="checkbox"/> 7 其它_____			
A7 上一年您的家庭年收入是： Income of a year <input type="checkbox"/> 1. <2 万元 <input type="checkbox"/> 2. (2~3.9)万 <input type="checkbox"/> 3.(5.9)万 <input type="checkbox"/> 4.(6~9.9)万 <input type="checkbox"/> 5.(10~14.9)万 <input type="checkbox"/> 6.15 万及以上 <input type="checkbox"/> 9.不详			
A8 填表日期 Date _____年_____月_____日			

## B 营养补充剂使用情况

营养补充剂种类 Nutritional supplement types	叶酸 Folic acid	复合维生素 multi-vitamins	单一维生素 Single vitamin
您在近三个月是否服用 Have you taken it in the last three months?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂？（如果没有对应选项请在其他处写明） Brand name	<input type="checkbox"/> 1、创盈金斯利安多维片 <input type="checkbox"/> 2、福施福胶囊营养素 <input type="checkbox"/> 3、汤臣倍健 <input type="checkbox"/> 4、安利纽崔莱铁 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、爱乐维 <input type="checkbox"/> 2、汤臣倍健孕妇专用 <input type="checkbox"/> 3、惠氏玛特纳 <input type="checkbox"/> 4、21 金维他 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> V <sub>C</sub> <input type="checkbox"/> V <sub>E</sub> <input type="checkbox"/> V <sub>B1</sub> <input type="checkbox"/> V <sub>B2</sub> <input type="checkbox"/> 其他_____
您这三个月的服用频率？（如果食用频率小于每天/周一次，请填写每周/月食用几次，并勾出周/月） How often did	_____次/□天 □周 □月	_____次/□天□周□月	_____次/□天 □周 □月

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>营养补充剂种类</b> Nutritional supplement types	<b>铁</b> Fe	<b>钙</b> Ca	<b>锌</b> Zn
<b>您在近三个月是否服用</b> Have you taken it in the last	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否

For peer review only

<b>you take in</b>			
--------------------	--	--	--

three months?			
您服用的什么品牌的营养补充剂？(如果没有, 选项请在其他处写明) Brand name	<input type="checkbox"/> 1、汤臣倍健叶酸亚铁片 <input type="checkbox"/> 2、安利纽崔莱铁片 <input type="checkbox"/> 3、金康倍叶酸铁片 <input type="checkbox"/> 4、其他_____	<input type="checkbox"/> 1、惠氏金钙尔奇 <input type="checkbox"/> 2、君宝康孕妇钙片 <input type="checkbox"/> 3、十月妈咪维生素 AD 钙锌咀嚼片 <input type="checkbox"/> 4、安利钙镁片 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、美康利健 MK 硒金牡蛎锌片 <input type="checkbox"/> 2、汤臣倍健 锌咀嚼片 <input type="checkbox"/> 3、宫诺肽片 <input type="checkbox"/> 4、其他_____
您这三个月的服用频率？(如果食用频率小于每天/周一次, 请填写每周/月食用几次, 并勾出周/月) How often did you take in	____次/□天 □周 □月	____次/□天□周□月	____次/□天 □周 □月

### B 营养补充剂使用情况

<b>C 吸烟情况</b>	
C1 您有吸烟史吗? Have you smoked cigarettes ever before?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否(跳至 F6)
C2 在您最近的 3 个月内, 您是否吸烟? Did you smoke cigarettes in 3 month	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C3 如果是, 您平均每天吸多少支烟? On average, how many cigarettes did you smoke each day in the month after your last menstrual period?	_____ 支
C4 如果您曾经戒过烟, 您戒了多少次? How many times did you stop smoking?	_____
C5 在您生活的大多数时间里, 您是否暴露于他人烟草烟雾中? On most days during your pregnancy, were you exposed to someone else's cigarette smoke?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 (跳至 G1)
C6 您在哪里暴露与烟草烟雾中 Where were you exposed to the smoke?	<input type="checkbox"/> 1 仅在家中 <input type="checkbox"/> 2 仅在工作单位 <input type="checkbox"/> 3 在家和在工作单位均暴露
<b>D 酒精</b>	
D1 您最近三个月的饮酒情况? During the 3 months before or during your pregnancy, did you ever drink any alcoholic beverages?	<input type="checkbox"/> 0.从未饮酒; <input type="checkbox"/> 1.尝试饮酒 (曾饮至少半瓶或一听啤酒, 一小盅白酒等); <input type="checkbox"/> 2.现在饮酒 (过去 30 天, 至少有一天喝过一杯酒); <input type="checkbox"/> 3.重度饮酒 (过去 30 天, 至少有一天在 2 小时内喝过五杯酒); <input type="checkbox"/> 4.醉酒 (过去 12 个月内, 因喝酒太多而感到头晕/头疼/嗜睡等醉酒症状)。

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

核查人员签名：\_\_\_\_\_

For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Appendix 2b pregnant questionnaire

Name of pregnancy : \_\_\_\_\_

ID no : \_\_\_\_\_

### 孕期危险因素暴露调查表

## Pregnancy risk factor exposure questionnaire

For peer review only

**A 一般情况 General information**

A1 您的出生日期是 Birth date	_____年_____月_____日
A2 民族 Nationality	<input type="checkbox"/> 1 汉族 Han <input type="checkbox"/> 2 其他 other_____
A3 您的最高学历 Education	<input type="checkbox"/> 1 初高中以下 Mid <input type="checkbox"/> 2 大专本科 High <input type="checkbox"/> 3 硕士研究生以上及以上 College
A4 您现在的主要职业 Occupation	<input type="checkbox"/> 1 管理人员/干部 <input type="checkbox"/> 2 技术人员 <input type="checkbox"/> 3. 企业主 <input type="checkbox"/> 4 工人 <input type="checkbox"/> 5 农民 <input type="checkbox"/> 6 个体户 <input type="checkbox"/> 7 其它_____
A6 家庭住址: Address	_____区/县_____街道/小区_____门牌号码/村
A7 联系电话 (请您认真填写, 以助于医生和您联系): Contact number	_____(手机) _____(固定电话) _____(Email) _____(微信号)

**B 本次妊娠情况**

B1 您孕前体重通常为? Current weight	_____ (公斤 Kg)
B2 您身高是? Height	_____ (厘米 cm)
B3 您的腰围是? Waist	_____ (厘米 cm)
B4 您此次怀孕的末次月经时间? What was the first day of the menstrual period that came right before this pregnancy (LMP)?	_____年_____月_____日
B5 孕期是否发生过重大负性生活事件而使您的精神受到刺激? Have you ever experienced the negative events which irritate you and generate some negative emotion?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
B6 生这个孩子是您第几次怀孕? How many times have you been pregnant?	_____次
B7 是否有不良生育史? Did you have the adverse reproductive history?	<input type="checkbox"/> 1 有 (继续回答 B6.1) <input type="checkbox"/> 0 无 (跳至 B7)
B6.1 流产史 Abortion	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B6.2 早产史 Preterm	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B6.3 死产史 Stillbirth	<input type="checkbox"/> 1 有 <input type="checkbox"/> 0 无
B8 您是否有糖尿病和高血压疾病? Do you have hypertension or diabetes	<input type="checkbox"/> 1 是 (继续回答 B8) <input type="checkbox"/> 0 否 (跳至 C1) <input type="checkbox"/> 999 不知道 (跳至 C1)
B9 您的直系亲属中是否患有糖尿病、高血压疾病? Is there the family history of hypertension or diabetes in children's immediate family members	<input type="checkbox"/> 1 是 (继续回答 B8) <input type="checkbox"/> 0 否 (跳至 C1) <input type="checkbox"/> 999 不知道 (跳至 C1)
B10 若有, 请选择出该亲属与您的关系 (可多选) If so, please choose the relationship with the child	<input type="checkbox"/> 1. 父亲 <input type="checkbox"/> 2. 母亲 <input type="checkbox"/> 3. 爷爷 <input type="checkbox"/> 4. 奶奶 <input type="checkbox"/> 5. 兄弟 <input type="checkbox"/> 6. 姐妹

**C 叶酸使用**

C1 在您末次月经前三个月内，您是否服用过叶酸？ <input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 Did you take folic acid in the month before your last period?			
C2 在您末次月经之后至今，您是否服用过叶酸？ <input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 Did you take any folic acid after your last period and during pregnancy?			
	叶酸 1	叶酸 2	叶酸 3
C3 药物名称(商品名) Brand name			
C4 使用时间 When did you take it?	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always
C5 是否在怀孕期间一直使用? Did you take it during the rest of your pregnancy?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C6 是否停止使用过? Did you stop taking it?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
C7 使用频率? How often did you take it?	____次/□天 □周 □月	____次/□天 □周 □月	____次/□天 □周 □月
C8 每次的使用量 What is the usage per time?	一次____片	一次____片	一次____片

**D 维生素使用**

D1 在您末次月经的前三个月内，您是否服用过维生素？ <input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 Did you take any vitamins in the three months before your last period ?			
D2 在您末次月经之后至今，您是否服用过维生素？ <input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 (跳至 E1) Did you take any vitamins after your last period and during pregnancy?			
	维生素 1	维生素 2	维生素 3
D3 维生素名称 Vitamin name			
D4 维生素商品名称 Brand name			
D5 是否是医生给药? Did your doctor give it to you?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
D6 是否包括叶酸? Does it contain folic acid?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 999 不知道

D7 使用时间 When did you take it?	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always	<input type="checkbox"/> 1 孕前 before pregnancy <input type="checkbox"/> 2 孕后 pregnancy <input type="checkbox"/> 3 孕前孕后都有 always
D8 是否停止使用过? Did you stop taking it?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
D9 使用频率? How often did you take it?	____次/□天 □周 □月	____次/□天 □周 □月	____次/□天 □周 □月
D10 每次的使用量 What is the usage per time?	一次____片	一次____片	一次____片

### E 其他营养补充剂使用情况 Other nutritional supplement use

营养补充剂种类 Nutritional supplement types	铁 Fe	钙 Ca	锌 Zn
您在近三个月是否服用 Did you take it around the time you became pregnant?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
您服用的什么品牌的营养补充剂? (如果没有, 选项请在其他处写明) Brand name	<input type="checkbox"/> 1、汤臣倍健叶酸亚铁片 <input type="checkbox"/> 2、安利纽崔莱铁片 <input type="checkbox"/> 3、金康倍叶酸铁片 <input type="checkbox"/> 4、其他_____	<input type="checkbox"/> 1、惠氏金钙尔奇 <input type="checkbox"/> 2、君宝康孕妇钙片 <input type="checkbox"/> 3、十月妈咪维生素 AD 钙锌咀嚼片 <input type="checkbox"/> 4、安利钙镁片 <input type="checkbox"/> 5、其他_____	<input type="checkbox"/> 1、美康利健 MK 硒金牡蛎锌片 <input type="checkbox"/> 2、汤臣倍健 锌咀嚼片 <input type="checkbox"/> 3、宫诺肽片 <input type="checkbox"/> 4、其他_____
您这三个月的服用频率? (如果食用频率小于每天/周一一次, 请填写每周/月食用几次, 并勾出周/月) How often did you take it?	____次/□天 □周 □月	____次/□天□周□月	____次/□天 □周 □月

### F 草本药物使用

F1 在您末次月经前三个月内, 您是否使用过任何一种草本药物/传统医学药物? Did you take any herbal supplements/traditional Chinese medicine in the three months before your last period

1 是  0 否

F2 在您末次月经之后，您是否使用过任何一种草本药物/传统医学药物 Did you take any herbal supplements/traditional Chinese medicine after your last period and during pregnancy? ? □ 1 是      □ 0 否 (跳至 F1)			
	草本药物 1 Herbal 1	草本药物 2 Herbal 2	草本药物 3 Herbal 3
F3 草本药物类型 Name of herb	□ 1 中成药 □ 2 中医草药	□ 1 中成药 □ 2 中医草药	□ 1 中成药 □ 2 中医草药
F4 药物名称(如果选择中医草药，请填写中药功效) The use of traditional Chinese medicine			
F5 用药持续多少天 How long did you take in?	_____天	_____天	_____天

### G 吸烟情况

G1 您在怀孕前或者怀孕期间吸烟吗? Did you smoke cigarettes before or during your pregnancy with the baby?	□ 1 是      □ 0 否(跳至 F9)
G2 在您末次月经的当月，您是否吸烟? Did you smoke during the month before your last menstrual period ?	□ 1 是      □ 0 否
G3 在您末次月经的一个月后（末次月经结束直至一个月后），您是否吸烟？ (跳至 5) Did you smoke during the month after your last menstrual period, that is between LMP and LMP+1 month	□ 1 是      □ 0 否
G4 如果是，您平均每天吸多少支烟? On average, how many cigarettes did you smoke each day in the month after your last menstrual period ? 支	
G5 在您怀孕期间，您是否吸烟? Did you smoke during your pregnancy?	□ 1 是      □ 0 否(跳至 F7)
G6 在您怀孕期间，您平均每天吸多少支烟? On average how many cigarettes did you smoke each	_____ 支
G7 在您末次月经期间至今，您是否戒过吸烟? Did you stop smoking at any time between your last menstrual period and the end of your pregnancy?	□ 1 是      □ 0 否 (跳至 F9)
G8 您戒烟有多少次？ How many times did you stop?	_____ 次
G9 在您怀孕的大多数时间里，您是否暴露于他人烟草烟雾中? On most days during your pregnancy, were you exposed to someone else's cigarette smoke?	□ 1 是      □ 0 否 (跳至 G1)

G10 您在哪里暴露与烟草烟雾中?

Where were you exposed to the smoke?

1 仅在家中      2 仅在工作单位      3 在家和在工作单位均暴露

## H 酒精

H1 在您怀孕前三个月至今，您是否饮用过任何含有酒精的饮料?

1 是      0 否

During the 3 months before or during your pregnancy, did you ever drink any alcoholic beverages?

H2 在这三个月内，您通常每次饮几杯酒?

\_\_\_\_\_ 杯

On those days that you drank, how many drinks did you have?

## I 环境暴露情况

I1 怀孕前三个月到现在，您是否染烫发?

1 是      0 否

Did you dye perm in the first three months of pregnancy?

I2 怀孕前三个月到现在，后您工作的地点或家里是否装修过?

1 是      0 否

Did you exposed to formaldehyde in the first three months of pregnancy?

I3 怀孕前后您是否接触过下列物质? Have you been exposed to the following substances before and after pregnancy? (Toxic chemicals)

1 除草剂    2 杀虫剂    3 灭鼠剂    4 有机溶剂    5 消毒剂  
6 金属制剂    7 有害气体    8 有害固体

## J 药物使用情况

以下问题是有关于您在末次月经之前三个月内至今期间的用药情况

	治疗高血压 药物 Medication for hypertension	胰岛素 Insulin for diabetes	口服降血糖 药物 Oral hypoglycemic for diabetes	抗癫痫药物 Medications for epilepsy	每天都要服用的 药物 Medications at least once a day	
1 您是否使用过? Did you take?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否	
2 您使用的药物名称? What did you take?	_____	_____	_____	_____	_____	
<b>如果下一个问题令您感到不安且不愿意回答，请在“拒答”上打√，我们将对您所有回答进行严格保密!</b>						
	安定\有助于 您放松药物 Valium\drugs to help you	使您感觉良好 精力旺盛 Make you feel	美沙酮\氧可酮\ 其他止痛药 Methadone oxymoron\other	可卡因 Cocaine or crack cocaine	海洛因 Heroin	大麻 Marijuana

	relax	good\have more energy	pain killers			
1 您是否使用过? Did you take?	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否 <input type="checkbox"/> 2 拒答 <input type="checkbox"/> 9 不清楚
2 您使用的药物名称? What did you take?	_____	_____	_____	_____	_____	_____

### I 您在怀孕期间是否患过以下疾病？

I.3 发热性疾病及呼吸道感染 Febrile illness and respiratory infections	<input type="checkbox"/> 1 是 <input type="checkbox"/> 0 否
I.3.1 您发烧时的最高温度是多少？ What was the highest temperature of your fever during your illness?	_____ °C
I.3.2 您发烧有几天？ How long did you have a fever?	_____ 天
I.6 其他 _____	

**调查结束，感谢您的配合！**

调查员姓名 \_\_\_\_\_

调查日期 \_\_\_\_/\_\_\_\_/\_\_\_\_  
                  年    月    日

### Appendix 3 Variable list

<b>Pre-pregnant variable list</b>		
No	Variables	Data type
	<b>General information</b>	
1	Wife id	Text
2	Husband nation	Text
3	Husband age	N
4	Husband education	Text
5	Husband id	Text
6	Husband occupation	Text
7	Wife nation	Text
8	Wife age	N
9	Wife education	Text
10	Wife occupation	Text
11	Tel No	Text
12	Mobile phone No	Text
	<b>Medical history</b>	
13	Female anemia	Category
14	Female EH	Category
15	Female heart disease	Category
16	Female DM	Category
17	Female epilepsy	Category
18	Female thyroid disease	Category
19	Female CGN	Category
20	Female mental disease	Category
21	Female tumour	Category
22	Female TB	Category
23	Female HBV	Category
24	Female VD	Category
25	Male anemia	Category
26	Male EH	Category
27	Male heart disease	Category
28	Male DM	Category
29	Male epilepsy	Category
30	Male thyroid disease	Category
31	Male CGN	Category
32	Male mental disease	Category
33	Male tumour	Category
34	Male TB	Category
35	Male HBV	Category
36	Male VD	Category



	<b>Vaccine</b>	
37	Female rubella vaccine	Category
38	Female hepB vaccine	Category
39	Male hepB vaccine	Category
	<b>Drug use</b>	
40	Female current medicine	Category
41	Female medicine name	Category
42	Male current medicine	Category
43	Male medicine name	Category
	<b>Childbearing history</b>	
44	Birth history	Category
45	Pregnancy times	Category
46	Live birth	Category
47	Dead fetus	Category
48	Dead birth	Category
49	Term delivery	Category
50	Premature delivery	Category
51	Natural abortion	Category
52	Abactio	Category
53	Children number	Category
54	Birth defect	Category
55	Defect type	Category
56	Menarche age	Category
57	Period menstruation	Category
58	Menstrual cycle	Category
59	Menstrual quantity	Category
60	LMP	Date
	<b>Family history of disease</b>	
61	Female family history thalassemia	Category
62	Female family history albinism	Category
63	Female family history favism	Category
64	Female family history hemophilia	Category
65	Female family history CHD	Category
66	Female family history DS	Category
67	Female family history openNTDs	Category
68	Female family history DM	Category
69	Female family history dysnoesia	Category
70	Female family history daysaudia	Category
71	Female family history viual disorder	Category
72	Female family history neuropsychiatric	Category
73	Female family history other birth defects	Category
74	Female family history fetal death	Category
75	Female family history intermarry	Category

76	Female family history relations	Category
77	Male family history thalassemia	Category
78	Male family history albinism	Category
79	Male family history favism	Category
80	Male family history hemophilia	Category
81	Male family history CHD	Category
82	Male family history DS	Category
83	Male family history openNTDs	Category
84	Male family history DM	Category
85	Male family history dysnoesia	Category
86	Male family history dysaudia	Category
87	Male family history vidual disorder	Category
88	Male family history neuropsychiatric	Category
89	Male family history other birth defects	Category
90	Male family history fetal death	Category
91	Male family history intermarry	Category
92	Male family history relations	Category
	<b>Anthroposomatology</b>	
93	Female height	Numeric
94	Female weight	Numeric
95	Female BMI	Numeric
96	Female heart rate	Numeric
97	Female SBP	Numeric
98	Female SDP	Numeric
99	Male height	Numeric
100	Male weight	Numeric
101	Male BMI	Numeric
102	Male heart rate	Numeric
103	Male SBP	Numeric
104	Male SDP	Numeric
	<b>Lab data</b>	
105	Leucorrhoea check	Numeric
106	Clue cell	Numeric
107	Monilia infection	Numeric
108	Trichomomas	Numeric
109	Cleanness	Numeric
110	Whiff test	Numeric
111	PH	Numeric
112	Wom blood analysis	Numeric
113	Female hb	Numeric
114	Female wbc	Numeric
115	Female rbc	Numeric
116	Wom urine test	Numeric

117	Female ABO	Numeric
118	Female Rh	Numeric
119	Female GLU	Numeric
120	Female GLU levels	Numeric
121	Female NG	Numeric
122	Female chlamydia	Numeric
123	Female syphilis	Numeric
124	Female HIV	Numeric
125	Female ALT	Numeric
126	Female ALT levels	Numeric
127	Female HBs-Ag	Numeric
128	Female HBs-Ab	Numeric
129	Female HBe-Ag	Numeric
130	Female HBe-Ab	Numeric
131	Female HBc-Ab	Numeric
132	Female HCV-Ab	Numeric
133	Female CMV IgM	Numeric
134	Female CMV IgG	Numeric
135	Female RV IgM	Numeric
136	Female RV IgG	Numeric
137	Female TOX IgM	Numeric
138	Female TOX IgG	Numeric
139	Male blood analysis	Numeric
140	Male hb	Numeric
141	Male wbc	Numeric
142	Male rbc	Numeric
<b>During-pregnancy variable list</b>		
	<b>Basic information</b>	
1	Hospital card number	Text
2	Inpatient number	Text
3	Name	Text
4	Age	Numeric
5	Pregnant times	Numeric
6	Delivery times	Numeric
7	Last menstrual period	Date
8	Gestational week at the first visit	Numeric
9	The first visit date	Date
10	Height	Numeric
11	Weight	Numeric
12	Systolic blood pressure at the first visit	Numeric
13	Diastolic blood pressure at the first visit	Numeric

14	Occupation	Text
15	Education	Text
	<b>Antenatal care record</b>	
16	Weight at each antenatal care	Numeric
17	Systolic blood pressure at each antenatal care	Numeric
18	Diastolic blood pressure at each antenatal care	Numeric
19	Gestational week at each antenatal care	Numeric
20	Antenatal care date	Date
	<b>Lab data</b>	
21	Cytomegalovirus	Numeric
22	Cytomegalovirus examination date	Date
23	Rubella virus	Numeric
24	Rubella virus examination date	Date
25	Toxoplasmosis	Numeric
26	Toxoplasmosis examination date	Date
27	Syphilis screening	Numeric
28	Syphilis screening examination date	Date
29	Fasting blood-glucose	Numeric
30	Fasting blood-glucose examination date	Date
31	HCT(hematokrit)	Numeric
32	HCT(hematokrit) examination date	Date
33	Serum folate	Numeric
34	Serum folate examination date	Date
35	HCY(homocysteine)	Numeric
36	HCY(homocysteine) examination date	Date
37	OGTT 0 hours	Numeric
38	OGTT 1 hours	Numeric
39	OGTT 2 hours	Numeric
40	OGTT examination date	Date
41	Triglyceride	Numeric
42	Triglyceride examination date	Date
43	Total cholesterol	Numeric
44	Total cholesterol examination date	Date
45	Hemoglobin	Numeric
46	Hemoglobin examination date	Date
	<b>Delivery date</b>	
47	Gestational week at delivery	Numeric
48	Delivery mode	Text
49	Birth weight	Numeric
50	Birth weight(second baby)	Numeric
51	Systolic blood pressure at delivery	Numeric
52	Diastolic blood pressure at delivery	Numeric
53	Apgar scoring	Numeric

54	Delivery date	Date
55	Birth defect records	Text
56	Weight blood pressure at delivery	Numeric
<b>Offspring variable list</b>		
	<b>0 - 6 years (6 weeks, 6 months, 12 months, 36 months, 60 months)</b>	
1	Name	Text
2	ID number	Text
3	Weight	Numeric
4	Height/ Length	Numeric
5	Vision detection	Numeric
6	DDST: Denver developmental screening test	Numeric
	<b>6 - 18 years (each year)</b>	
7	Weight	Numeric
8	Height	Numeric
9	Diastolic blood pressure	Numeric
10	Systolic blood pressure	Numeric
11	Vision detection	Numeric
12	Vital capacity	Numeric
13	Physical fitness measurement (running, jumping, solid balls, etc)	Text
The clinical diagnosis during 0 – 18 years will be extracted from the routine medical system each year.		

## **Future Plan of Shanghai PreConception Cohort, Shanghai, China (SPCC)**

The Shanghai PreConception Cohort (SPCC) is a long-term cohort and meets the “Cohort profile” requirement. We have a complete plan to follow-up offspring to the age of 18 years old. The cohort will be financially supported by different grants. The current manuscript focuses on the first phase, the establishment of the baseline and our first main outcome, the congenital heart disease (CHD).

The second phase of this cohort study is from birth to 6 years old. Follow-up work will rely on Shanghai Community health care centers-child care. The third phase is from 6 to the age of 18 (school age). We will cooperate with Shanghai Student Health and Fitness Surveillance Center for the follow-up of the school age children.

Multiple outcomes for pediatrics, including growth, physical and neuro-developments, obesity, common and rare diseases will be investigated. Nested case-control design will be used for rare outcomes.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

The data collection plan for infants and children

	At birth	6 weeks	6 months	12 months	36 months	60 months	6 – 18 years*
General information (gender, ID number, Home Address, etc)	√	√					
Delivery outcome (Congenital malformation, preterm birth, miscarriage, stillbirth)	√						
Body measurement(weight, height, waistline, hipline)	√	√	√	√	√	√	√
Diet investigation (questionnaire)	√	√	√	√	√	√	√
Neurobehavioral developmental assessment (DDST <sup>\$</sup> )		√	√	√	√	√	
Anthropometrics data (Shanghai Community health care centers-child care and Shanghai Student Health and Fitness Surveillance Center) weight, height, waist circumference	√	√	√	√	√	√	√
Physical fitness measurement (running, jumping, solid balls, etc)							√
Blood pressure measurement, annually							√
Hemachrome (anemia)							√
Renal functions, at grade 9 and 12							√
Cardiovascular-related chronic diseases (Hypertension, Obesity, Diabetes/Pre-diabetes and Dyslipidemia)							√
Venous blood <sup>#</sup>							√

Note: \* Shanghai Student Health and Fitness Surveillance Center routinely conducts all-round physical examinations for students in the school as a health care policy for Shanghai students. It is usually in September-November of each year.

\$ DDST: Denver developmental screening test.

# Venous blood will be collected at 12, 15 and 18 years of age.